



Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004145
Article Type:	Research
Date Submitted by the Author:	29-Sep-2013
Complete List of Authors:	Cui, Ai; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Jin, Xiao-Guang; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Zhai, Kan; Beijing Institute of Respiratory Diseases, Center of Medical Research Tong, Zhao-Hui; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Shi, Huan-Zhong; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine
Primary Subject Heading:	Diagnostics
Secondary Subject Heading:	Diagnostics, Respiratory medicine
Keywords:	Adult thoracic medicine < THORACIC MEDICINE, Immunology < THORACIC MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts

only

1
2
3
4 Diagnostic values of soluble mesothelin-related peptides for malignant pleural
5
6 mesothelioma: meta-analyses
7
8
9

10
11 Short running head: SMRPs in mesothelioma
12
13

14
15
16 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
17
18
19

20
21 * These authors contributed equally to the present work
22
23
24
25

26 ¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
27
28 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
29
30 Respiratory Diseases, Beijing, China.
31
32
33
34
35

36 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
37
38 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
39
40 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
41
42 85231412; E-mail: shihuanzhong@sina.com
43
44
45
46
47
48

49 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin-related peptides
50
51
52
53

54 **Word counts:** 2,822
55
56
57
58
59
60

ABSTRACT

Objective Although the values of soluble mesothelin-related peptides (SMRPs), including mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for diagnosing malignant pleural mesothelioma have been extensively studied, the exact diagnostic accuracy of these SMRPs remains controversial. The purpose of the present meta-analyses was to update the overall diagnostic accuracy of SMRPs in serum, and further to establish that of SMRPs in pleural fluid for mesothelioma.

Design Systematic review and meta-analysis.

Methods In total, 27 articles from 30 diagnostic studies were included in the current meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMRPs in serum and pleural fluid for the diagnosis of malignant pleural mesothelioma were pooled using random effects models. Summary receiver operating characteristic curves were used to summarize overall test performance.

Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.63, 0.87, 5.68, 0.42, and 14.95, respectively; pleural fluid: 0.80, 0.83, 4.00, 0.30, and 15.31, respectively. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared to mesothelin for MPM.

Conclusions SMRPs in both serum and pleural fluid were helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMRP determinations were not sufficiently to exclude non-MPM, and the positive test results indicated that further

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

invasive diagnostic steps might be necessary for the diagnosis of MPM.

For peer review only

ARTICLE SUMMARY

Article focus

- The diagnosis of MPM is always a challenging endeavor because.
- To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.
- The concentrations of soluble mesothelin-related peptides, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Key messages

- Soluble mesothelin-related peptides in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- The negative test results are not sufficiently to exclude non-mesothelioma, while the positive test results would indicate that further invasive diagnostic steps might be necessary.

Strengths and limitations of this study

- The studies included this meta-analysis were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mesothelioma and the other diseases.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-004145 on 24 February 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in malignant mesothelioma, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble megakaryocyte potentiating factor (MPF).⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin-related peptides (SMRPs), including both soluble mesothelin and MPF, have been found in human serum and pleural fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMRP detections for MPM has been extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we

1
2
3
4 performed and published first meta-analysis reporting the overall diagnostic accuracy of
5
6 serum SMRPs for diagnosing MPM, and our results showed that serum SMRP determinations
7
8 played a role in the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an
9
10 individual patient data meta-analysis to evaluate serum SMRP for diagnosing MPM, and
11
12 found that a positive test result at a high-specificity threshold is a strong incentive to urge
13
14 further diagnostic steps; however, the poor sensitivity of SMRPs limits its added value to
15
16 early diagnosis of MPM.¹² Since that time, many additional clinical studies determining the
17
18 concentrations of SMRPs in serum and PF have been reported. We thus performed the present
19
20 meta-analyses to update the overall diagnostic accuracy of serum SMRPs, and further to
21
22 establish that of PF SMRPs for diagnosing MPM.
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until July, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin-related peptides/SMRP”, “mesothelin”, “megakaryocyte potentiating factor/MPF”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were also searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMRP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected in the study, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ). Data retrieved from the reports included author, publication year, study characteristics,

1
2
3
4 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
5
6 and methodological quality. All eligible studies were assessed for methodologic quality using
7
8 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
9
10 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
11
12 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
13
14 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
15
16 consensus to assess the quality of primary studies of diagnostic accuracy).
17
18
19

20 21 22 23 24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38
39

40
41 The analyses were based on a summary receiver operating characteristic (SROC)
42
43 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
44
45 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
46
47 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
48
49 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
50
51 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
52
53 potential presence of this bias using funnel plots and the Egger test.²⁰
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, fifty-six publications determining concentrations of human SMRPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, twenty-nine were excluded (Appendix excluded references, available online). Subsequently, twenty-seven publications²¹⁻⁴⁷ were available for analysis of diagnostic accuracy of SMRPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 16 publications from 18 studies³²⁻⁴⁷ were added in the current meta-analyses.

The methods of determining SMRPs in all studies included were enzyme-linked immunosorbent assay. Serum mesothelin concentrations were determined in 20 studies (19 articles),^{21,23-28,30,31,33,34,36-39,41,43,45,47} and serum MPF concentrations were determined in 5 studies^{22,29,30,32,36} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMRP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. In addition, another 2 articles^{30,36} were also treated as independent studies, since both mesothelin and MPF in serum were investigated in these 2 articles. PF mesothelin concentrations were determined in 9 studies.^{23,35,40-44,46,47}

The clinical characteristics of the studies, along with STARD and QUADAS scores, are outlined in Table 1 and Table 2.

Study characteristics

On review, the studies showed large differences in number of participants, clinical characteristics (especially histologic subtypes of MPM, and type of control groups), and reported diagnostic cut-off values of SMRPs (Appendix Table 1). For serum SMRP studies, the average samples size was 270 (range from 40 – 1,086), the subjects included 1,046 patients with MPM and 5,356 non-MPM. For PF SMRP studies, the average samples size was 127 (range from 40 – 275), the subjects included 352 patients with MPM and 794 non-MPM.

Except for 2 studies, all samples were collected from the consecutive patients in the remaining 28 studies. Nine studies reported blinded interpretation of SMRP assays independent of the reference standard. Eight studies reported the study design was prospective. In 21 studies, MPM diagnosis was completely based on pathological findings in pleural biopsies, with or without positive cytological results; while in the remaining 9 studies, some MPM patients were diagnosed just based on the cytological findings. Totally, the quality of study design and reporting diagnostic accuracy of most studies were good, since 23 of 27 publications had higher STARD scores (≥ 13) and 18 studies had higher QUADAS scores (≥ 10).

Publication bias

The funnel plots for publication bias showed asymmetry for serum SMRP studies (Figure 1A), evaluation of publication bias showed that Egger tests were significant for serum SMRPs ($p = 0.044$). Although the funnel plots for publication bias showed somehow asymmetry due to the

1
2
3
4 limited number of PF SMRP studies (Figure 1B), Egger tests showed that this was not
5
6 significant for PF SMRPs ($p = 0.149$). These results indicated a potential for publication bias
7
8 for serum SMRP, but not for PF SMRP studies.
9

10 11 12 13 14 **Diagnostic accuracy**

15
16 Figure 2A shows forest plot of sensitivity and specificity for 25 serum SMRP assays in the
17
18 diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.63, 95% CI 0.60 –
19
20 0.65), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was
21
22 also noted that PLR was 5.68 (95% CI 4.15 – 7.76), NLR was 0.42 (95% CI 0.36 – 0.49), and
23
24 DOR was 14.95 (95% CI 9.93 – 22.50). X^2 values of sensitivity, specificity, PLR, NLR, and
25
26 DOR were 121.53, 443.37, 261.05, 107.18, and 137.67, respectively, with all $p < 0.001$,
27
28 indicating a significant heterogeneity between studies.
29
30
31
32

33
34 Figure 2B shows forest plot of sensitivity and specificity 9 PF SMRP assays in the
35
36 diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.80, 95% CI 0.76 –
37
38 0.84), while specificity ranged from 0.65 – 0.90 (pooled 0.83, 95% CI 0.80 – 0.85). We also
39
40 noted that PLR was 4.00 (95% CI 2.98 – 5.36), NLR was 0.30 (95% CI 0.23 – 0.39), and
41
42 DOR was 15.31 (95% CI 9.32 – 25.16). X^2 values of sensitivity, specificity, PLR, NLR, and
43
44 DOR were 37.07 ($p < 0.001$), 30.45 ($p < 0.001$), 23.85 ($p = 0.002$), 11.30 ($p = 0.185$), and
45
46 15.14 ($p = 0.056$), respectively, indicating somehow a heterogeneity between studies.
47
48
49
50

51
52 The graphs of SROC curves for SMRP determinations showing sensitivity versus 1 –
53
54 specificity from individual studies are shown in Figure 3. SROC curve of serum SMRPs was
55
56 not positioned near the desirable upper left corner of SROC curve, and that the maximum
57
58
59
60

1
2
3
4 joint sensitivity and specificity was 0.737 (SEM, 0.031) (Figure 3A); while area under curve
5
6 (AUC) was 0.802 (SEM, 0.035). The maximum joint sensitivity and specificity of PF SMRP
7
8 was 0.805 (SEM, 0.022); while AUC was 0.875 (SEM, 0.023) (Figure 3B).
9

10
11 Totally, the diagnostic performance of SMRPs in serum and PF was similar.
12

13 14 15 16 **Subgroup analysis**

17
18 We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the
19
20 results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR,
21
22 NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of
23
24 serum mesothelin.
25
26
27

28
29 Data from 6 studies^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of
30
31 serum SMRPs differentiating MPM from healthy control subjects, 9 studies
32
33^{21,23,24,26,30,31,33,44,45} were available for comparing that of differentiating MPM from other
34
35 malignancies, 8 studies^{21,23,24,25,28,30,33,39} were available for comparing that of differentiating
36
37 MPM from asbestos-exposed subjects. As shown in Table 4, the values of sensitivity,
38
39 specificity, PLR, NLR, DOR, and AUC of SMRPs for discriminating MPM from healthy
40
41 control subjects were quite acceptable, which were better than those for discriminating MPM
42
43 from patients with the other cancers or from asbestos-exposed people. By using serum
44
45 SMRPs, it was the most difficult to identify MPM from other cancers, compared with from
46
47 healthy controls or asbestos-exposed people.
48
49
50
51
52

53
54 Five studies^{23,35,40,41,46} provided required data for comparing diagnostic accuracy of PF
55
56 mesothelin differentiating MPM from the other cancers, and 4 studies^{35,40,41,46} for
57
58
59
60

1
2
3
4 differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of
5
6 PF SMRP differentiating MPM from the other cancers was very similar to that of
7
8
9 differentiating MPM from benign pleural effusions.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{48,49}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMRPs was 0.63 and 0.80, respectively; and their specificity was 0.87 and 0.83 respectively. These data indicated that sensitivity and specificity of SMRPs in serum and PF were not as high as expected. The positive SMRPs results might be somehow helpful in confirming (ruling in) MPM, suggesting that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. However, the relative low sensitivity, especially serum SMRPs, that was not sufficiently low to exclude non-MPM when a patient's SMRP results were lower than the cut-off values. Therefore, the associated poor sensitivity of SMRPs clearly limits their added value to diagnosis of MPM.

Unlike a traditional ROC plot that explores the effect of varying cut-off values on sensitivity and specificity in a single study, each data point in the SROC plot represents a separate study. The SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMRPs were 0.737 and 0.805, respectively; while their AUCs were 0.802 and 0.875, respectively, indicating level

1
2
3
4 of overall accuracy were also not as high as expected.

5
6 The DOR is a single indicator of test accuracy⁵⁰ that combines the data from sensitivity
7
8 and specificity into a single number. The DOR of a test is the ratio of the odds of positive test
9
10 results in the diseased relative to the odds of positive test results in the non-diseased. The
11
12 value of a DOR ranges from 0 to infinity, with higher values indicating better discriminatory
13
14 test performance. A DOR of 1.0 indicates that a test does not discriminate between patients
15
16 with the disorder and those without it. In the current meta-analyses, we found that the pooled
17
18 DORs of serum and PF SMRPs were 14.95, and 15.31, respectively, indicating that SMRPs
19
20 seemed to be helpful in the diagnosis of MPM.
21
22
23
24

25
26 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
27
28 PLR and NLR are considered more clinically meaningful,^{51,52} we further presented both PLR
29
30 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
31
32 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
33
34 (indicating high accuracy).⁵³ A PLR value of 5.68 with serum SMRPs suggests that patients
35
36 with MPM have a near 6-fold higher chance of being SMRP-positive compared with patients
37
38 without MPM, and this was not high enough for the clinical purpose. This might lead to an
39
40 inordinate number of individuals undergoing unnecessary diagnostic work-ups or biopsies. On
41
42 the other hand, NLR of serum SMRPs was found to be 0.42. If serum SMRP results were
43
44 negative, the probability that this patient has MPM is 42%, which is not low enough to rule
45
46 out MPM. The very similar results were found with PF SMRPs.
47
48
49
50
51
52

53
54 Although both mesothelin and MPF belong to SMRPs, we noted in the current
55
56 meta-analyses that the overall diagnostic measures, including sensitivity, specificity, PLR,
57
58
59
60

1
2
3
4 NLR, DOR, and AUC, of serum MPF, were better than those of serum mesothelin. Therefore,
5
6 MPF had a superior diagnostic accuracy compared to mesothelin for MPM. We also noted
7
8 that diagnostic performance of serum SMRP for discriminating MPM from healthy control
9
10 subjects was the best (although not as good as expected), followed by that for discriminating
11
12 MPM from patients with other cancers or from asbestos-exposed people. In addition, the
13
14 overall diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was
15
16 similar to that of differentiating MPM from benign pleural effusions.
17
18
19

20
21 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
22
23 letters to the editors, and non-English language studies may have led to publication bias.
24
25 Indeed, we observed a publication bias for serum SMRP studies, but not for PF SMRP studies.
26
27 Publication bias may also be introduced by inflation of diagnostic accuracy estimates since
28
29 studies that report positive results are more likely to be accepted for publication. Second,
30
31 pathological types of MPM were not specified in 2 studies,^{34,41} epithelioid subtype of MPM
32
33 was the most common pathological type in all remaining studies, but not one.²⁵ Totally, 69.9%
34
35 (982/1404) MPM were epithelioid subtype (ranged from 29.9% to 100%). Analysis in terms
36
37 of histologic type has shown that SMRP levels were significantly elevated in epithelioid
38
39 subtype MPM than other types.^{21,23,29} This could explain partly the quite low sensitivity of
40
41 SMRPs in MPM diagnosis. Third, control groups were very heterogeneous from one study to
42
43 another; and various cutoff points were used for distinguishing between MPM and controls,
44
45 other cancers or benign respiratory diseases, according to the best combination of sensitivity
46
47 and specificity. These issues regarding accuracy of diagnosis could also lead to biased results
48
49
50
51
52
53
54
55

56
57 In conclusion, current evidence supported that SMRPs in both serum and PF were
58
59
60

1
2
3 helpful markers for the diagnosis of MPM. The overall diagnostic performance of SMRPs in
4
5 serum and PF was similar, and serum MPF had superior diagnostic accuracy compared to serum
6
7 mesothelin. The negative results of SMRP determinations were not sufficiently to exclude
8
9 non-MPM; on the other hand, the positive test results would indicate that further invasive
10
11 diagnostic steps might be necessary and could possibly lead to an earlier diagnosis.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Funding: This work was supported by a grant from National Natural Science Foundation of China (No. 81270149).

Competing interests: The authors have declared that no conflict of interest exists.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a licence to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ Group products and to exploit all subsidiary rights, as set out in our licence set out at: http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf

Data sharing statement: There is no additional data available.

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.
- 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in

- mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.
- 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. *Pathol Int* 2006; 56:649-54.
- 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
- 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
- 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012; 30:1541-9.
- 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
- 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003; 3:25.
- 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
- 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 1993; 12:1293-316.
- 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.

- 1
2
3
4 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
5
6 J Clin Epidemiol 1995; 48:119-30.
7
8
9 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
10
11 review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-86.
12
13
14 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
15
16 graphical test. BMJ 1997; 315:629-34.
17
18
19 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
20
21 mesothelioma. Lancet 2003; 362:1612-6.
22
23
24 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
25
26 mesothelin precursor is a useful tumor marker in the serum of patients with
27
28 mesothelioma. Clin Cancer Res 2006; 12:4225-31.
29
30
31 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
32
33 diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;
34
35 173:1155-60.
36
37
38 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
39
40 pleural mesothelioma. Clin Chem 2007; 53:666-72.
41
42
43 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
44
45 diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
46
47
48 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
49
50 patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
51
52
53 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
54
55 mesothelioma: analytical evaluation of an automated immunoassay and preliminary
56
57
58
59
60

- 1
2
3
4 clinical results. *Clin Chem Lab Med* 2007; 45:634-8.
- 5
6 28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early
7
8 detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol*
9
10 *Biomarkers Prev* 2008; 17:163-70.
- 11
12
13 29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked
14
15 immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum
16
17 tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.
- 18
19
20
21 30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker
22
23 of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung*
24
25 *Cancer* 2008; 62:45-54.
- 26
27
28 31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural
29
30 malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.
- 31
32
33 32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte
34
35 potentiating factor, and mesothelin proteins as markers in the serum of patients with
36
37 malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.
- 38
39
40
41 33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble
42
43 mesothelin-related proteins in patients with malignant pleural mesothelioma in
44
45 comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.
- 46
47
48
49 34 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of
50
51 soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related
52
53 pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers*
54
55 *Prev* 2009; 18:646-50.
- 56
57
58
59
60

- 1
2
3
4 35 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
5
6 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
7
8 1:313-7.
9
10
11 36 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
12
13 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
14
15 *Care Med* 2010; 181:620-5.
16
17
18 37 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
19
20 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
21
22 2011; 74:55-60.
23
24
25
26 38 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
27
28 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
29
30 6:1587-93.
31
32
33 39 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
34
35 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
36
37 26:160-5.
38
39
40 40 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
41
42 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.
43
44
45 41 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin
46
47 and osteopontin for the diagnosis of malignant pleural mesothelioma. *Egyptian*
48
49 *Journal of Chest Diseases and Tuberculosis* 2012; 61:121-8.
50
51
52 42 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination
53
54 improves the diagnosis of mesothelioma in pleural effusions. *J Thorac Oncol* 2012;
55
56
57
58
59
60

- 1
2
3 7:883-9.
4
5
6 43 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic
7
8 and prognostic markers of malignant pleural mesothelioma in Egyptian patients
9
10 undergoing pleurodesis. *Egyptian Journal of Chest Diseases and Tuberculosis* 2013;
11
12 62:115-20.
13
14
15 44 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related
16
17 peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its
18
19 contribution to cytology. *Cancer Invest* 2013; 31:43-50.
20
21
22 45 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in
23
24 serum in the diagnosis of pleural mesothelioma. *Anticancer Res* 2013; 33:2707-13.
25
26
27 46 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids:
28
29 comparison with CYFRA 21-1 and CEA. *Med Oncol* 2013; 30:543.
30
31
32 47 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin
33
34 in undiagnosed pleural effusions. *Eur Respir J* 2013; 41:18-24.
35
36
37 48 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of
38
39 malignant mesothelioma: a consensus statement from the International Mesothelioma
40
41 Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.
42
43
44 49 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant
45
46 pleural mesothelioma. *Biomark Med* 2011; 5:261-73.
47
48
49 50 Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test
50
51 performance. *J Clin Epidemiol* 2003; 56:1129-35.
52
53
54 51 JJ D. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M,
55
56
57
58
59
60

1
2
3
4 Smith GD, Altman DG, eds. Systematic reviews in health care. Meta-analysis in
5
6 context. London: BMJ Publishing Group 2001:248-82.
7

8
9 52 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. Users' guides to
10
11 the medical literature. A manual for evidence-based clinical practice. Chicago: AMA
12
13 Press, 2002; 121-40.
14

15
16 53 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in
17
18 mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-72.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of SMPRs in sera

Study	Subjects, n	SMPRs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	MPF	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Portal et al ³⁴	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
Hollevoet et al ³⁶	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
Hollevoet et al ³⁶	507	MPF	13.46 ng/ml	58	13	27	409	20	11
Creaney et al ³⁷	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
Cristaudo et al ³⁸	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
Dipalma et al ³⁹	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
Ashour et al ⁴¹	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
Amany et al ⁴³	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
Ferro et al ⁴⁵	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
Hooper et al ⁴⁷	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12

SMRP = soluble mesothelin-related peptide; OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 2. Study summary of SMPRs in pleural fluids *

Study	Patients, n	SMPRs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Fujimoto et al ³⁵	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴⁰	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴¹	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴²	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴³	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁴	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Filiberti et al ⁴⁶	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁷	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMRP = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23, 24, 25, 26, 27, 28, 30, 31, 33, 34, 36, 37, 38, 39, 41, 43, 45, 47	22, 29, 30, 32, 36
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.66 (0.60 – 0.71)
Heterogeneity* (p)	70.03 (< 0.001)	50.26 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.95 (0.93 – 0.96)
Heterogeneity (p)	345.53 (< 0.001)	19.42 (0.001)
PLR (95% CI)	4.75 (3.51 – 6.44)	12.31 (6.21 – 24.42)
Heterogeneity (p)	179.04 (< 0.001)	15.48 (0.004)
NLR (95% CI)	0.45 (0.39 – 0.51)	0.30 (0.14 – 0.64)
Heterogeneity (p)	50.33 (< 0.001)	74.23 (< 0.001)
DOR (95% CI)	11.84 (7.91 – 17.70)	40.15 (16.55 – 97.39)
Heterogeneity (p)	92.67 (< 0.001)	12.07 (0.017)
AUC (SEM)	0.791 (0.035)	0.933 (0.083)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 44, 45	21, 23, 24, 25, 28, 30, 33, 39
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM <i>vs</i> other cancers	MPM <i>vs</i> benign diseases
Study, Ref. No.	23, 35, 40, 41, 46	35, 40, 41, 46
Sensitivity (95% CI)	0.75 (0.69 – 0.81)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.14 (0.887)	1.08 (0.783)
Specificity (95% CI)	0.75 (0.68 – 0.81)	0.87 (0.80 – 0.93)
Heterogeneity (p)	3.93 (0.416)	6.74 (0.081)
PLR (95% CI)	2.81 (2.13 – 3.70)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.22 (0.337)	7.01 (0.071)
NLR (95% CI)	0.34 (0.26 – 0.44)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.90 (0.755)	1.83 (0.608)
DOR (95% CI)	8.75 (5.41 – 14.15)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.28 (0.512)	5.26 (0.154)
AUC (SEM)	0.812 (0.026)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.




Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.
162x69mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.
101x118mm (300 x 300 DPI)




Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.
205x101mm (300 x 300 DPI)

Review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Supplemental Data

Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: meta-analyses

Short running head: SMRPs in mesothelioma

Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}

* These authors contributed equally to the present work

¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of Respiratory Diseases, Beijing, China.

Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10 85231412; E-mail: shihuanzhong@sina.com

Appendix Excluded References

One were excluded because it recruited less than 10 patients in one of study groups,¹ seven were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered,²⁻⁸ twenty-one were excluded because they did not allow the calculation of sensitivity or specificity.⁹⁻²⁹

- 1 Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. *Cancer Sci* 2006; 97:928-32.
- 2 Robinson BW, Creaney J, Lake R, et al. Soluble mesothelin-related protein--a blood test for mesothelioma. *Lung Cancer* 2005; 49 Suppl 1:S109-11.
- 3 Creaney J, Christansen H, Lake R, et al. Soluble mesothelin related protein in mesothelioma. *J Thorac Oncol* 2006; 1:172-4.
- 4 Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. *Clin Cancer Res* 2006; 12:447-53.
- 5 Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. *Clin Cancer Res* 2007; 13:2928-35.
- 6 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85:265-72.
- 7 Grigoriu B, Chahine B, Zerimech F, et al. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. *Clin Biochem* 2009; 42:1046-50.
- 8 Hollevoet K, Nackaerts K, Thas O, et al. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. *Chest* 2012; 141:477-84.
- 9 Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. *Thorax* 2007; 62:569-76.
- 10 Weber DG, Taeger D, Pesch B, et al. Soluble mesothelin-related peptides (SMRP) - high

- 1
2
3
4 stability of a potential tumor marker for mesothelioma. *Cancer Biomark* 2007;
5 3:287-92.
6
7
8 11 Roe OD, Creaney J, Lundgren S, et al. Mesothelin-related predictive and prognostic
9 factors in malignant mesothelioma: a nested case-control study. *Lung Cancer* 2008;
10 61:235-43.
11
12
13 12 Grigoriu BD, Chahine B, Vachani A, et al. Kinetics of soluble mesothelin in patients with
14 malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009;
15 179:950-4.
16
17
18
19 13 Aleman C, Manuel Porcel J, Ma Segura R, et al. Pleural fluid mesothelin for the
20 differential diagnosis of exudative pleural effusions. *Med Clin (Barc)* 2009;
21 133:449-53.
22
23
24
25 14 Rai AJ, Flores RM, Mathew A, et al. Soluble mesothelin related peptides (SMRP) and
26 osteopontin as protein biomarkers for malignant mesothelioma: analytical validation
27 of ELISA based assays and characterization at mRNA and protein levels. *Clin Chem*
28 *Lab Med* 2010; 48:271-8.
29
30
31
32 15 Creaney J, Olsen NJ, Brims F, et al. Serum mesothelin for early detection of
33 asbestos-induced cancer malignant mesothelioma. *Cancer Epidemiol Biomarkers Prev*
34 2010; 19:2238-46.
35
36
37
38 16 Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and
39 osteopontin as markers of response in malignant mesothelioma. *J Clin Oncol* 2010;
40 28:3316-22.
41
42
43
44 17 Gube M, Taeger D, Weber DG, et al. Performance of biomarkers SMRP, CA125, and
45 CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer
46 in a cohort of workers formerly exposed to asbestos. *Arch Toxicol* 2011; 85:185-92.
47
48
49
50 18 Creaney J, Francis RJ, Dick IM, et al. Serum soluble mesothelin concentrations in
51 malignant pleural mesothelioma: relationship to tumor volume, clinical stage and
52 changes in tumor burden. *Clin Cancer Res* 2011; 17:1181-9.
53
54
55
56 19 Nelson HH, Almquist LM, LaRocca JL, et al. The relationship between tumor MSLN
57 methylation and serum mesothelin (SMRP) in mesothelioma. *Epigenetics* 2011;
58
59
60

- 1
2
3
4 6:1029-34.
5
6 20 Imashimizu K, Shiomi K, Maeda M, et al. Feasibility of large-scale screening using
7 N-ERC/mesothelin levels in the blood for the early diagnosis of malignant
8 mesothelioma. *Exp Ther Med* 2011; 2:409-11.
9
10 21 Hollevoet K, Van Cleemput J, Thimpont J, et al. Serial measurements of mesothelioma
11 serum biomarkers in asbestos-exposed individuals: a prospective longitudinal cohort
12 study. *J Thorac Oncol* 2011; 6:889-95.
13
14 22 Hollevoet K, Nackaerts K, Gosselin R, et al. Soluble mesothelin, megakaryocyte
15 potentiating factor, and osteopontin as markers of patient response and outcome in
16 mesothelioma. *J Thorac Oncol* 2011; 6:1930-7.
17
18 23 Boudville N, Paul R, Robinson BW, et al. Mesothelin and kidney function--analysis of
19 relationship and implications for mesothelioma screening. *Lung Cancer* 2011;
20 73:320-4.
21
22 24 Santarelli L, Strafella E, Staffolani S, et al. Association of MiR-126 with soluble
23 mesothelin-related peptides, a marker for malignant mesothelioma. *PLoS One* 2011;
24 6:e18232.
25
26 25 Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in
27 soluble mesothelin-related protein (SMRP) levels. *Clin Chem Lab Med* 2012;
28 50:2199-2204.
29
30 26 Franko A, Dolzan V, Kovac V, et al. Soluble mesothelin-related peptides levels in patients
31 with malignant mesothelioma. *Dis Markers* 2012; 32:123-31.
32
33 27 Mori T, Tajima K, Hiramata M, et al. The N-ERC index is a novel monitoring and prognostic
34 marker for advanced malignant pleural mesothelioma. *J Thorac Dis* 2013; 5:145-8.
35
36 28 Muley T, Dienemann H, Herth FJ, et al. Combination of Mesothelin and CEA Significantly
37 Improves the Differentiation between Malignant Pleural Mesothelioma, Benign
38 Asbestos Disease, and Lung Cancer. *J Thorac Oncol* 2013; 8:947-51.
39
40 29 Creaney J, Dick IM, Dare H, et al. Does CA125 binding to mesothelin impact the detection
41 of malignant mesothelioma? *Lung Cancer* 2013; 80:39-44.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Appendix Table 1 The characteristics of subjects studied

Study	MPM Patients	Non-MPM Subjects
Robinson et al ²¹	Epithelioid type (n = 25) Sarcomatoid type (n = 4) Other or not specified (n = 15)	Healthy controls without asbestos exposure (n = 28) Healthy controls with asbestos exposure (n = 40) Patients with inflammatory non-pleural lung disease (n = 92) Patients with non-MPM pleural diseases (n = 38) Patients with non-pleural malignant lung disease (n = 30)
Onda et al ²²	Epithelioid type (n = 56)	Healthy controls (n = 70)
Scherpereel et al ²³	Epithelioid type (n = 55) Sarcomatoid type (n = 6) Other or not specified (n = 13)	Patients with benign asbestos-related pleural diseases (n = 28) Patients with pleural metastasis of carcinomas (n = 35)
Beyer et al ²⁴	Epithelioid type (n = 59) Sarcomatoid type (n = 8) Other or not specified (n = 21)	Healthy controls (n = 409) Patients with non-MPM malignancy (n = 412) Patients with nonmalignant conditions (n = 116) Subjects with asbestos exposure (n = 61)
Creaney et al ²⁵	Epithelioid type (n = 35) Sarcomatoid type (n = 15)	Healthy controls with asbestos exposure (n = 33) Patients with benign asbestos-related diseases (n = 53)

	Other or not specified (n = 67)	Patients with benign pleural effusions (n = 30)
Cristaudo et al ²⁶	Epithelioid type (n = 72) Sarcomatoid type (n = 10) Other or not specified (n = 25)	Healthy controls (n = 262) Patients with benign respiratory diseases (n = 130) Patients with lung cancer (n = 215)
Di Serio et al ²⁷	Epithelioid type (n = 20) Sarcomatoid type (n = 2) Other or not specified (n = 2)	Healthy controls with asbestos exposure (n = 26) Patients with asbestos-related diseases (n = 66)
Amati et al ²⁸	Epithelioid type (n = 11) Sarcomatoid type (n = 6) Other or not specified (n = 5)	Healthy controls without asbestos exposure (n = 54) Subjects with asbestos exposure (n = 94)
Shiomi et al ²⁹	Epithelioid type (n = 21) Sarcomatoid type (n = 9) Other or not specified (n = 9)	Patients with benign asbestos-related diseases and healthy controls with asbestos exposure (n = 241) Patients with lung cancer (n = 45) Others (n = 8)
Iwahori et al ³⁰	Epithelioid type (n = 13) Sarcomatoid type (n = 3) Other or not specified (n = 11)	Healthy controls without asbestos exposure (n = 38) Healthy controls with asbestos exposure (n = 9) Patients with lung cancer (n = 47) Patients with other cancers (n = 5)

van den Heuvel ³¹	Epithelioid type (n = 43) Sarcomatoid type (n = 10) Other or not specified (n = 20)	Healthy controls (n = 50) Patients with lung cancer (n = 105)
Creaney et al ³²	Epithelioid type (n = 57) Sarcomatoid type (n = 9)	Healthy controls without asbestos exposure (n = 10) Healthy controls with asbestos exposure (n = 10) Patients with benign asbestos-related diseases (n = 21) Patients with lung cancer (n = 105)
Schneider et al ³³	Epithelioid type (n = 81) Sarcomatoid type (n = 14) Other or not specified (n = 34)	Patients with lung cancer (n = 130) Patients with benign asbestos-related diseases (n = 75)
Portal et al ³⁴	Not specified (n = 36)	Healthy controls (n = 48) Patients with asbestos exposure and no pleural disease (n = 177) Patients with benign asbestos-related diseases (n = 101)
Fujimoto et al ³⁵	Epithelioid type (n = 15) Sarcomatoid type (n = 4) Other or not specified (n = 4)	Patients with lung cancer (n = 38) Patients with benign asbestos pleurisy (n = 26) Patients with tuberculosis pleurisy (n = 5) Patients with no pleural diseases (n = 4)
Hollevoet et al ³⁶	Epithelioid type (n = 73)	Healthy controls (n = 101)

	Sarcomatoid type (n = 4) Other or not specified (n = 8)	Healthy controls with asbestos exposure (n = 89) Patients with benign asbestos-related diseases (n = 123) Patients with benign respiratory diseases (n = 46) Patients with lung cancer (n = 6)
Creaney et al ³⁷	Epithelioid type (n = 59) Other or not specified (n = 7)	Patients with benign asbestos-related diseases (n = 47) Patients with benign respiratory diseases (n = 42)
Cristaudo et al ³⁸	Epithelioid type (n = 31)	Healthy controls (n = 93) Patients with benign respiratory diseases (n = 111)
Dipalma et al ³⁹	Epithelioid type (n = 29) Sarcomatoid type (n = 4) Other or not specified (n = 3)	Healthy controls without asbestos exposure (n = 109) Healthy controls with asbestos exposure (n = 26) Patients with benign asbestos-related diseases (n = 48) Patients with benign respiratory diseases (n = 110) Patients with lung cancer (n = 25)
Yamada et al ⁴⁰	Epithelioid type (n = 37) Sarcomatoid type (n = 5) Other or not specified (n = 3)	Patients with non-malignant pleural effusions (n = 24) Patients with lung cancer involving malignant pleural effusion (n = 29)
Ashour et al ⁴¹	Not specified (n = 38)	Healthy controls with asbestos exposure (n = 32) Patients with benign pleural diseases (n = 29)

		Patients with pleural carcinomas (n = 24)
Blanquart et al ⁴²	Epithelioid type (n = 49) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Patients with adenocarcinoma effusions (n = 25) Patients with benign pleural effusions (n = 15)
Amany et al ⁴³	Epithelioid type (n = 14) Sarcomatoid type (n = 4) Other or not specified (n = 2)	Patients with benign asbestos pleural effusions (n = 10) Patients with tuberculosis pleural effusions (n = 10)
Canessa et al ⁴⁴	Epithelioid type (n = 35) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignant effusions (n = 94) Patients with benign pleural effusions (n = 129)
Ferro et al ⁴⁵	Epithelioid type (n = 26) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignancy (n = 23) Patients with benign diseases (n = 36)
Filiberti et al ⁴⁶	Epithelioid type (n = 43) Sarcomatoid type (n = 3) Other or not specified (n = 2)	Patients with malignant effusions (n = 64) Patients with benign effusions (n = 56)
Hooper et al ⁴⁷	Epithelioid type (n = 23) Sarcomatoid type (n = 3)	Patients with non-MPM malignant effusions (n = 74) Patients with benign asbestos-related effusions (n = 13)

	Other or not specified (n = 2)	Patients with benign pleural diseases (n = 100)
--	--------------------------------	---

MPM = malignant pleural mesothelioma.

For peer review only

bmjopen-2013-004146 on 24 February 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	0-2
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	7,8
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	11
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	12
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	12
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	12
<i>Test methods</i>	7	The reference standard and its rationale.	12
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	12
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	11,12
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	A/N
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	12
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	A/N
	13	Methods for calculating test reproducibility, if done.	A/N
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	A/N
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	11
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	A/N
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	A/N
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	12
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	12-15
	20	Any adverse events from performing the index tests or the reference standard.	A/N
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	14,15
	22	How indeterminate results, missing data and outliers of the index tests were handled.	A/N
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	14,15
	24	Estimates of test reproducibility, if done.	A/N
DISCUSSION	25	Discuss the clinical applicability of the study findings.	18,19



Diagnostic values of soluble mesothelin family proteins for malignant pleural mesothelioma: updated meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004145.R1
Article Type:	Research
Date Submitted by the Author:	11-Nov-2013
Complete List of Authors:	Cui, Ai; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Jin, Xiao-Guang; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Zhai, Kan; Beijing Institute of Respiratory Diseases, Center of Medical Research Tong, Zhao-Hui; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Shi, Huan-Zhong; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine
Primary Subject Heading:	Diagnostics
Secondary Subject Heading:	Diagnostics, Respiratory medicine
Keywords:	Adult thoracic medicine < THORACIC MEDICINE, Immunology < THORACIC MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts

only

1
2
3
4 Diagnostic values of soluble mesothelin family proteins for malignant pleural
5
6 mesothelioma: updated meta-analyses
7
8
9

10
11 Short running head: Mesothelin family proteins in mesothelioma
12

13 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
14
15

16 * These authors contributed equally to the present work
17
18
19
20

21 ¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
22
23 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
24
25 Respiratory Diseases, Beijing, China.
26
27
28
29
30

31 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
32
33 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
34
35 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
36
37 85231412; E-mail: shihuanzhong@sina.com
38
39
40
41
42
43

44 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin family proteins
45
46
47
48

49 **Word counts:** 2,729
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objective Although the values of soluble mesothelin family proteins (SMFPs), including mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for diagnosing malignant pleural mesothelioma have been extensively studied, the exact diagnostic accuracy of these SMFPs remains controversial. The purpose of the present meta-analyses was to update the overall diagnostic accuracy of SMFPs in serum, and further to establish that of SMFPs in pleural fluid for mesothelioma.

Design Systematic review and meta-analysis.

Methods In total, 27 articles from 30 diagnostic studies were included in the current meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMFPs in serum and pleural fluid for the diagnosis of malignant pleural mesothelioma were pooled using random effects models. Summary receiver operating characteristic curves were used to summarize overall test performance.

Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.63, 0.87, 5.68, 0.42, and 14.95, respectively; pleural fluid: 0.80, 0.83, 4.00, 0.30, and 15.31, respectively. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared to mesothelin for MPM.

Conclusions SMFPs in both serum and pleural fluid were helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMFP determinations were not sufficiently to exclude non-MPM, and the positive test results indicated that further invasive diagnostic steps might be necessary for the diagnosis of MPM.

ARTICLE SUMMARY

Article focus

- The diagnosis of MPM is always a challenging endeavor because.
- To date, no single marker or panel of soluble biomarkers is available for a clear diagnosis of MPM.
- The concentrations of soluble mesothelin family proteins, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Key messages

- Soluble mesothelin family proteins in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- Determination of soluble mesothelin family proteins might be helpful in confirming pleural mesothelioma if the results were higher than the cut-off values, while the negative results were not sufficiently to exclude non-mesothelioma.

Strengths and limitations of this study

- The studies included this meta-analysis were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural mesothelioma and the other diseases.

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in malignant mesothelioma, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble megakaryocyte potentiating factor (MPF).⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin family proteins (SMFPs), including both soluble mesothelin and MPF, have been found in human serum and pleural fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMFP detections for MPM has been extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we performed and published first meta-analysis reporting the overall diagnostic accuracy of serum SMFPs for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

diagnosing MPM, and our results showed that serum SMFP determinations played a role in the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an individual patient data meta-analysis to evaluate serum SMFP for diagnosing MPM, and found that a positive test result at a high-specificity threshold is a strong incentive to urge further diagnostic steps; however, the poor sensitivity of SMFPs limits its added value to early diagnosis of MPM.¹² Since that time, many additional clinical studies determining the concentrations of SMFPs in serum and PF have been reported. We thus performed the present meta-analyses to update the overall diagnostic accuracy of serum SMFPs, and further to establish that of PF SMFPs for diagnosing MPM.

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until July, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin family proteins”, “soluble mesothelin-related peptides”, “mesothelin”, “megakaryocyte potentiating factor”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were also searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMFP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected to be included in the meta-analyses, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ).

Data retrieved from the reports included author, publication year, study characteristics,

1
2
3
4 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
5
6 and methodological quality. All eligible studies were assessed for methodologic quality using
7
8 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
9
10 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
11
12 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
13
14 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
15
16 consensus to assess the quality of primary studies of diagnostic accuracy).
17
18
19

20 21 22 23 24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38
39

40
41 The analyses were based on a summary receiver operating characteristic (SROC)
42
43 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
44
45 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
46
47 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
48
49 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
50
51 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
52
53 potential presence of this bias using funnel plots and the Egger test.²⁰
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, fifty-six publications determining concentrations of human SMFPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, twenty-nine were excluded (Online supplementary appendix 1). Subsequently, twenty-seven publications²¹⁻⁴⁷ were available for analysis of diagnostic accuracy of SMFPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 16 publications from 18 studies³²⁻⁴⁷ were added in the current meta-analyses.

The methods of determining SMFPs in all studies included were enzyme-linked immunosorbent assay. Serum mesothelin concentrations were determined in 20 studies (19 articles),^{21,23-28,30,31,33,34,36-39,41,43,45,47} and serum MPF concentrations were determined in 5 studies^{22,29,30,32,36} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMFP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. In addition, another 2 articles^{30,36} were also treated as independent studies, since both mesothelin and MPF in serum were investigated in these 2 articles. PF mesothelin concentrations were determined in 9 studies.^{23,35,40-44,46,47}

The clinical characteristics of the studies, along with STARD and QUADAS scores, are outlined in Table 1 and Table 2.

Study characteristics

On review, the studies showed large differences in number of participants, clinical characteristics (especially histologic subtypes of MPM, and type of control groups), and reported diagnostic cut-off values of SMFPs (Online supplementary appendix 2). For serum SMFP studies, the average samples size was 270 (range from 40 – 1,086), the subjects included 1,046 patients with MPM and 5,356 non-MPM. For PF SMFP studies, the average samples size was 127 (range from 40 – 275), the subjects included 352 patients with MPM and 794 non-MPM.

The samples were collected from the consecutive patients in all studies but not 2 studies. Nine studies reported blinded interpretation of SMFP assays independent of the reference standard. Eight studies reported the study design was prospective. In 21 studies, MPM diagnosis was completely based on pathological findings in pleural biopsies, with or without positive cytological results; while in the remaining 9 studies, some MPM patients were diagnosed just based on the cytological findings. Totally, the quality of study design and reporting diagnostic accuracy of most studies were good, since 23 of 27 publications had higher STARD scores (≥ 13) and 18 studies had higher QUADAS scores (≥ 10).

Publication bias

The funnel plots for publication bias showed asymmetry for serum SMFP studies (Figure 1A), evaluation of publication bias showed that Egger tests were significant for serum SMFPs ($p = 0.044$). Although the funnel plots for publication bias showed somehow asymmetry due to the limited number of PF SMFP studies (Figure 1B), Egger tests showed that this was not

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

significant for PF SMFPs ($p = 0.149$). These results indicated a potential for publication bias for serum SMFP, but not for PF SMFP studies.

Diagnostic accuracy

Figure 2A shows forest plot of sensitivity and specificity for 25 serum SMFP studies in the diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.63, 95% CI 0.60 – 0.65), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was also noted that PLR was 5.68 (95% CI 4.15 – 7.76), NLR was 0.42 (95% CI 0.36 – 0.49), and DOR was 14.95 (95% CI 9.93 – 22.50). X^2 values of sensitivity, specificity, PLR, NLR, and DOR were 121.53, 443.37, 261.05, 107.18, and 137.67, respectively, with all $p < 0.001$, indicating a significant heterogeneity between studies.

Figure 2B shows forest plot of sensitivity and specificity 9 PF SMFP studies in the diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.80, 95% CI 0.76 – 0.84), while specificity ranged from 0.65 – 0.90 (pooled 0.83, 95% CI 0.80 – 0.85). We also noted that PLR was 4.00 (95% CI 2.98 – 5.36), NLR was 0.30 (95% CI 0.23 – 0.39), and DOR was 15.31 (95% CI 9.32 – 25.16). X^2 values of sensitivity, specificity, PLR, NLR, and DOR were 37.07 ($p < 0.001$), 30.45 ($p < 0.001$), 23.85 ($p = 0.002$), 11.30 ($p = 0.185$), and 15.14 ($p = 0.056$), respectively, indicating some a heterogeneity between studies.

The graphs of SROC curves for SMFP determinations showing sensitivity versus 1 – specificity from individual studies are shown in Figure 3. SROC curve of serum SMFPs was not positioned near the desirable upper left corner of SROC curve, and the maximum joint sensitivity and specificity was 0.737 (SEM, 0.031) (Figure 3A); while area under curve (AUC)

1
2
3 was 0.802 (SEM, 0.035). The maximum joint sensitivity and specificity of PF SMFP was
4
5
6 0.805 (SEM, 0.022); while AUC was 0.875 (SEM, 0.023) (Figure 3B).
7
8

9 Totally, the diagnostic performance of SMFPs in serum and PF was similar.
10

11 12 13 **Subgroup analysis**

14
15 We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the
16
17 results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR,
18
19 NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of
20
21 serum mesothelin.
22
23

24
25 Data from 6 studies^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of
26
27 serum SMFPs differentiating MPM from healthy control subjects, 9 studies^{21,23,24,26,30,31,33,44,45}
28
29 were available for comparing that of differentiating MPM from other malignancies, 8 studies
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
21,23,24,25,28,30,33,39 were available for comparing that of differentiating MPM from
asbestos-exposed subjects. As shown in Table 4, the values of sensitivity, specificity, PLR,
NLR, DOR, and AUC of SMFPs for discriminating MPM from healthy control subjects were
quite acceptable, which were better than those for discriminating MPM from patients with the
other cancers or from asbestos-exposed people. By using serum SMFPs, it was the most
difficult to identify MPM from other cancers, compared with healthy controls or
asbestos-exposed people.

51
52
53
54
55
56
57
58
59
60
Five studies^{23,35,40,41,46} provided required data for comparing diagnostic accuracy of PF
mesothelin differentiating MPM from the other cancers, and 4 studies^{35,40,41,46} for
differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of

1
2
3
4 PF SMFP differentiating MPM from the other cancers was very similar to that of
5
6 differentiating MPM from benign pleural effusions.
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{48,49}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMFPs was 0.63 and 0.80, respectively; and their specificity was 0.87 and 0.83 respectively. These data indicated that sensitivity and specificity of SMFPs in serum and PF were not as high as expected. SMFPs might be helpful in confirming (ruling in) MPM if the results were higher than the cut-off values. Thus, positive SMFP test results suggested that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. However, the relative low sensitivity, especially serum SMFPs, that was not sufficiently low to exclude non-MPM when a patient's SMFP results were lower than the cut-off values. Therefore, the associated poor sensitivity of SMFPs clearly limits their added value to diagnosis of MPM.

As previously described,¹¹ SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity, while DOR is a single indicator of test accuracy that combines the data from sensitivity and specificity into a single number. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMFPs were 0.737 and 0.805, respectively; while their AUCs were 0.802 and 0.875, respectively, indicating level of overall accuracy were also not as high

1
2
3
4 as expected. We also found that the pooled DORs of serum and PF SMFPs were 14.95, and
5
6 15.31, respectively, indicating that SMFPs seemed to be helpful in the diagnosis of MPM.
7
8

9
10 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
11 PLR and NLR are considered more clinically meaningful,^{50,51} we further presented both PLR
12 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
13 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
14 (indicating high accuracy).⁵² A PLR value of 5.68 with serum SMFPs suggests that patients
15 with MPM have a near 6-fold higher chance of being SMFP-positive compared with patients
16 without MPM, and this was not high enough for the clinical purpose. On the other hand, NLR
17 of serum SMFPs was found to be 0.42. If serum SMFP results were negative, the probability
18 that this patient has MPM is 42%, which is not low enough to rule out MPM. The very similar
19 results were found with PF SMFPs.
20
21
22
23
24
25
26
27
28
29
30
31
32

33
34 Although both mesothelin and MPF belong to SMFPs, we noted in the current
35 meta-analyses that the overall diagnostic measures, including sensitivity, specificity, PLR,
36 NLR, DOR, and AUC, of serum MPF, were better than those of serum mesothelin. Therefore,
37 MPF had a superior diagnostic accuracy compared to mesothelin for MPM. We also noted
38 that diagnostic performance of serum SMFP for discriminating MPM from healthy control
39 subjects was the best (although not as good as expected), followed by that for discriminating
40 MPM from patients with other cancers or from asbestos-exposed people. In addition, the
41 overall diagnostic accuracy of PF SMFP differentiating MPM from the other cancers was
42 similar to that of differentiating MPM from benign pleural effusions.
43
44
45
46
47
48
49
50
51
52
53
54

55
56 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
57
58
59
60

1
2
3 letters to the editors, and non-English language studies may have led to publication bias.
4
5
6 Indeed, we observed a publication bias for serum SMFP studies, but not for PF SMFP studies.
7
8
9 Publication bias may also be introduced by inflation of diagnostic accuracy estimates since
10
11 studies that report positive results are more likely to be accepted for publication. Second,
12
13 pathological types of MPM were not specified in 2 studies,^{34,41} epithelioid subtype of MPM
14
15 was the most common pathological type in all studies, excluding the one reported by Creaney
16
17 et al.²⁵ Totally, 69.9% (982/1404) MPM were epithelioid subtype (ranged from 29.9% to
18
19 100%). Analysis in terms of histologic type has shown that SMFP levels were significantly
20
21 elevated in epithelioid subtype MPM than other types.^{21,23,29} This could explain partly the
22
23 quite low sensitivity of SMFPs in MPM diagnosis. Third, control groups were very
24
25 heterogeneous from one study to another; and various cutoff points were used for
26
27 distinguishing between MPM and controls, other cancers or benign respiratory diseases,
28
29 according to the best combination of sensitivity and specificity. Fourth, multiple assays were
30
31 available for determining mesothelin concentrations, and Mesomark, which has been
32
33 approved by the US Food and Drug Administration, was used in most studies. The other
34
35 mesothelin ELISA kits were used in 4 studies.^{21, 30, 31, 35} These issues regarding accuracy of
36
37 diagnosis could also lead to biased results
38
39
40
41
42
43
44
45

46 In conclusion, current evidence supported that SMFPs in both serum and PF were helpful
47
48 markers for the diagnosis of MPM. The overall diagnostic performance of SMFPs in serum
49
50 and PF was similar, and serum MPF had superior diagnostic accuracy compared to serum
51
52 mesothelin. The negative results of SMFP determinations were not sufficiently to exclude
53
54 non-MPM, whereas the positive test results might be helpful in confirming MPM.
55
56
57
58
59
60

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Funding: This work was supported by a grant from National Natural Science Foundation of China (No. 81270149).

Competing interests: The authors have declared that no conflict of interest exists.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin family proteins for malignant pleural mesothelioma: updated meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ Group products and to exploit all subsidiary rights, as set out in our license set out at: http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf

Data sharing statement: There is no additional data available.

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.
- 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in

- mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.
- 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. *Pathol Int* 2006; 56:649-54.
- 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
- 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
- 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012; 30:1541-9.
- 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
- 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003; 3:25.
- 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
- 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 1993; 12:1293-316.
- 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.

- 1
2
3
4 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
5
6 J Clin Epidemiol 1995; 48:119-30.
7
8
9 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
10
11 review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-86.
12
13
14 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
15
16 graphical test. BMJ 1997; 315:629-34.
17
18
19 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
20
21 mesothelioma. Lancet 2003; 362:1612-6.
22
23
24 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
25
26 mesothelin precursor is a useful tumor marker in the serum of patients with
27
28 mesothelioma. Clin Cancer Res 2006; 12:4225-31.
29
30
31 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
32
33 diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;
34
35 173:1155-60.
36
37
38 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
39
40 pleural mesothelioma. Clin Chem 2007; 53:666-72.
41
42
43 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
44
45 diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
46
47
48 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
49
50 patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
51
52
53 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
54
55 mesothelioma: analytical evaluation of an automated immunoassay and preliminary
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- clinical results. *Clin Chem Lab Med* 2007; 45:634-8.
- 28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol Biomarkers Prev* 2008; 17:163-70.
- 29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.
- 30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung Cancer* 2008; 62:45-54.
- 31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.
- 32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.
- 33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.
- 34 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers Prev* 2009; 18:646-50.

- 1
2
3
4 35 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
5
6 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
7
8 1:313-7.
9
10
11 36 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
12
13 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
14
15 *Care Med* 2010; 181:620-5.
16
17
18 37 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
19
20 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
21
22 2011; 74:55-60.
23
24
25
26 38 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
27
28 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
29
30 6:1587-93.
31
32
33
34 39 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
35
36 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
37
38 26:160-5.
39
40
41 40 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
42
43 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.
44
45
46 41 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin
47
48 and osteopontin for the diagnosis of malignant pleural mesothelioma. *Egyptian*
49
50 *Journal of Chest Diseases and Tuberculosis* 2012; 61:121-8.
51
52
53
54 42 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination
55
56 improves the diagnosis of mesothelioma in pleural effusions. *J Thorac Oncol* 2012;
57
58
59
60

- 7:883-9.
- 43 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis. *Egyptian Journal of Chest Diseases and Tuberculosis* 2013; 62:115-20.
- 44 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. *Cancer Invest* 2013; 31:43-50.
- 45 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. *Anticancer Res* 2013; 33:2707-13.
- 46 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. *Med Oncol* 2013; 30:543.
- 47 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. *Eur Respir J* 2013; 41:18-24.
- 48 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.
- 49 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant pleural mesothelioma. *Biomark Med* 2011; 5:261-73.
- 50 Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, eds. *Systematic reviews in health care. Meta-analysis in context*. London: BMJ Publishing Group 2001:248-82.

1
2
3
4 51 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. Users' guides to
5
6 the medical literature. A manual for evidence-based clinical practice. Chicago: AMA
7
8 Press, 2002; 121-40.
9

10
11 52 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in
12
13 mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-72.
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of SMPRs in sera

Study	Subjects, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	MPF	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

Portal et al ³⁴	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
Hollevoet et al ³⁶	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
Hollevoet et al ³⁶	507	MPF	13.46 ng/ml	58	13	27	409	20	11
Creaney et al ³⁷	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
Cristaudo et al ³⁸	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
Dipalma et al ³⁹	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
Ashour et al ⁴¹	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
Amany et al ⁴³	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
Ferro et al ⁴⁵	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
Hooper et al ⁴⁷	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12

SMRP = soluble mesothelin-related peptide; OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 2. Study summary of SMPRs in pleural fluids *

Study	Patients, n	SMPRs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Fujimoto et al ³⁵	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴⁰	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴¹	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴²	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴³	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁴	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Filiberti et al ⁴⁶	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁷	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMPR = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23, 24, 25, 26, 27, 28, 30, 31, 33, 34, 36, 37, 38, 39, 41, 43, 45, 47	22, 29, 30, 32, 36
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.66 (0.60 – 0.71)
Heterogeneity* (p)	70.03 (< 0.001)	50.26 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.95 (0.93 – 0.96)
Heterogeneity (p)	345.53 (< 0.001)	19.42 (0.001)
PLR (95% CI)	4.75 (3.51 – 6.44)	12.31 (6.21 – 24.42)
Heterogeneity (p)	179.04 (< 0.001)	15.48 (0.004)
NLR (95% CI)	0.45 (0.39 – 0.51)	0.30 (0.14 – 0.64)
Heterogeneity (p)	50.33 (< 0.001)	74.23 (< 0.001)
DOR (95% CI)	11.84 (7.91 – 17.70)	40.15 (16.55 – 97.39)
Heterogeneity (p)	92.67 (< 0.001)	12.07 (0.017)
AUC (SEM)	0.791 (0.035)	0.933 (0.083)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 44, 45	21, 23, 24, 25, 28, 30, 33, 39
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM vs other cancers	MPM vs benign diseases
Study, Ref. No.	23, 35, 40, 41, 46	35, 40, 41, 46
Sensitivity (95% CI)	0.75 (0.69 – 0.81)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.14 (0.887)	1.08 (0.783)
Specificity (95% CI)	0.75 (0.68 – 0.81)	0.87 (0.80 – 0.93)
Heterogeneity (p)	3.93 (0.416)	6.74 (0.081)
PLR (95% CI)	2.81 (2.13 – 3.70)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.22 (0.337)	7.01 (0.071)
NLR (95% CI)	0.34 (0.26 – 0.44)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.90 (0.755)	1.83 (0.608)
DOR (95% CI)	8.75 (5.41 – 14.15)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.28 (0.512)	5.26 (0.154)
AUC (SEM)	0.812 (0.026)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

1
2
3
4
5
6
7 Diagnostic values of soluble mesothelin-related peptides for malignant pleural
8 mesothelioma: updated meta-analyses
9
10

Comment [U1]: mesothelin family proteins (throughout)

Comment [U2]: added

11
12
13
14 Short running head: SMRPs in mesothelioma

15
16
17
18 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
19

20
21
22 * These authors contributed equally to the present work
23

24
25
26
27 ¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
28 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
29 Respiratory Diseases, Beijing, China.
30
31
32

33
34
35 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
36 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
37 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
38 85231412; E-mail: shihuanzhong@sina.com
39
40
41
42
43
44

45
46 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin-related peptides
47
48

49
50 **Word counts:** 2,822
51
52
53
54
55
56
57
58
59
60

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Funding: This work was supported by a grant from National Natural Science Foundation of China (No. 81270149).


Competing interests: The authors have declared that no conflict of interest exists.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ Group products and to exploit all subsidiary rights, as set out in our license set out at: http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data sharing statement: There is no additional data available.

For peer review only



1
2
3
4
5
6
7 ABSTRACT
8
9

10
11 **Objective** Although the values of soluble mesothelin-related peptides (SMRPs), including
12 mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for
13 diagnosing malignant pleural mesothelioma have been extensively studied, the exact
14 diagnostic accuracy of these SMRPs remains controversial. The purpose of the present
15 meta-analyses was to update the overall diagnostic accuracy of SMRPs in serum, and further
16 to establish that of SMRPs in pleural fluid for mesothelioma.
17
18
19

20
21 **Design** Systematic review and meta-analysis.
22
23

24
25 **Methods** In total, 27 articles from 30 diagnostic studies were included in the current
26 meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMRPs in serum
27 and pleural fluid for the diagnosis of malignant pleural mesothelioma were pooled using
28 random effects models. Summary receiver operating characteristic curves were used to
29 summarize overall test performance.
30
31
32


33
34 **Results** The summary estimates of sensitivity, specificity, positive likelihood ratio, negative
35 likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.63, 0.87, 5.68, 0.42, and
36 14.95, respectively; pleural fluid: 0.80, 0.83, 4.00, 0.30, and 15.31, respectively. It was also
37 found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy
38 compared to mesothelin for MPM.
39
40
41
42
43
44
45
46
47

48
49 **Conclusions** SMRPs in both serum and pleural fluid were helpful markers for diagnosing
50 MPM with similar diagnostic accuracy. The negative results of SMRP determinations were
51 not sufficiently to exclude non-MPM, and the positive test results indicated that further
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

invasive diagnostic steps might be necessary for the diagnosis of MPM.

For peer review only



ARTICLE SUMMARY

Article focus

- The diagnosis of MPM is always a challenging endeavor because.
- To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.
- The concentrations of soluble mesothelin-related peptides, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Key messages

- Soluble mesothelin-related peptides in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- The negative test results are not sufficiently to exclude non-mesothelioma, while the positive test results would indicate that further invasive diagnostic steps might be necessary.

Strengths and limitations of this study

- The studies included this meta-analysis were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural

Comment [U3]: is


Comment [U4]: revised

Comment [U5]: revised

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mesothelioma and the other diseases.

For peer review only



INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in malignant mesothelioma, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble megakaryocyte potentiating factor (MPF).⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin-related peptides (SMRPs), including both soluble mesothelin and MPF, have been found in human serum and pleural fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMRP detections for MPM has been extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we

1
2
3
4
5
6
7 performed and published first meta-analysis reporting the overall diagnostic accuracy of
8 serum SMRPs for diagnosing MPM, and our results showed that serum SMRP determinations
9 played a role in the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an
10 individual patient data meta-analysis to evaluate serum SMRP for diagnosing MPM, and
11 found that a positive test result at a high-specificity threshold is a strong incentive to urge
12 further diagnostic steps; however, the poor sensitivity of SMRPs limits its added value to
13 early diagnosis of MPM.¹² Since that time, many additional clinical studies determining the
14 concentrations of SMRPs in serum and PF have been reported. We thus performed the present
15 meta-analyses to update the overall diagnostic accuracy of serum SMRPs, and further to
16 establish that of PF SMRPs for diagnosing MPM.
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until July, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin-related peptides/SMRP”, “mesothelin”, “megakaryocyte potentiating factor/MPF”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were also searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMRP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected in the study, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ). Data retrieved from the reports included author, publication year, study characteristics,

Comment [U6]: revised

1
2
3
4
5
6
7 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
8
9 and methodological quality. All eligible studies were assessed for methodologic quality using
10
11 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
12
13 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
14
15 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
16
17 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
18
19 consensus to assess the quality of primary studies of diagnostic accuracy).
20
21
22
23

24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38

39
40 The analyses were based on a summary receiver operating characteristic (SROC)
41
42 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
43
44 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
45
46 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
47
48 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
49
50 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
51
52 potential presence of this bias using funnel plots and the Egger test.²⁰
53
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, fifty-six publications determining concentrations of human SMRPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, twenty-nine were excluded (Appendix excluded references, available online).

Subsequently, twenty-seven publications²¹⁻⁴⁷ were available for analysis of diagnostic accuracy of SMRPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 16 publications from 18 studies³²⁻⁴⁷ were added in the current meta-analyses.

The methods of determining SMRPs in all studies included were enzyme-linked immunosorbent assay. Serum mesothelin concentrations were determined in 20 studies (19 articles),^{21,23-28,30,31,33,34,36-39,41,43,45,47} and serum MPF concentrations were determined in 5 studies^{22,29,30,32,36} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMRP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. In addition, another 2 articles^{30,36} were also treated as independent studies, since both mesothelin and MPF in serum were investigated in these 2 articles. PF mesothelin concentrations were determined in 9 studies.^{23,35,40-44,46,47}

The clinical characteristics of the studies, along with STARD and QUADAS scores, are outlined in Table 1 and Table 2.

Comment [U7]: Online supplementary appendix 1

Study characteristics

On review, the studies showed large differences in number of participants, clinical characteristics (especially histologic subtypes of MPM, and type of control groups), and reported diagnostic cut-off values of SMRPs (Appendix Table 1). For serum SMRP studies, the average samples size was 270 (range from 40 – 1,086), the subjects included 1,046 patients with MPM and 5,356 non-MPM. For PF SMRP studies, the average samples size was 127 (range from 40 – 275), the subjects included 352 patients with MPM and 794 non-MPM.

Except for 2 studies, all samples were collected from the consecutive patients in the remaining 28 studies. Nine studies reported blinded interpretation of SMRP assays independent of the reference standard. Eight studies reported the study design was prospective. In 21 studies, MPM diagnosis was completely based on pathological findings in pleural biopsies, with or without positive cytological results; while in the remaining 9 studies, some MPM patients were diagnosed just based on the cytological findings. Totally, the quality of study design and reporting diagnostic accuracy of most studies were good, since 23 of 27 publications had higher STARD scores (≥ 13) and 18 studies had higher QUADAS scores (≥ 10).

Publication bias

The funnel plots for publication bias showed asymmetry for serum SMRP studies (Figure 1A), evaluation of publication bias showed that Egger tests were significant for serum SMRPs ($p = 0.044$). Although the funnel plots for publication bias showed somehow asymmetry due to the

Comment [U8]: Online supplementary appendix 2

Comment [U9]: revised

1
2
3
4
5
6
7 limited number of PF SMRP studies (Figure 1B), Egger tests showed that this was not
8 significant for PF SMRPs ($p = 0.149$). These results indicated a potential for publication bias
9 for serum SMRP, but not for PF SMRP studies.
10
11
12

13 14 15 16 **Diagnostic accuracy**

17
18 Figure 2A shows forest plot of sensitivity and specificity for 25 serum SMRP assays in the
19 diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.63, 95% CI 0.60 –
20 0.65), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was
21 also noted that PLR was 5.68 (95% CI 4.15 – 7.76), NLR was 0.42 (95% CI 0.36 – 0.49), and
22 DOR was 14.95 (95% CI 9.93 – 22.50). X^2 values of sensitivity, specificity, PLR, NLR, and
23 DOR were 121.53, 443.37, 261.05, 107.18, and 137.67, respectively, with all $p < 0.001$,
24 indicating a significant heterogeneity between studies.
25
26
27
28
29
30
31
32

33
34 Figure 2B shows forest plot of sensitivity and specificity 9 PF SMRP assays in the
35 diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.80, 95% CI 0.76 –
36 0.84), while specificity ranged from 0.65 – 0.90 (pooled 0.83, 95% CI 0.80 – 0.85). We also
37 noted that PLR was 4.00 (95% CI 2.98 – 5.36), NLR was 0.30 (95% CI 0.23 – 0.39), and
38 DOR was 15.31 (95% CI 9.32 – 25.16). X^2 values of sensitivity, specificity, PLR, NLR, and
39 DOR were 37.07 ($p < 0.001$), 30.45 ($p < 0.001$), 23.85 ($p = 0.002$), 11.30 ($p = 0.185$), and
40 15.14 ($p = 0.056$), respectively, indicating somehow a heterogeneity between studies.
41
42
43
44
45
46
47
48

49
50 The graphs of SROC curves for SMRP determinations showing sensitivity versus 1 –
51 specificity from individual studies are shown in Figure 3. SROC curve of serum SMRPs was
52 not positioned near the desirable upper left corner of SROC curve, and that the maximum
53
54
55
56
57
58
59
60

Comment [U10]: studies

Comment [U11]: studies

Comment [U12]: some

Comment [U13]: deleted

1
2
3
4
5
6
7 joint sensitivity and specificity was 0.737 (SEM, 0.031) (Figure 3A); while area under curve
8
9 (AUC) was 0.802 (SEM, 0.035). The maximum joint sensitivity and specificity of PF SMRP
10
11 was 0.805 (SEM, 0.022); while AUC was 0.875 (SEM, 0.023) (Figure 3B).

12
13
14 Totally, the diagnostic performance of SMRPs in serum and PF was similar.

15 16 17 18 **Subgroup analysis**

19
20 We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the
21
22 results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR,
23
24 NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of
25
26 serum mesothelin.
27

28
29 Data from 6 studies ^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of
30
31 serum SMRPs differentiating MPM from healthy control subjects, 9 studies
32
33 ^{21,23,24,26,30,31,33,44,45} were available for comparing that of differentiating MPM from other
34
35 malignancies, 8 studies ^{21,23,24,25,28,30,33,39} were available for comparing that of differentiating
36
37 MPM from asbestos-exposed subjects. As shown in Table 4, the values of sensitivity,
38
39 specificity, PLR, NLR, DOR, and AUC of SMRPs for discriminating MPM from healthy
40
41 control subjects were quite acceptable, which were better than those for discriminating MPM
42
43 from patients with the other cancers or from asbestos-exposed people. By using serum
44
45 SMRPs, it was the most difficult to identify MPM from other cancers, compared with from
46
47 healthy controls or asbestos-exposed people.
48
49

50
51 Five studies ^{23,35,40,41,46} provided required data for comparing diagnostic accuracy of PF
52
53 mesothelin differentiating MPM from the other cancers, and 4 studies ^{35,40,41,46} for
54
55

1
2
3
4
5
6
7 differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of
8
9 PF SMRP differentiating MPM from the other cancers was very similar to that of
10
11 differentiating MPM from benign pleural effusions.
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{48,49}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMRPs was 0.63 and 0.80, respectively; and their specificity was 0.87 and 0.83 respectively. These data indicated that sensitivity and specificity of SMRPs in serum and PF were not as high as expected. The positive SMRPs results might be somehow helpful in confirming (ruling in) MPM, suggesting that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. However, the relative low sensitivity, especially serum SMRPs, that was not sufficiently low to exclude non-MPM when a patient's SMRP results were lower than the cut-off values. Therefore, the associated poor sensitivity of SMRPs clearly limits their added value to diagnosis of MPM.

As previously described,¹¹ Unlike a traditional ROC plot that explores the effect of varying cut-off values on sensitivity and specificity in a single study, each data point in the SROC plot represents a separate study. The SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMRPs were 0.737 and 0.805, respectively; while their AUCs were 0.802 and 0.875,

Comment [U15]: revised

Comment [U16]: added

Comment [U17]: deleted

1
2
3
4
5
6
7 respectively, indicating level of overall accuracy were also not as high as expected.

8
9 The DOR is a single indicator of test accuracy⁵⁰ that combines the data from sensitivity
10 and specificity into a single number. The DOR of a test is the ratio of the odds of positive test
11 results in the diseased relative to the odds of positive test results in the non-diseased. The
12 value of a DOR ranges from 0 to infinity, with higher values indicating better discriminatory
13 test performance. A DOR of 1.0 indicates that a test does not discriminate between patients
14 with the disorder and those without it. In the current meta-analyses, we found that the pooled
15 DORs of serum and PF SMRPs were 14.95, and 15.31, respectively, indicating that SMRPs
16 seemed to be helpful in the diagnosis of MPM.
17
18
19
20
21
22
23
24
25
26

27 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
28 PLR and NLR are considered more clinically meaningful,^{51,52} we further presented both PLR
29 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
30 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
31 (indicating high accuracy).⁵³ A PLR value of 5.68 with serum SMRPs suggests that patients
32 with MPM have a near 6-fold higher chance of being SMRP-positive compared with patients
33 without MPM, and this was not high enough for the clinical purpose. This might lead to an
34 inordinate number of individuals undergoing unnecessary diagnostic work-ups or biopsies. On
35 the other hand, NLR of serum SMRPs was found to be 0.42. If serum SMRP results were
36 negative, the probability that this patient has MPM is 42%, which is not low enough to rule
37 out MPM. The very similar results were found with PF SMRPs.
38
39
40
41
42
43
44
45
46
47
48
49
50

51 Although both mesothelin and MPF belong to SMRPs, we noted in the current
52 meta-analyses that the overall diagnostic measures, including sensitivity, specificity, PLR,
53
54
55

1
2
3
4
5
6
7 NLR, DOR, and AUC, of serum MPF, were better than those of serum mesothelin. Therefore,
8
9 MPF had a superior diagnostic accuracy compared to mesothelin for MPM. We also noted
10
11 that diagnostic performance of serum SMRP for discriminating MPM from healthy control
12
13 subjects was the best (although not as good as expected), followed by that for discriminating
14
15 MPM from patients with other cancers or from asbestos-exposed people. In addition, the
16
17 overall diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was
18
19 similar to that of differentiating MPM from benign pleural effusions.
20
21

22
23 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
24
25 letters to the editors, and non-English language studies may have led to publication bias.
26
27 Indeed, we observed a publication bias for serum SMRP studies, but not for PF SMRP studies.
28
29 Publication bias may also be introduced by inflation of diagnostic accuracy estimates since
30
31 studies that report positive results are more likely to be accepted for publication. Second,
32
33 pathological types of MPM were not specified in 2 studies,^{34,41} epithelioid subtype of MPM
34
35 was the most common pathological type in all remaining studies, but not one.²⁵ Totally, 69.9%
36
37 (982/1404) MPM were epithelioid subtype (ranged from 29.9% to 100%). Analysis in terms
38
39 of histologic type has shown that SMRP levels were significantly elevated in epithelioid
40
41 subtype MPM than other types.^{21,23,29} This could explain partly the quite low sensitivity of
42
43 SMRPs in MPM diagnosis. Third, control groups were very heterogeneous from one study to
44
45 another; and various cutoff points were used for distinguishing between MPM and controls,
46
47 other cancers or benign respiratory diseases, according to the best combination of sensitivity
48
49 and specificity. Fourth, multiple assays were available for determining mesothelin
50
51 concentrations, and Mesomark, which has been approved by the US Food and Drug
52
53
54
55
56
57
58
59
60

Comment [U22]: revised

1
2
3
4
5
6
7 Administration, was used in most studies. The other mesothelin ELISA kits were used in 4
8
9 studies.^{21, 30, 31, 35} These issues regarding accuracy of diagnosis could also lead to biased
10
11 results

Comment [U23]: added

12
13
14 In conclusion, current evidence supported that SMRPs in both serum and PF were
15
16 helpful markers for the diagnosis of MPM. The overall diagnostic performance of SMRPs in
17
18 serum and PF was similar, and serum MPF had superior diagnostic accuracy compared to
19
20 serum mesothelin. The negative results of SMRP determinations were not sufficiently to
21
22 exclude non-MPM; on the other hand, the positive test results would indicate that further
23
24 invasive diagnostic steps might be necessary and could possibly lead to an earlier diagnosis.
25
26

Comment [U24]: revised

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.
- 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in

- mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.
- 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. *Pathol Int* 2006; 56:649-54.
- 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
- 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
- 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012; 30:1541-9.
- 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
- 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003; 3:25.
- 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
- 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 1993; 12:1293-316.
- 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.

- 1
2
3
4
5
6
7 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
8
9 J Clin Epidemiol 1995; 48:119-30.
10
11 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
12
13 review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-86.
14
15 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
16
17 graphical test. BMJ 1997; 315:629-34.
18
19 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
20
21 mesothelioma. Lancet 2003; 362:1612-6.
22
23 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
24
25 mesothelin precursor is a useful tumor marker in the serum of patients with
26
27 mesothelioma. Clin Cancer Res 2006; 12:4225-31.
28
29 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
30
31 diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;
32
33 173:1155-60.
34
35 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
36
37 pleural mesothelioma. Clin Chem 2007; 53:666-72.
38
39 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
40
41 diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
42
43 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
44
45 patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
46
47 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
48
49 mesothelioma: analytical evaluation of an automated immunoassay and preliminary
50
51
52
53
54
55
56
57
58
59
60

clinical results. *Clin Chem Lab Med* 2007; 45:634-8.

- 28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol Biomarkers Prev* 2008; 17:163-70.
- 29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.
- 30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung Cancer* 2008; 62:45-54.
- 31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.
- 32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.
- 33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.
- 34 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers Prev* 2009; 18:646-50.

- 1
2
3
4
5
6
7 35 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
8
9 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
10 1:313-7.
11
12
13 36 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
14 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
15 *Care Med* 2010; 181:620-5.
16
17
18 37 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
19 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
20 2011; 74:55-60.
21
22
23 38 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
24 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
25 6:1587-93.
26
27
28 39 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
29 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
30 26:160-5.
31
32
33 40 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
34 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.
35
36
37 41 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin
38 and osteopontin for the diagnosis of malignant pleural mesothelioma. *Egyptian*
39 *Journal of Chest Diseases and Tuberculosis* 2012; 61:121-8.
40
41
42 42 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination
43 improves the diagnosis of mesothelioma in pleural effusions. *J Thorac Oncol* 2012;
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

7:883-9.

43 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis. *Egyptian Journal of Chest Diseases and Tuberculosis* 2013; 62:115-20.

44 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. *Cancer Invest* 2013; 31:43-50.

45 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. *Anticancer Res* 2013; 33:2707-13.

46 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. *Med Oncol* 2013; 30:543.

47 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. *Eur Respir J* 2013; 41:18-24.

48 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.

49 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant pleural mesothelioma. *Biomark Med* 2011; 5:261-73.

50 Glas AS, Lijmer JG, Prins MH, et al. The diagnostic odds ratio: a single indicator of test performance. *J Clin Epidemiol* 2003; 56:1129-35.

51 JJ D. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M,

Comment [U25]: deleted

Comment [U26]: corrected

1
2
3
4
5
6
7 Smith GD, Altman DG, eds. Systematic reviews in health care. Meta-analysis in
8 context. London: BMJ Publishing Group 2001:248-82.
9

10
11 52 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. Users' guides to
12 the medical literature. A manual for evidence-based clinical practice. Chicago: AMA
13 Press, 2002; 121-40.
14
15

16
17
18 53 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in
19 mesothelioma serum and pleural effusions. Ann Thorac Surg 2008; 85:265-72.
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of SMPRs in sera

Study	Subjects, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	MPF	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Portal et al ³⁴	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
Hollevoet et al ³⁶	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
Hollevoet et al ³⁶	507	MPF	13.46 ng/ml	58	13	27	409	20	11
Creaney et al ³⁷	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
Cristaudo et al ³⁸	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
Dipalma et al ³⁹	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
Ashour et al ⁴¹	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
Amany et al ⁴³	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
Ferro et al ⁴⁵	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
Hooper et al ⁴⁷	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12

SMRP = soluble mesothelin-related peptide; OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49




Table 2. Study summary of SMPRs in pleural fluids *

Study	Patients, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Fujimoto et al ³⁵	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴⁰	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴¹	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴²	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴³	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁴	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Filiberti et al ⁴⁶	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁷	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMRP = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23, 24, 25, 26, 27, 28, 30, 31, 33, 34, 36, 37, 38, 39, 41, 43, 45, 47	22, 29, 30, 32, 36
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.66 (0.60 – 0.71)
Heterogeneity* (p)	70.03 (< 0.001)	50.26 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.95 (0.93 – 0.96)
Heterogeneity (p)	345.53 (< 0.001)	19.42 (0.001)
PLR (95% CI)	4.75 (3.51 – 6.44)	12.31 (6.21 – 24.42)
Heterogeneity (p)	179.04 (< 0.001)	15.48 (0.004)
NLR (95% CI)	0.45 (0.39 – 0.51)	0.30 (0.14 – 0.64)
Heterogeneity (p)	50.33 (< 0.001)	74.23 (< 0.001)
DOR (95% CI)	11.84 (7.91 – 17.70)	40.15 (16.55 – 97.39)
Heterogeneity (p)	92.67 (< 0.001)	12.07 (0.017)
AUC (SEM)	0.791 (0.035)	0.933 (0.083)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 44, 45	21, 23, 24, 25, 28, 30, 33, 39
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM vs other cancers	MPM vs benign diseases
Study, Ref. No.	23, 35, 40, 41, 46	35, 40, 41, 46
Sensitivity (95% CI)	0.75 (0.69 – 0.81)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.14 (0.887)	1.08 (0.783)
Specificity (95% CI)	0.75 (0.68 – 0.81)	0.87 (0.80 – 0.93)
Heterogeneity (p)	3.93 (0.416)	6.74 (0.081)
PLR (95% CI)	2.81 (2.13 – 3.70)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.22 (0.337)	7.01 (0.071)
NLR (95% CI)	0.34 (0.26 – 0.44)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.90 (0.755)	1.83 (0.608)
DOR (95% CI)	8.75 (5.41 – 14.15)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.28 (0.512)	5.26 (0.154)
AUC (SEM)	0.812 (0.026)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.




Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.
 162x69mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.
101x118mm (300 x 300 DPI)




Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin-related peptides in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.
205x101mm (300 x 300 DPI)

Review only

Online supplementary appendix 1

Excluded References

One were excluded because it recruited less than 10 patients in one of study groups [1], seven were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered [2-8], twenty-one were excluded because they did not allow the calculation of sensitivity or specificity [9-29].

1. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. *Cancer Sci* 2006; 97(9): 928-932.
2. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein--a blood test for mesothelioma. *Lung Cancer* 2005; 49 Suppl 1: S109-111.
3. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. *J Thorac Oncol* 2006; 1(2): 172-174.
4. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. *Clin Cancer Res* 2006; 12(2): 447-453.
5. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. *Clin Cancer Res* 2007; 13(10): 2928-2935.
6. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85(1): 265-272; discussion 272.

- 1
2
3
4 7. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P,
5 Lassalle P, Scherpereel A. Serum mesothelin has a higher diagnostic utility than hyaluronic
6 acid in malignant mesothelioma. *Clin Biochem* 2009; 42(10-11): 1046-1050.
- 7
8
9
10 8. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P, Bosquee L,
11 Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical
12 covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte
13 potentiating factor. *Chest* 2012; 141(2): 477-484.
- 14
15
16
17 9. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N,
18 Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of
19 malignant mesothelioma. *Thorax* 2007; 62(7): 569-576.
- 20
21
22
23 10. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, Johnen G. Soluble mesothelin-related
24 peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. *Cancer*
25 *Biomark* 2007; 3(6): 287-292.
- 26
27
28
29 11. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson
30 B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant
31 mesothelioma: a nested case-control study. *Lung Cancer* 2008; 61(2): 235-243.
- 32
33
34
35 12. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte
36 H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant
37 pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009; 179(10): 950-954.
- 38
39
40
41 13. Aleman C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de
42 Sevilla TF. Pleural fluid mesothelin for the differential diagnosis of exudative pleural
43 effusions. *Med Clin (Barc)* 2009; 133(12): 449-453.
- 44
45
46
47 14. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V,
48 Fleisher M. Soluble mesothelin related peptides (SMRP) and osteopontin as protein
49 biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and
50 characterization at mRNA and protein levels. *Clin Chem Lab Med* 2010; 48(2): 271-278.
- 51
52
53
54 15. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson
55 BW. Serum mesothelin for early detection of asbestos-induced cancer malignant
56 mesothelioma. *Cancer Epidemiol Biomarkers Prev* 2010; 19(9): 2238-2246.
- 57
58
59
60

- 1
2
3
4 16. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC,
5 O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G.
6 Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant
7 mesothelioma. *J Clin Oncol* 2010; 28(20): 3316-3322.
8
9
10
11 17. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Muller-Lux A, Gross IM,
12 Wiethage T, Weber A, Raithel HJ, Kraus T, Bruning T. Performance of biomarkers SMRP,
13 CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung
14 cancer in a cohort of workers formerly exposed to asbestos. *Arch Toxicol* 2011; 85(3):
15 185-192.
16
17
18 18. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum
19 soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor
20 volume, clinical stage and changes in tumor burden. *Clin Cancer Res* 2011; 17(5): 1181-1189.
21
22
23 19. Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, Sugarbaker
24 DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT. The relationship between
25 tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. *Epigenetics* 2011;
26 6(8): 1029-1034.
27
28
29 20. Imashimizu K, Shiomi K, Maeda M, Aoki N, Igarashi K, Suzuki F, Koizumi M, Suzuki K,
30 Hino O. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for
31 the early diagnosis of malignant mesothelioma. *Exp Ther Med* 2011; 2(3): 409-411.
32
33
34 21. Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K,
35 Germonpre P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Serial measurements
36 of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective
37 longitudinal cohort study. *J Thorac Oncol* 2011; 6(5): 889-895.
38
39
40 22. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, Germonpre
41 P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP. Soluble mesothelin,
42 megakaryocyte potentiating factor, and osteopontin as markers of patient response and
43 outcome in mesothelioma. *J Thorac Oncol* 2011; 6(11): 1930-1937.
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 23. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function--analysis
5 of relationship and implications for mesothelioma screening. *Lung Cancer* 2011; 73(3):
6 320-324.
7
8
9
10 24. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V,
11 Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J,
12 Tomasetti M. Association of MiR-126 with soluble mesothelin-related peptides, a marker for
13 malignant mesothelioma. *PLoS One* 2011; 6(4): e18232.
14
15
16
17 25. Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in
18 soluble mesothelin-related protein (SMRP) levels. *Clin Chem Lab Med* 2012; 50(12):
19 2199-2204.
20
21
22
23 26. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related
24 peptides levels in patients with malignant mesothelioma. *Dis Markers* 2012; 32(2): 123-131.
25
26
27 27. Mori T, Tajima K, Hiramata M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K,
28 Maeda M, Hino O, Takahashi K. The N-ERC index is a novel monitoring and prognostic
29 marker for advanced malignant pleural mesothelioma. *J Thorac Dis* 2013; 5(2): 145-148.
30
31
32 28. Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J. Combination of
33 Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural
34 Mesothelioma, Benign Asbestos Disease, and Lung Cancer. *J Thorac Oncol* 2013; 8(7):
35 947-951.
36
37
38 29. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW. Does
39 CA125 binding to mesothelin impact the detection of malignant mesothelioma? *Lung Cancer*
40 2013; 80(1): 39-44.
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4 **Online supplementary appendix 2**
5
6
7
8

9
10 **The characteristics of subjects studied**

Study	MPM Patients	Non-MPM Subjects
Robinson et al ²¹	Epithelioid type (n = 25) Sarcomatoid type (n = 4) Other or not specified (n = 15)	Healthy controls without asbestos exposure (n = 28) Healthy controls with asbestos exposure (n = 40) Patients with inflammatory non-pleural lung disease (n = 92) Patients with non-MPM pleural diseases (n = 38) Patients with non-pleural malignant lung disease (n = 30)
Onda et al ²²	Epithelioid type (n = 56)	Healthy controls (n = 70)
Scherpereel et al ²³	Epithelioid type (n = 55) Sarcomatoid type (n = 6) Other or not specified (n = 13)	Patients with benign asbestos-related pleural diseases (n = 28) Patients with pleural metastasis of carcinomas (n = 35)
Beyer et al ²⁴	Epithelioid type (n = 59) Sarcomatoid type (n = 8) Other or not specified (n = 21)	Healthy controls (n = 409) Patients with non-MPM malignancy (n = 412) Patients with nonmalignant conditions (n = 116)

		Subjects with asbestos exposure (n = 61)
Creaney et al ²⁵	Epithelioid type (n = 35) Sarcomatoid type (n = 15) Other or not specified (n = 67)	Healthy controls with asbestos exposure (n = 33) Patients with benign asbestos-related diseases (n = 53) Patients with benign pleural effusions (n = 30)
Cristaudo et al ²⁶	Epithelioid type (n = 72) Sarcomatoid type (n = 10) Other or not specified (n = 25)	Healthy controls (n = 262) Patients with benign respiratory diseases (n = 130) Patients with lung cancer (n = 215)
Di Serio et al ²⁷	Epithelioid type (n = 20) Sarcomatoid type (n = 2) Other or not specified (n = 2)	Healthy controls with asbestos exposure (n = 26) Patients with asbestos-related diseases (n = 66)
Amati et al ²⁸	Epithelioid type (n = 11) Sarcomatoid type (n = 6) Other or not specified (n = 5)	Healthy controls without asbestos exposure (n = 54) Subjects with asbestos exposure (n = 94)
Shiomi et al ²⁹	Epithelioid type (n = 21) Sarcomatoid type (n = 9) Other or not specified (n = 9)	Patients with benign asbestos-related diseases and healthy controls with asbestos exposure (n = 24) Patients with lung cancer (n = 4) Others (n = 8)
Iwahori et al ³⁰	Epithelioid type (n = 13)	Healthy controls without asbestos exposure (n = 38)

	Sarcomatoid type (n = 3) Other or not specified (n = 11)	Healthy controls with asbestos exposure (n = 9) Patients with lung cancer (n = 47) Patients with other cancers (n = 5)
van den Heuvel ³¹	Epithelioid type (n = 43) Sarcomatoid type (n = 10) Other or not specified (n = 20)	Healthy controls (n = 50) Patients with lung cancer (n = 10)
Creaney et al ³²	Epithelioid type (n = 57) Sarcomatoid type (n = 9)	Healthy controls without asbestos exposure (n = 10) Healthy controls with asbestos exposure (n = 10) Patients with benign asbestos-related diseases (n = 21) Patients with lung cancer (n = 10)
Schneider et al ³³	Epithelioid type (n = 81) Sarcomatoid type (n = 14) Other or not specified (n = 34)	Patients with lung cancer (n = 139) Patients with benign asbestos-related diseases (n = 75)
Portal et al ³⁴	Not specified (n = 36)	Healthy controls (n = 48) Patients with asbestos exposure and no pleural disease (n = 177) Patients with benign asbestos-related diseases (n = 101)
Fujimoto et al ³⁵	Epithelioid type (n = 15) Sarcomatoid type (n = 4)	Patients with lung cancer (n = 38) Patients with benign asbestos pleurisy (n = 26)

	Other or not specified (n = 4)	Patients with tuberculosis pleurisy (n = 5) Patients with no pleural diseases (n = 4)
Hollevoet et al ³⁶	Epithelioid type (n = 73) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Healthy controls (n = 101) Healthy controls with asbestos exposure (n = 89) Patients with benign asbestos-related diseases (n = 123) Patients with benign respiratory diseases (n = 46) Patients with lung cancer (n = 63)
Creaney et al ³⁷	Epithelioid type (n = 59) Other or not specified (n = 7)	Patients with benign asbestos-related diseases (n = 47) Patients with benign respiratory diseases (n = 42)
Cristaudo et al ³⁸	Epithelioid type (n = 31)	Healthy controls (n = 93) Patients with benign respiratory diseases (n = 111)
Dipalma et al ³⁹	Epithelioid type (n = 29) Sarcomatoid type (n = 4) Other or not specified (n = 3)	Healthy controls without asbestos exposure (n = 109) Healthy controls with asbestos exposure (n = 26) Patients with benign asbestos-related diseases (n = 48) Patients with benign respiratory diseases (n = 110) Patients with lung cancer (n = 25)
Yamada et al ⁴⁰	Epithelioid type (n = 37) Sarcomatoid type (n = 5)	Patients with non-malignant pleural effusions (n = 24) Patients with lung cancer involving malignant pleural effusion (n =

bmjopen-2013-004145 on 24 February 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2025 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

	Other or not specified (n = 3)	29)
Ashour et al ⁴¹	Not specified (n = 38)	Healthy controls with asbestos exposure (n = 32) Patients with benign pleural diseases (n = 29) Patients with pleural carcinomas (n = 24)
Blanquart et al ⁴²	Epithelioid type (n = 49) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Patients with adenocarcinoma effusions (n = 25) Patients with benign pleural effusions (n = 15)
Amany et al ⁴³	Epithelioid type (n = 14) Sarcomatoid type (n = 4) Other or not specified (n = 2)	Patients with benign asbestos pleural effusions (n = 10) Patients with tuberculosis pleural effusions (n = 10)
Canessa et al ⁴⁴	Epithelioid type (n = 35) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignant effusions (n = 94) Patients with benign pleural effusions (n = 129)
Ferro et al ⁴⁵	Epithelioid type (n = 26) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignancy (n = 23) Patients with benign diseases (n = 36)
Filiberti et al ⁴⁶	Epithelioid type (n = 43) Sarcomatoid type (n = 3)	Patients with malignant effusions (n = 64) Patients with benign effusions (n = 56)

bmjopen-2013-004145 on 2 February 2014. Downloaded from http://bmjopen.bmj.com/ on April 18, 2024 by guest. Protected by copyright.

	Other or not specified (n = 2)	
Hooper et al ⁴⁷	Epithelioid type (n = 23)	Patients with non-MPM malignant effusions (n = 74)
	Sarcomatoid type (n = 3)	Patients with benign asbestos-related effusions (n = 13)
	Other or not specified (n = 2)	Patients with benign pleural diseases (n = 100)

MPM = malignant pleural mesothelioma.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	0-2
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	7,8
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	11
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	12
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	12
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	12
<i>Test methods</i>	7	The reference standard and its rationale.	12
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	12
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	11,12
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	12
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	N/A
	13	Methods for calculating test reproducibility, if done.	N/A
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	N/A
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	11
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	12
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	12-15
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	14,15
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	14,15
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	18,19



Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004145.R2
Article Type:	Research
Date Submitted by the Author:	06-Dec-2013
Complete List of Authors:	Cui, Ai; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Jin, Xiao-Guang; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Zhai, Kan; Beijing Institute of Respiratory Diseases, Center of Medical Research Tong, Zhao-Hui; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Shi, Huan-Zhong; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine
Primary Subject Heading:	Diagnostics
Secondary Subject Heading:	Diagnostics, Respiratory medicine
Keywords:	Adult thoracic medicine < THORACIC MEDICINE, Immunology < THORACIC MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts

only

1
2
3
4 Diagnostic values of soluble mesothelin-related peptides for malignant pleural
5
6 mesothelioma: updated meta-analyses
7
8
9

10
11 Short running head: SMRPs in mesothelioma
12
13

14
15
16 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
17
18
19

20
21 * These authors contributed equally to the present work
22
23
24
25

26 ¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
27
28 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
29
30 Respiratory Diseases, Beijing, China.
31
32
33
34
35

36 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
37
38 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
39
40 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
41
42 85231412; E-mail: shihuanzhong@sina.com
43
44
45
46
47
48

49 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin family proteins
50
51
52
53

54 **Word counts:** 2,767
55
56
57
58
59
60

ABSTRACT

Objective Although the values of soluble mesothelin-related peptides (SMRPs), including mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact diagnostic accuracy of these SMRPs remains controversial. The purpose of the present meta-analyses was to update the overall diagnostic accuracy of SMRPs in serum, and further to establish that of SMRPs in pleural fluid for MPM.

Design Systematic review and meta-analysis.

Methods In total, 30 articles of diagnostic studies were included in the current meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMRPs in serum and pleural fluid for the diagnosis of MPM were pooled using random effects models. Summary receiver operating characteristic curves were used to summarize overall test performance.

Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.61, 0.87, 5.71, 0.43, and 14.43, respectively; pleural fluid: 0.79, 0.85, 4.78, 0.30, and 19.50, respectively. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared to mesothelin for MPM.

Conclusions SMRPs in both serum and pleural fluid were helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMRP determinations were

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

not sufficiently to exclude non-MPM, and the positive test results indicated that further
invasive diagnostic steps might be necessary for the diagnosis of MPM.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-004145 on 24 February 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

ARTICLE SUMMARY

Article focus

- The diagnosis of malignant pleural mesothelioma is always a challenging endeavor.
- To date, no single marker or panel of soluble biomarkers is available for a clear diagnosis of malignant pleural mesothelioma.
- The concentrations of soluble mesothelin-related peptides, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Key messages

- Soluble mesothelin-related peptides in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- Determination of soluble mesothelin-related peptides might be helpful in confirming pleural mesothelioma if the results were higher than the cut-off values, while the negative results were not sufficiently to exclude non-mesothelioma.

Strengths and limitations of this study

- The studies included this meta-analyses were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

mesothelioma and the other diseases.

For peer review only

BMJ Open: first published as 10.1136/bmjopen-2013-004145 on 24 February 2014. Downloaded from <http://bmjopen.bmj.com/> on April 18, 2024 by guest. Protected by copyright.

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in MPM, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble 31-kD N-terminal fraction, megakaryocyte potentiating factor (MPF), also denominated “N-ERC/mesothelin”.⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin-related peptides (SMRPs), including both soluble mesothelin and MPF, have been found in human serum and pleural fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMRP detections for MPM has been

1
2
3 extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we
4
5 performed and published first meta-analysis reporting the overall diagnostic accuracy of
6
7 serum SMRPs for diagnosing MPM, and our results showed that serum SMRP determinations
8
9 played a role in the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an
10
11 individual patient data meta-analysis to evaluate serum SMRP for diagnosing MPM, and
12
13 found that a positive test result at a high-specificity threshold is a strong incentive to urge
14
15 further diagnostic steps; however, the poor sensitivity of SMRPs limits its added value to
16
17 early diagnosis of MPM.¹² Since that time, many additional clinical studies determining the
18
19 concentrations of SMRPs in serum and PF have been reported. We thus performed the present
20
21 meta-analyses to update the overall diagnostic accuracy of serum SMRPs, and further to
22
23 establish that of PF SMRPs for diagnosing MPM.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until November 28, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin-related peptides/SMRP”, “mesothelin”, “megakaryocyte potentiating factor/MPF”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were further searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMRP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected to be included in the meta-analyses, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ). Data retrieved from the reports included author, publication year, study characteristics,

1
2
3
4 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
5
6 and methodological quality. All eligible studies were assessed for methodologic quality using
7
8 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
9
10 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
11
12 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
13
14 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
15
16 consensus to assess the quality of primary studies of diagnostic accuracy).
17
18
19

20 21 22 23 24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38
39

40
41 The analyses were based on a summary receiver operating characteristic (SROC)
42
43 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
44
45 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
46
47 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
48
49 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
50
51 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
52
53 potential presence of this bias using funnel plots and the Egger test.²⁰
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, sixty-two publications determining concentrations of human SMRPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, thirty-two were excluded (Online supplementary appendix 1). Subsequently, thirty publications²¹⁻⁵⁰ were available for analysis of diagnostic accuracy of SMRPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 19 publications from 28 studies³²⁻⁵⁰ were added in the current meta-analyses.

Multiple ELISA kits were available for determining SMRP concentrations. Mesomark, which has been approved by the US Food and Drug Administration, was used to determine mesothelin in most studies, and the other mesothelin ELISA kits were used in the other 4 studies.^{21,30,31,34} Serum mesothelin concentrations were determined in 23 studies (22 articles),^{21,23-31,33,35,37-40,42,44,46,47,49,50} and serum MPF concentrations were determined in 5 studies^{22,30,32,37,46} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMRP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. SMRP concentrations in PF were determined in 11 articles from 12 studies (mesothelin in 11 and MPF in 1) (Table 2).^{23,34,36,41-47,49}

The clinical characteristics of the studies, along with STARD and QUADAS scores, are

1
2
3 outlined in Table 1 and Table 2.
4
5
6
7

8 **Study characteristics**

9
10 On review, the studies showed large differences in number of participants, clinical
11 characteristics (especially histologic subtypes of MPM, and type of control groups), and
12 reported diagnostic cut-off values of SMRPs (Online supplementary appendix 2). For serum
13 SMRP studies, the average samples size was 265 (range from 40 – 1,086), the subjects
14 included 1,562 patients with MPM and 5,988 non-MPM. For PF SMRP studies, the average
15 samples size was 126 (range from 40 – 275), the subjects included 460 patients with MPM
16 and 1,046 non-MPM.
17
18
19
20
21
22
23
24
25
26
27

28
29 In 21 publications, MPM diagnosis was completely based on pathological findings in
30 pleural biopsies, with or without positive cytological results; while in the remaining 9
31 publications, some MPM patients were diagnosed just based on the cytological findings.
32
33 Totally, the quality of study design and reporting diagnostic accuracy of most studies were
34 good, since 26 of 30 publications had higher STARD scores (≥ 13) and 21 studies had higher
35 QUADAS scores (≥ 10).
36
37
38
39
40
41
42
43
44
45

46 **Publication bias**

47
48 The funnel plots for publication bias showed asymmetry for serum SMRP studies (Figure 1A),
49 evaluation of publication bias showed that Egger tests were significant for serum SMRPs ($p =$
50 0.038). Similarly, the funnel plots for publication bias also showed asymmetry for PF SMRP
51 studies (Figure 1B), Egger tests showed that this was significant for PF SMRPs ($p = 0.035$).
52
53
54
55
56
57
58
59
60

1
2
3
4 These results indicated a potential for publication bias for both serum and PF SMRP studies.
5
6
7

8 9 **Diagnostic accuracy**

10
11 Figure 2A shows forest plot of sensitivity and specificity for 28 serum SMRP studies in the
12 diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.61, 95% CI 0.58 –
13 0.63), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was
14 also noted that PLR was 5.71 (95% CI 4.28 – 7.62), NLR was 0.43 (95% CI 0.38 – 0.50), and
15 DOR was 14.43 (95% CI 9.98 – 20.87). X^2 values of sensitivity, specificity, PLR, NLR, and
16 DOR were 153.68, 460.32, 272.50, 143.64, and 142.07, respectively, with all $p < 0.001$,
17 indicating a significant heterogeneity between studies.
18
19
20
21
22
23
24
25
26
27

28
29 Figure 2B shows forest plot of sensitivity and specificity 12 PF SMRP studies in the
30 diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.79, 95% CI 0.75 –
31 0.83), while specificity ranged from 0.65 – 0.95 (pooled 0.85, 95% CI 0.83 – 0.87). We also
32 noted that PLR was 4.78 (95% CI 3.52 – 6.50), NLR was 0.30 (95% CI 0.24 – 0.36), and
33 DOR was 19.50 (95% CI 12.14 – 31.33). X^2 values of sensitivity, specificity, PLR, NLR, and
34 DOR were 41.33 ($p < 0.001$), 46.78 ($p < 0.001$), 38.64 ($p < 0.001$), 14.53 ($p = 0.205$), and
35 23.49 ($p = 0.015$), respectively, indicating some a heterogeneity between studies.
36
37
38
39
40
41
42
43
44
45

46
47 The graphs of SROC curves for SMRP determinations showing sensitivity versus 1 –
48 specificity from individual studies are shown in Figure 3. SROC curve of serum SMRPs was
49 not positioned near the desirable upper left corner of SROC curve, and the maximum joint
50 sensitivity and specificity was 0.741 (SEM, 0.029) (Figure 3A); while area under curve (AUC)
51 was 0.806 (SEM, 0.032). The maximum joint sensitivity and specificity of PF SMRP was
52
53
54
55
56
57
58
59
60

0.820 (SEM, 0.022); while AUC was 0.890 (SEM, 0.021) (Figure 3B).

Totally, the diagnostic performance of SMRPs in serum and PF was similar.

Subgroup analysis

We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR, NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of serum mesothelin.

Data from 6 studies^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of serum SMRPs differentiating MPM from healthy control subjects, 9 studies^{21,23,24,26,30,31,33,45,47} were available for comparing that of differentiating MPM from other malignancies, 8 studies^{21,23,24,25,28,30,33,40} were available for comparing that of differentiating MPM from asbestos-exposed subjects. As shown in Table 4, the values of sensitivity, specificity, PLR, NLR, DOR, and AUC of SMRPs for discriminating MPM from healthy control subjects were quite acceptable, which were better than those for discriminating MPM from patients with the other cancers or from asbestos-exposed people. By using serum SMRPs, it was the most difficult to identify MPM from other cancers, compared with healthy controls or asbestos-exposed people.

Five studies^{23,35,41,42,48} provided required data for comparing diagnostic accuracy of PF mesothelin differentiating MPM from the other cancers, and 4 studies^{36,41,42,48} for differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was very similar to that of

1
2
3
4 differentiating MPM from benign pleural effusions.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{51,52}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMRPs was 0.61 and 0.79, respectively; and their specificity was 0.87 and 0.85 respectively. These data indicated that sensitivity and specificity of SMRPs in serum and PF were not as high as expected. SMRPs might be helpful in confirming (ruling in) MPM if the results were higher than the cut-off values. Thus, positive SMRP test results suggested that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. However, the relative low sensitivity, especially serum SMRPs, that was not sufficiently low to exclude non-MPM when a patient's SMRP results were lower than the cut-off values. Therefore, the associated poor sensitivity of SMRPs clearly limits their added value to diagnosis of MPM.

As previously described,¹¹ SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity, while DOR is a single indicator of test accuracy that combines the data from sensitivity and specificity into a single number. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMRPs were 0.741 and 0.820, respectively; while their AUCs were 0.806 and 0.890, respectively, indicating level of overall accuracy were also not as high

1
2
3
4 as expected. We also found that the pooled DORs of serum and PF SMRPs were 14.43, and
5
6 19.50, respectively, indicating that SMRPs seemed to be helpful in the diagnosis of MPM,
7
8 although they were not perfect.
9

10
11 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
12
13 PLR and NLR are considered more clinically meaningful,^{53,54} we further presented both PLR
14
15 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
16
17 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
18
19 (indicating high accuracy).⁵⁵ A PLR value of 5.71 with serum SMRPs suggests that patients
20
21 with MPM have a near 6-fold higher chance of being SMRP-positive compared with patients
22
23 without MPM, and this was not high enough for the clinical purpose. On the other hand, NLR
24
25 of serum SMRPs was found to be 0.43. If serum SMRP results were negative, the probability
26
27 that this patient has MPM is 43%, which is not low enough to rule out MPM. The very similar
28
29 results were found with PF SMRPs.
30
31
32
33
34
35

36
37 Although both mesothelin and MPF belong to SMRPs, we noted in the current
38
39 meta-analyses that the overall diagnostic measures, including sensitivity, specificity, PLR,
40
41 NLR, DOR, and AUC, of serum MPF, were better than those of serum mesothelin. Therefore,
42
43 MPF had a superior diagnostic accuracy compared to mesothelin for MPM. We also noted
44
45 that diagnostic performance of serum SMRP for discriminating MPM from healthy control
46
47 subjects was the best (although not as good as expected), followed by that for discriminating
48
49 MPM from patients with other cancers or from asbestos-exposed people. In addition, the
50
51 overall diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was
52
53 similar to that of differentiating MPM from benign pleural effusions.
54
55
56
57
58
59
60

1
2
3
4 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
5
6 letters to the editors, and non-English language studies may have led to publication bias.
7
8 Indeed, we observed a publication bias for both serum and PF SMRP studies. Publication bias
9
10 may also be introduced by inflation of diagnostic accuracy estimates since studies that report
11
12 positive results are more likely to be accepted for publication. Second, pathological types of
13
14 MPM were not specified in 5 studies,^{35,42,50} epithelioid subtype of MPM was the most
15
16 common pathological type in all studies, excluding the one reported by Creaney et al.²⁵
17
18 Totally, 69.9% (982/1404) MPM were epithelioid subtype (ranged from 29.9% to 100%).
19
20 Analysis in terms of histologic type has shown that SMRP levels were significantly elevated
21
22 in epithelioid subtype MPM than other types.^{21,23,29} This could explain partly the quite low
23
24 sensitivity of SMRPs in MPM diagnosis. Third, control populations were very heterogeneous
25
26 from one study to another; and various cutoff points were used for distinguishing between
27
28 MPM and controls, other cancers or benign respiratory diseases, according to the best
29
30 combination of sensitivity and specificity. These issues regarding accuracy of diagnosis could
31
32 also lead to biased results.
33
34
35
36
37
38
39
40

41 In conclusion, current evidence supported that SMRPs in both serum and PF were
42
43 helpful markers for the diagnosis of MPM. The overall diagnostic performance of SMRPs in
44
45 serum and PF was similar, and serum MPF had superior diagnostic accuracy compared to
46
47 serum mesothelin. The negative results of SMRP determinations were not sufficiently to
48
49 exclude non-MPM, whereas the positive test results might be helpful in confirming MPM.
50
51

52 Finally, it should be mentioned that since our previous meta-analysis¹¹ had been
53
54 published, the field concerning the use of SMRPs in clinical practice moved forward
55
56
57
58
59
60

1
2
3 significantly.¹⁰ It has been recognized that SMRPs are not only diagnostic markers, but also
4
5
6 serve as markers of disease course and response to treatment.^{56,57} Therefore, the application of
7
8
9 SMRPs in the near future clinical practice may probably be in monitoring response to therapy,
10
11 rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed
12
13
14 populations.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Funding: This work was supported in part by a grant from National Natural Science Foundation of China (No. 81270149), and in part by a grant from the 12th Five-Year National Science and Technology Program of Social Development, Ministry of Science and Technology, China (No. 2012BAI05B02).

Competing interests: The authors have declared that no conflict of interest exists.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin family proteins for malignant pleural mesothelioma: updated meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ Group products and to exploit all subsidiary rights, as set out in our license set out at:

1
2
3
4 http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf
5
6
7

8
9 **Data sharing statement:** There is no additional data available.
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.

- 1
2
3
4 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in
5
6 mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.
7
8
9 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum
10
11 diagnostic markers. *Pathol Int* 2006; 56:649-54.
12
13
14 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins
15
16 and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
17
18
19 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides
20
21 for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
22
23
24 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant
25
26 pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012;
27
28 30:1541-9.
29
30
31 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of
32
33 studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
34
35
36 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the
37
38 quality assessment of studies of diagnostic accuracy included in systematic reviews.
39
40 *BMC Med Res Methodol* 2003; 3:25.
41
42
43 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic
44
45 studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
46
47
48 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test
49
50 into a summary ROC curve: data-analytic approaches and some additional
51
52 considerations. *Stat Med* 1993; 12:1293-316.
53
54
55 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant
56
57
58
59
60

- 1
2
3
4 pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.
- 5
6 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
7
8 *J Clin Epidemiol* 1995; 48:119-30.
- 9
10 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
11
12 review of the concepts and methods. *Arch Pathol Lab Med* 1998; 122:675-86.
- 13
14 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
15
16 graphical test. *BMJ* 1997; 315:629-34.
- 17
18 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
19
20 mesothelioma. *Lancet* 2003; 362:1612-6.
- 21
22 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
23
24 mesothelin precursor is a useful tumor marker in the serum of patients with
25
26 mesothelioma. *Clin Cancer Res* 2006; 12:4225-31.
- 27
28 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
29
30 diagnosis of malignant pleural mesothelioma. *Am J Respir Crit Care Med* 2006;
31
32 173:1155-60.
- 33
34 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
35
36 pleural mesothelioma. *Clin Chem* 2007; 53:666-72.
- 37
38 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
39
40 diagnosis of malignant mesothelioma. *Chest* 2007; 132:1239-46.
- 41
42 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
43
44 patients with mesothelioma and lung cancer. *Clin Cancer Res* 2007; 13:5076-81.
- 45
46 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results. *Clin Chem Lab Med* 2007; 45:634-8.
- 28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol Biomarkers Prev* 2008; 17:163-70.
- 29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.
- 30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung Cancer* 2008; 62:45-54.
- 31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.
- 32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.
- 33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.
- 34 Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. *Am J Respir Crit Care Med* 2009; 180: 437-44.

- 1
2
3
4 35 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of
5
6 soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related
7
8 pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers*
9
10 *Prev* 2009; 18:646-50.
11
12
13
14 36 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
15
16 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
17
18 1:313-7.
19
20
21
22 37 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
23
24 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
25
26 *Care Med* 2010; 181:620-5.
27
28
29
30 38 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
31
32 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
33
34 2011; 74:55-60.
35
36
37
38 39 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
39
40 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
41
42 6:1587-93.
43
44
45
46 40 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
47
48 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
49
50 26:160-5.
51
52
53
54 41 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
55
56 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.
57
58
59
60 42 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin

- 1
2
3
4 and osteopontin for the diagnosis of malignant pleural mesothelioma. Egyptian
5
6 Journal of Chest Diseases and Tuberculosis 2012; 61:121-8.
7
8
9 43 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination
10
11 improves the diagnosis of mesothelioma in pleural effusions. J Thorac Oncol 2012;
12
13 7:883-9.
14
15
16 44 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic
17
18 and prognostic markers of malignant pleural mesothelioma in Egyptian patients
19
20 undergoing pleurodesis. Egyptian Journal of Chest Diseases and Tuberculosis 2013;
21
22 62:115-20.
23
24
25
26 45 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related
27
28 peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its
29
30 contribution to cytology. Cancer Invest 2013; 31:43-50.
31
32
33
34 46 Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson
35
36 BW. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin
37
38 and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural
39
40 effusions and serum. Dis Markers 2013; 35: 119-27.
41
42
43
44 47 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in
45
46 serum in the diagnosis of pleural mesothelioma. Anticancer Res 2013; 33:2707-13.
47
48
49 48 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids:
50
51 comparison with CYFRA 21-1 and CEA. Med Oncol 2013; 30:543.
52
53
54 49 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin
55
56 in undiagnosed pleural effusions. Eur Respir J 2013; 41:18-24.
57
58
59
60

- 1
2
3
4 50 Bayram M, Dongel I, Akbaş A, et al. Serum biomarkers in patients with mesothelioma and
5
6 pleural plaques and healthy subjects exposed to naturally occurring asbestos. *Lung*.
7
8 DOI 10.1007/s00408-013-9526-9.
9
- 10
11 51 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of
12
13 malignant mesothelioma: a consensus statement from the International Mesothelioma
14
15 Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.
16
17
- 18
19 52 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant
20
21 pleural mesothelioma. *Biomark Med* 2011; 5:261-73.
22
23
- 24
25 53 Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M,
26
27 Smith GD, Altman DG, eds. *Systematic reviews in health care. Meta-analysis in*
28
29 *context*. London: BMJ Publishing Group 2001:248-82.
30
- 31
32 54 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. *Users' guides to*
33
34 *the medical literature. A manual for evidence-based clinical practice*. Chicago: AMA
35
36 Press, 2002; 121-40.
37
38
- 39
40 55 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in
41
42 mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85:265-72.
43
- 44
45 56 Grigoriu BD, Chahine B, Vachani A, et al. Kinetics of soluble mesothelin in patients with
46
47 malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009;
48
49 179: 950-4.
50
- 51
52 57 Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and
53
54 osteopontin as markers of response to treatment in malignant mesothelioma. *J Clin*
55
56 *Oncol* 2010; 28: 3316-22.
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of soluble mesothelin-related peptides in sera

Study	Subjects, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	MPF	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Portal et al ³⁵	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
Hollevoet et al ³⁷	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
Hollevoet et al ³⁷	507	MPF	13.46 ng/ml	58	13	27	409	20	11
Creaney et al ³⁸	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
Cristaudo et al ³⁹	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
Dipalma et al ⁴⁰	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
Ashour et al ⁴²	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
Amany et al ⁴⁴	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
Creaney et al ⁴⁶	121	Mesothelin	2.4 nmol/L	40	3	26	52	13	11
Creaney et al ⁴⁶	121	MPF	33.2 ng/mL	34	3	32	52	13	11
Ferro et al ⁴⁷	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
Hooper et al ⁴⁹	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12
Bayram et al ⁵⁰	546	Mesothelin	1.63 nmol/L	14	89	10	433	13	10

SMRP = soluble mesothelin-related peptide; MPF = megakaryocyte potentiating factor, OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 2. Study summary of soluble mesothelin-related peptides in pleural fluids *

Study	Patients, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Davies et al ³⁴	166	Mesothelin	20.0 nmol/L	17	14	7	128	14	11
Fujimoto et al ³⁶	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴¹	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴²	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴³	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴⁴	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁵	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Creaney et al ⁴⁶	98	Mesothelin	20.0 nmol/L	30	3	13	52	13	11
Creaney et al ⁴⁶	98	MPF	600.0 ng/mL	35	3	6	52	13	11
Filiberti et al ⁴⁸	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁹	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMRP = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23-28, 30, 31, 33, 35, 37-40, 42, 44, 46, 47, 49, 50	22, 29, 30, 32, 37, 46
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.62 (0.56 – 0.67)
Heterogeneity* (p)	70.20 (< 0.001)	53.08 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.96 (0.94 – 0.97)
Heterogeneity (p)	352.24 (< 0.001)	17.60 (0.001)
PLR (95% CI)	4.78 (3.59 – 6.36)	12.39 (5.53 – 27.74)
Heterogeneity (p)	185.80 (< 0.001)	14.42 (0.006)
NLR (95% CI)	0.45 (0.40 – 0.51)	0.34 (0.19 – 0.63)
Heterogeneity (p)	50.65 (< 0.001)	67.07 (< 0.001)
DOR (95% CI)	11.84 (8.12 – 17.27)	36.08 (12.91 – 100.85)
Heterogeneity (p)	95.80 (< 0.001)	13.40 (0.009)
AUC (SEM)	0.785 (0.033)	0.941 (0.094)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 45, 47	21, 23, 24, 25, 28, 30, 33, 40
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM vs other cancers	MPM vs benign diseases
Study, Ref. No.	23, 34, 36, 41, 42, 48	36, 41, 42, 48
Sensitivity (95% CI)	0.75 (0.69 – 0.80)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.36 (0.929)	1.08 (0.783)
Specificity (95% CI)	0.76 (0.71 – 0.82)	0.87 (0.80 – 0.93)
Heterogeneity (p)	4.88 (0.430)	6.74 (0.081)
PLR (95% CI)	2.95 (2.32 – 3.75)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.83 (0.437)	7.01 (0.071)
NLR (95% CI)	0.34 (0.27 – 0.43)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.94 (0.857)	1.83 (0.608)
DOR (95% CI)	8.96 (5.78 – 13.89)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.34 (0.648)	5.26 (0.154)
AUC (SEM)	0.809 (0.025)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

1
2
3
4
5
6
7 Diagnostic values of soluble mesothelin family proteins for malignant pleural
8 mesothelioma: updated meta-analyses
9
10

11
12
13
14 Short running head: Mesothelin family proteins in mesothelioma
15

16
17
18 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
19

20
21
22 * These authors contributed equally to the present work
23

24
25
26
27 ¹Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
28 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
29 Respiratory Diseases, Beijing, China.
30
31
32

33
34
35 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
36 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
37 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
38 85231412; E-mail: shihuanzhong@sina.com
39
40
41
42
43
44

45
46 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin family proteins
47
48

49
50 **Word counts:** 2,729
51
52
53
54
55
56
57
58
59
60

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Funding: This work was supported by a grant from National Natural Science Foundation of China (No. 81270149).


Competing interests: The authors have declared that no conflict of interest exists.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin family proteins for malignant pleural mesothelioma: updated meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ Group products and to exploit all subsidiary rights, as set out in our license set out at: http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Data sharing statement: There is no additional data available.

For peer review only



ABSTRACT

Objective Although the values of soluble mesothelin family proteins (SMFPs), including mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact diagnostic accuracy of these SMFPs remains controversial. The purpose of the present meta-analyses was to update the overall diagnostic accuracy of SMFPs in serum, and further to establish that of SMFPs in pleural fluid for mesothelioma.

Design Systematic review and meta-analysis.

Methods In total, 30 articles with diagnostic studies were included in the current meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMFPs in serum and pleural fluid for the diagnosis of malignant pleural mesothelioma were pooled using random effects models. Summary receiver operating characteristic curves were used to summarize overall test performance.

Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.63, 0.87, 5.68, 0.42, and 14.95, respectively; pleural fluid: 0.80, 0.83, 4.00, 0.30, and 15.31, respectively. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared to mesothelin for MPM.

Conclusions SMFPs in both serum and pleural fluid were helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMFP determinations were not sufficiently to exclude non-MPM, and the positive test results indicated that further

Comment [U1]: added

Comment [U2]: MPM

Comment [U3]: changed

Comment [U4]: MPM

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

invasive diagnostic steps might be necessary for the diagnosis of MPM.

For peer review only

ARTICLE SUMMARY

Article focus

- The diagnosis of MPM is always a challenging endeavor.
- To date, no single marker or panel of soluble biomarkers is available for a clear diagnosis of MPM.
- The concentrations of soluble mesothelin family proteins, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Key messages

- Soluble mesothelin family proteins in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- Determination of soluble mesothelin family proteins might be helpful in confirming pleural mesothelioma if the results were higher than the cut-off values, while the negative results were not sufficiently to exclude non-mesothelioma.

Strengths and limitations of this study

- The studies included this meta-analyses were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural

mesothelioma and the other diseases.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in malignant mesothelioma, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble megakaryocyte potentiating factor (MPF).⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin family proteins (SMFPs), including both soluble mesothelin and MPF, have been found in human serum and pleural fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMFP detections for MPM has been extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we performed and

Comment [U5]: MPM

Comment [U6]: revised

1
2
3
4
5
6
7 published first meta-analysis reporting the overall diagnostic accuracy of serum SMFPs for
8 diagnosing MPM, and our results showed that serum SMFP determinations played a role in
9 the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an individual patient data
10 meta-analysis to evaluate serum SMFP for diagnosing MPM, and found that a positive test
11 result at a high-specificity threshold is a strong incentive to urge further diagnostic steps;
12 however, the poor sensitivity of SMFPs limits its added value to early diagnosis of MPM.¹²
13
14 Since that time, many additional clinical studies determining the concentrations of SMFPs in
15 serum and PF have been reported. We thus performed the present meta-analyses to update the
16 overall diagnostic accuracy of serum SMFPs, and further to establish that of PF SMFPs for
17 diagnosing MPM.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until July, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin family proteins”, “soluble mesothelin-related peptides”, “mesothelin”, “megakaryocyte potentiating factor”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were also searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMFP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected to be included in the meta-analyses, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ). Data retrieved from the reports included author, publication year, study characteristics,

Comment [U7]: further

1
2
3
4
5
6
7 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
8
9 and methodological quality. All eligible studies were assessed for methodologic quality using
10
11 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
12
13 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
14
15 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
16
17 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
18
19 consensus to assess the quality of primary studies of diagnostic accuracy).
20
21
22
23

24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38

39
40 The analyses were based on a summary receiver operating characteristic (SROC)
41
42 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
43
44 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
45
46 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
47
48 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
49
50 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
51
52 potential presence of this bias using funnel plots and the Egger test.²⁰
53
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, fifty-six publications determining concentrations of human SMFPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, thirty-two were excluded (Online supplementary appendix 1). Subsequently, twenty-seven publications²¹⁻⁴⁷ were available for analysis of diagnostic accuracy of SMFPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 16 publications from 18 studies³²⁻⁴⁷ were added in the current meta-analyses.

The methods of determining SMFPs in all studies included were enzyme-linked immunosorbent assay. Multiple enzyme-linked immunosorbent assays were available for determining SMRP concentrations. Mesomark, which has been approved by the US Food and Drug Administration, was used to determine mesothelin in most studies, and the other mesothelin ELISA kits were used in the other 4 studies.^{21,30,31,34} Serum mesothelin concentrations were determined in 20 studies (19 articles),^{21,23-28,30,31,33,34,36-39,41,43,45,47} and serum MPF concentrations were determined in 5 studies^{22,29,30,32,36} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMFP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. In addition, another 2 articles^{30,36} were also treated as independent studies, since both mesothelin and MPF in serum were investigated in these 2 articles. PF mesothelin concentrations were determined in 9 studies.^{23,35,40-44,46,47}

Comment [U8]: deleted

Comment [U9]: added

1
2
3
4
5
6
7 The clinical characteristics of the studies, along with STARD and QUADAS scores, are
8 outlined in Table 1 and Table 2.
9

10 11 12 13 **Study characteristics**

14
15 On review, the studies showed large differences in number of participants, clinical
16 characteristics (especially histologic subtypes of MPM, and type of control groups), and
17 reported diagnostic cut-off values of SMFPs (Online supplementary appendix 2). For serum
18 SMFP studies, the average samples size was 270 (range from 40 – 1,086), the subjects
19 included 1,046 patients with MPM and 5,356 non-MPM. For PF SMFP studies, the average
20 samples size was 127 (range from 40 – 275), the subjects included 352 patients with MPM
21 and 794 non-MPM.
22
23
24
25
26
27
28
29

30
31 The samples were collected from the consecutive patients in all studies but not 2 studies.

32
33 Nine studies reported blinded interpretation of SMFP assays independent of the reference
34 standard. Eight studies reported the study design was prospective. In 21 studies, MPM
35 diagnosis was completely based on pathological findings in pleural biopsies, with or without
36 positive cytological results; while in the remaining 9 studies, some MPM patients were
37 diagnosed just based on the cytological findings. Totally, the quality of study design and
38 reporting diagnostic accuracy of most studies were good, since 23 of 27 publications had
39 higher STARD scores (≥ 13) and 18 studies had higher QUADAS scores (≥ 10).
40
41
42
43
44
45
46
47
48
49
50

Comment [U10]: revised

51 **Publication bias**

52
53 The funnel plots for publication bias showed asymmetry for serum SMFP studies (Figure 1A),
54
55

1
2
3
4
5
6
7 evaluation of publication bias showed that Egger tests were significant for serum SMFPs ($p =$
8 0.044). Although the funnel plots for publication bias showed somehow asymmetry due to the
9 limited number of PF SMFP studies (Figure 1B), Egger tests showed that this was not
10 significant for PF SMFPs ($p = 0.149$). These results indicated a potential for publication bias
11 for serum SMFP, but not for PF SMFP studies.
12
13
14
15
16
17
18
19

20 **Diagnostic accuracy**

21
22 Figure 2A shows forest plot of sensitivity and specificity for 25 serum SMFP studies in the
23 diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.63, 95% CI 0.60 –
24 0.65), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was
25 also noted that PLR was 5.68 (95% CI 4.15 – 7.76), NLR was 0.42 (95% CI 0.36 – 0.49), and
26 DOR was 14.95 (95% CI 9.93 – 22.50). X^2 values of sensitivity, specificity, PLR, NLR, and
27 DOR were 121.53, 443.37, 261.05, 107.18, and 137.67, respectively, with all $p < 0.001$,
28 indicating a significant heterogeneity between studies.
29
30
31
32
33
34
35
36

37
38 Figure 2B shows forest plot of sensitivity and specificity 9 PF SMFP studies in the
39 diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.80, 95% CI 0.76 –
40 0.84), while specificity ranged from 0.65 – 0.90 (pooled 0.83, 95% CI 0.80 – 0.85). We also
41 noted that PLR was 4.00 (95% CI 2.98 – 5.36), NLR was 0.30 (95% CI 0.23 – 0.39), and
42 DOR was 15.31 (95% CI 9.32 – 25.16). X^2 values of sensitivity, specificity, PLR, NLR, and
43 DOR were 37.07 ($p < 0.001$), 30.45 ($p < 0.001$), 23.85 ($p = 0.002$), 11.30 ($p = 0.185$), and
44 15.14 ($p = 0.056$), respectively, indicating some a heterogeneity between studies.
45
46
47
48
49
50
51
52

53 The graphs of SROC curves for SMFP determinations showing sensitivity versus 1 –
54
55
56
57
58
59
60

1
2
3
4
5
6
7 specificity from individual studies are shown in Figure 3. SROC curve of serum SMFPs was
8
9 not positioned near the desirable upper left corner of SROC curve, and the maximum joint
10
11 sensitivity and specificity was 0.737 (SEM, 0.031) (Figure 3A); while area under curve (AUC)
12
13 was 0.802 (SEM, 0.035). The maximum joint sensitivity and specificity of PF SMFP was
14
15 0.805 (SEM, 0.022); while AUC was 0.875 (SEM, 0.023) (Figure 3B).

16
17
18 Totally, the diagnostic performance of SMFPs in serum and PF was similar.
19
20

21 22 **Subgroup analysis**

23
24 We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the
25
26 results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR,
27
28 NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of
29
30 serum mesothelin.
31
32

33 Data from 6 studies^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of
34
35 serum SMFPs differentiating MPM from healthy control subjects, 9 studies^{21,23,24,26,30,31,33,44,45}
36
37 were available for comparing that of differentiating MPM from other malignancies, 8 studies
38
39^{21,23,24,25,28,30,33,39} were available for comparing that of differentiating MPM from
40
41 asbestos-exposed subjects. As shown in Table 4, the values of sensitivity, specificity, PLR,
42
43 NLR, DOR, and AUC of SMFPs for discriminating MPM from healthy control subjects were
44
45 quite acceptable, which were better than those for discriminating MPM from patients with the
46
47 other cancers or from asbestos-exposed people. By using serum SMFPs, it was the most
48
49 difficult to identify MPM from other cancers, compared with healthy controls or
50
51 asbestos-exposed people.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Five studies^{23,35,40,41,46} provided required data for comparing diagnostic accuracy of PF mesothelin differentiating MPM from the other cancers, and 4 studies^{35,40,41,46} for differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of PF SMFP differentiating MPM from the other cancers was very similar to that of differentiating MPM from benign pleural effusions.

DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{48,49}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMFPs was 0.63 and 0.80, respectively; and their specificity was 0.87 and 0.83 respectively. These data indicated that sensitivity and specificity of SMFPs in serum and PF were not as high as expected. SMFPs might be helpful in confirming (ruling in) MPM if the results were higher than the cut-off values. Thus, positive SMFP test results suggested that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. However, the relative low sensitivity, especially serum SMFPs, that was not sufficiently low to exclude non-MPM when a patient's SMFP results were lower than the cut-off values. Therefore, the associated poor sensitivity of SMFPs clearly limits their added value to diagnosis of MPM.

As previously described,¹¹ SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity, while DOR is a single indicator of test accuracy that combines the data from sensitivity and specificity into a single number. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMFPs were 0.737 and 0.805, respectively; while their AUCs were 0.802 and 0.875, respectively, indicating level of overall accuracy were also not as high

1
2
3
4
5
6
7 as expected. We also found that the pooled DORs of serum and PF SMFPs were 14.95, and
8
9 15.31, respectively, indicating that SMFPs seemed to be helpful in the diagnosis of MPM,
10
11 although they were not perfect.

Comment [U11]: added

12
13
14 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
15
16 PLR and NLR are considered more clinically meaningful,^{50,51} we further presented both PLR
17
18 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
19
20 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
21
22 (indicating high accuracy).⁵² A PLR value of 5.68 with serum SMFPs suggests that patients
23
24 with MPM have a near 6-fold higher chance of being SMFP-positive compared with patients
25
26 without MPM, and this was not high enough for the clinical purpose. On the other hand, NLR
27
28 of serum SMFPs was found to be 0.42. If serum SMFP results were negative, the probability
29
30 that this patient has MPM is 42%, which is not low enough to rule out MPM. The very similar
31
32 results were found with PF SMFPs.
33
34

35
36 Although both mesothelin and MPF belong to SMFPs, we noted in the current
37
38 meta-analyses that the overall diagnostic measures, including sensitivity, specificity, PLR,
39
40 NLR, DOR, and AUC, of serum MPF, were better than those of serum mesothelin. Therefore,
41
42 MPF had a superior diagnostic accuracy compared to mesothelin for MPM. We also noted
43
44 that diagnostic performance of serum SMFP for discriminating MPM from healthy control
45
46 subjects was the best (although not as good as expected), followed by that for discriminating
47
48 MPM from patients with other cancers or from asbestos-exposed people. In addition, the
49
50 overall diagnostic accuracy of PF SMFP differentiating MPM from the other cancers was
51
52 similar to that of differentiating MPM from benign pleural effusions.
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
8 letters to the editors, and non-English language studies may have led to publication bias.
9
10 Indeed, we observed a publication bias for serum SMFP studies, but not for PF SMFP studies.
11
12 Publication bias may also be introduced by inflation of diagnostic accuracy estimates since
13 studies that report positive results are more likely to be accepted for publication. Second,
14 pathological types of MPM were not specified in 2 studies,^{34,41} epithelioid subtype of MPM
15 was the most common pathological type in all studies, excluding the one reported by Creaney
16 et al.²⁵ Totally, 69.9% (982/1404) MPM were epithelioid subtype (ranged from 29.9% to
17 100%). Analysis in terms of histologic type has shown that SMFP levels were significantly
18 elevated in epithelioid subtype MPM than other types.^{21,23,29} This could explain partly the
19 quite low sensitivity of SMFPs in MPM diagnosis. Third, control groups were very
20 heterogeneous from one study to another; and various cutoff points were used for
21 distinguishing between MPM and controls, other cancers or benign respiratory diseases,
22 according to the best combination of sensitivity and specificity. Fourth, multiple assays were
23 available for determining mesothelin concentrations, and Mesomark, which has been
24 approved by the US Food and Drug Administration, was used in most studies. The other
25 mesothelin ELISA kits were used in 4 studies.^{21, 30, 31, 35} These issues regarding accuracy of
26 diagnosis could also lead to biased results

27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46 In conclusion, current evidence supported that SMFPs in both serum and PF were helpful
47 markers for the diagnosis of MPM. The overall diagnostic performance of SMFPs in serum
48 and PF was similar, and serum MPF had superior diagnostic accuracy compared to serum
49 mesothelin. The negative results of SMFP determinations were not sufficiently to exclude
50
51
52
53
54

1
2
3
4
5
6
7 non-MPM, whereas the positive test results might be helpful in confirming MPM.

8
9 Finally, it should be mentioned that since our previous meta-analysis ¹¹ had been
10 published, the field concerning the use of SMRPs in clinical practice moved forward
11 significantly.¹⁰ It has been recognized that SMRPs are not only diagnostic markers, but also
12 serve as markers of disease course and response to treatment.^{56,57} Therefore, the application of
13 SMRPs in the near future clinical practice may probably be in monitoring response to therapy,
14 rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed
15 populations.
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Comment [U13]: added

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.
- 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in

- mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.
- 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. *Pathol Int* 2006; 56:649-54.
- 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
- 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
- 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012; 30:1541-9.
- 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
- 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003; 3:25.
- 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
- 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 1993; 12:1293-316.
- 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.

- 1
2
3
4
5
6
7 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
8
9 J Clin Epidemiol 1995; 48:119-30.
10
11 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
12
13 review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-86.
14
15 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
16
17 graphical test. BMJ 1997; 315:629-34.
18
19 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
20
21 mesothelioma. Lancet 2003; 362:1612-6.
22
23 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
24
25 mesothelin precursor is a useful tumor marker in the serum of patients with
26
27 mesothelioma. Clin Cancer Res 2006; 12:4225-31.
28
29 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
30
31 diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;
32
33 173:1155-60.
34
35 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
36
37 pleural mesothelioma. Clin Chem 2007; 53:666-72.
38
39 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
40
41 diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
42
43 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
44
45 patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
46
47 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
48
49 mesothelioma: analytical evaluation of an automated immunoassay and preliminary
50
51
52
53
54

clinical results. *Clin Chem Lab Med* 2007; 45:634-8.

28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol Biomarkers Prev* 2008; 17:163-70.

29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.

30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung Cancer* 2008; 62:45-54.

31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.

32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.

33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.

34 Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC. Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. *Am J Respir Crit Care Med* 2009; 180: 437-44.

Comment [W用14]: added

34 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of

1
2
3
4
5
6
7 soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related
8 pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers*
9 *Prev* 2009; 18:646-50.

10
11
12
13 35 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
14 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
15 1:313-7.

16
17
18
19
20 36 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
21 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
22 *Care Med* 2010; 181:620-5.

23
24
25
26
27 37 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
28 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
29 2011; 74:55-60.

30
31
32
33 38 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
34 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
35 6:1587-93.

36
37
38
39 39 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
40 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
41 26:160-5.

42
43
44
45 40 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
46 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.

47
48
49
50 41 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin
51 and osteopontin for the diagnosis of malignant pleural mesothelioma. *Egyptian*
52

Journal of Chest Diseases and Tuberculosis 2012; 61:121-8.

42 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. *J Thorac Oncol* 2012; 7:883-9.

43 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis. *Egyptian Journal of Chest Diseases and Tuberculosis* 2013; 62:115-20.

44 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. *Cancer Invest* 2013; 31:43-50.

46 Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. *Dis Markers* 2013; 35: 119-27.

Comment [U15]: added

45 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. *Anticancer Res* 2013; 33:2707-13.

46 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. *Med Oncol* 2013; 30:543.

47 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. *Eur Respir J* 2013; 41:18-24.

50 Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND. Serum biomarkers in

patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos. *Lung*. DOI 10.1007/s00408-013-9526-9.

Comment [W用16]: added

48 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.

49 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant pleural mesothelioma. *Biomark Med* 2011; 5:261-73.

50 Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, eds. *Systematic reviews in health care. Meta-analysis in context*. London: BMJ Publishing Group 2001:248-82.

51 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. *Users' guides to the medical literature. A manual for evidence-based clinical practice*. Chicago: AMA Press, 2002; 121-40.

52 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85:265-72.

56 Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009; 179: 950-4.

57 Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC, O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G. Soluble mesothelin-related Peptide and osteopontin as markers of response to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

treatment in malignant mesothelioma. J Clin Oncol 2010; 28: 3316-22.

Comment [U17]: added

For peer review only

Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of SMPRs in sera

Study	Subjects, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	N-ERC/ Mesothelin	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

Portal et al ³⁵	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
Hollevoet et al ³⁷	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
Hollevoet et al ³⁷	507	MPF	13.46 ng/ml	58	13	27	409	20	11
Creaney et al ³⁸	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
Cristaudo et al ³⁹	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
Dipalma et al ⁴⁰	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
Ashour et al ⁴²	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
Amany et al ⁴⁴	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
Creaney et al ⁴⁶	121	Mesothelin	2.4 nmol/L	40	3	26	52	13	11
Creaney et al ⁴⁶	121	MPF	33.2 ng/mL	34	3	32	52	13	11
Ferro et al ⁴⁷	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
Hooper et al ⁴⁹	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12
Bayram et al ⁵⁰	546	Mesothelin	1.63 nmol/L	14	89	10	433	13	10

Comment [U18]: added

Comment [U19]: added

SMRP = soluble mesothelin-related peptide; MPF = megakaryocyte potentiating factor, OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 2. Study summary of SMPRs in pleural fluids *

Study	Patients, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Davies et al ³⁴	166	Mesothelin	20.0 nmol/L	17	14	7	128	14	11
Fujimoto et al ³⁶	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴¹	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴²	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴³	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴⁴	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁵	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Creaney et al ⁴⁶	98	Mesothelin	20.0 nmol/L	30	3	13	52	13	11
Creaney et al ⁴⁶	98	MPF	600.0 ng/mL	35	3	6	52	13	11
Filiberti et al ⁴⁷	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁹	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMRP = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23, 24, 25, 26, 27, 28, 30, 31, 33, 34, 36, 37, 38, 39, 41, 43, 45, 47	22, 29, 30, 32, 36
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.66 (0.60 – 0.71)
Heterogeneity* (p)	70.03 (< 0.001)	50.26 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.95 (0.93 – 0.96)
Heterogeneity (p)	345.53 (< 0.001)	19.42 (0.001)
PLR (95% CI)	4.75 (3.51 – 6.44)	12.31 (6.21 – 24.42)
Heterogeneity (p)	179.04 (< 0.001)	15.48 (0.004)
NLR (95% CI)	0.45 (0.39 – 0.51)	0.30 (0.14 – 0.64)
Heterogeneity (p)	50.33 (< 0.001)	74.23 (< 0.001)
DOR (95% CI)	11.84 (7.91 – 17.70)	40.15 (16.55 – 97.39)
Heterogeneity (p)	92.67 (< 0.001)	12.07 (0.017)
AUC (SEM)	0.791 (0.035)	0.933 (0.083)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 44, 45	21, 23, 24, 25, 28, 30, 33, 39
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM vs other cancers	MPM vs benign diseases
Study, Ref. No.	23, 35, 40, 41, 46	35, 40, 41, 46
Sensitivity (95% CI)	0.75 (0.69 – 0.81)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.14 (0.887)	1.08 (0.783)
Specificity (95% CI)	0.75 (0.68 – 0.81)	0.87 (0.80 – 0.93)
Heterogeneity (p)	3.93 (0.416)	6.74 (0.081)
PLR (95% CI)	2.81 (2.13 – 3.70)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.22 (0.337)	7.01 (0.071)
NLR (95% CI)	0.34 (0.26 – 0.44)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.90 (0.755)	1.83 (0.608)
DOR (95% CI)	8.75 (5.41 – 14.15)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.28 (0.512)	5.26 (0.154)
AUC (SEM)	0.812 (0.026)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.




Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

160x66mm (300 x 300 DPI)




Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.
94x134mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.
160x78mm (300 x 300 DPI)

Review only

Online supplementary appendix 1

Excluded References

One were excluded because it recruited less than 10 patients in one of study groups [1], nine were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered [2-10], twenty-two were excluded because they did not allow the calculation of sensitivity or specificity [11-32].

1. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. *Cancer Sci* 2006; 97(9): 928-932.
2. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein--a blood test for mesothelioma. *Lung Cancer* 2005; 49 Suppl 1: S109-111.
3. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. *J Thorac Oncol* 2006; 1(2): 172-174.
4. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. *Clin Cancer Res* 2006; 12(2): 447-453.
5. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. *Clin Cancer Res* 2007; 13(10): 2928-2935.
6. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85(1): 265-272; discussion 272.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
7. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. *Clin Biochem* 2009; 42(10-11): 1046-1050.
 8. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P, Bosquee L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. *Chest* 2012; 141(2): 477-484.
 9. Canessa PA, Ferro P, Manta C, Sivori M, Franceschini MC, Fedeli F, Roncella S. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. *Med Oncol* 2013; 30(3): 649.
 10. Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. *Lung Cancer*, 2013;82: 491-498.
 11. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. *Thorax* 2007; 62(7): 569-576.
 12. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, Johnen G. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. *Cancer Biomark* 2007; 3(6): 287-292.
 13. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer* 2008; 61(2): 235-243.
 14. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009; 179(10): 950-954.
 15. Aleman C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. *Med Clin (Barc)* 2009; 133(12): 449-453.
 16. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M. Soluble mesothelin related peptides (SMRP) and osteopontin as protein

1
2
3 biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and
4 characterization at mRNA and protein levels. *Clin Chem Lab Med* 2010; 48(2): 271-278.

5
6
7 17. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson
8 BW. Serum mesothelin for early detection of asbestos-induced cancer malignant
9 mesothelioma. *Cancer Epidemiol Biomarkers Prev* 2010; 19(9): 2238-2246.

10
11
12 18. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC,
13 O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G.
14 Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant
15 mesothelioma. *J Clin Oncol* 2010; 28(20): 3316-3322.

16
17
18 19. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Muller-Lux A, Gross IM,
19 Wiethage T, Weber A, Raithel HJ, Kraus T, Bruning T. Performance of biomarkers SMRP,
20 CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung
21 cancer in a cohort of workers formerly exposed to asbestos. *Arch Toxicol* 2011; 85(3):
22 185-192.

23
24
25 20. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum
26 soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor
27 volume, clinical stage and changes in tumor burden. *Clin Cancer Res* 2011; 17(5): 1181-1189.

28
29
30 21. Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, Sugarbaker
31 DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT. The relationship between
32 tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. *Epigenetics* 2011;
33 6(8): 1029-1034.

34
35
36 22. Imashimizu K, Shiomi K, Maeda M, Aoki N, Igarashi K, Suzuki F, Koizumi M, Suzuki K,
37 Hino O. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for
38 the early diagnosis of malignant mesothelioma. *Exp Ther Med* 2011; 2(3): 409-411.

39
40
41 23. Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K,
42 Germonpre P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Serial measurements
43 of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective
44 longitudinal cohort study. *J Thorac Oncol* 2011; 6(5): 889-895.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, Germonpre P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. *J Thorac Oncol* 2011; 6(11): 1930-1937.
25. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. *Lung Cancer* 2011; 73(3): 320-324.
26. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, Tomasetti M. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. *PLoS One* 2011; 6(4): e18232.
27. Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels. *Clin Chem Lab Med* 2012; 50(12): 2199-2204.
28. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. *Dis Markers* 2012; 32(2): 123-131.
29. Mori T, Tajima K, Hiramata M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. *J Thorac Dis* 2013; 5(2): 145-148.
30. Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J. Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer. *J Thorac Oncol* 2013; 8(7): 947-951.
31. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? *Lung Cancer* 2013; 80(1): 39-44.
32. Mundt F, Nilsson G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. *PLoS One* 2013; 8(8): e72030.

1
2
3
4
5
6 **Online supplementary appendix 2**
7
8
9

10
11 **The characteristics of subjects studied**
12

Study	MPM Patients	Non-MPM Subjects
Robinson et al ²¹	Epithelioid type (n = 25) Sarcomatoid type (n = 4) Other or not specified (n = 15)	Healthy controls without asbestos exposure (n = 28) Healthy controls with asbestos exposure (n = 40) Patients with inflammatory non-pleural lung disease (n = 92) Patients with non-MPM pleural diseases (n = 38) Patients with non-pleural malignant lung disease (n = 30)
Onda et al ²²	Epithelioid type (n = 56)	Healthy controls (n = 70)
Scherpereel et al ²³	Epithelioid type (n = 55) Sarcomatoid type (n = 6) Other or not specified (n = 13)	Patients with benign asbestos-related pleural diseases (n = 28) Patients with pleural metastasis of carcinomas (n = 35)
Beyer et al ²⁴	Epithelioid type (n = 59) Sarcomatoid type (n = 8) Other or not specified (n = 21)	Healthy controls (n = 409) Patients with non-MPM malignancy (n = 412) Patients with nonmalignant conditions (n = 116)

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		Subjects with asbestos exposure (n = 61)
Creaney et al ²⁵	Epithelioid type (n = 35) Sarcomatoid type (n = 15) Other or not specified (n = 67)	Healthy controls with asbestos exposure (n = 33) Patients with benign asbestos-related diseases (n = 53) Patients with benign pleural effusions (n = 30)
Cristaudo et al ²⁶	Epithelioid type (n = 72) Sarcomatoid type (n = 10) Other or not specified (n = 25)	Healthy controls (n = 262) Patients with benign respiratory diseases (n = 130) Patients with lung cancer (n = 215)
Di Serio et al ²⁷	Epithelioid type (n = 20) Sarcomatoid type (n = 2) Other or not specified (n = 2)	Healthy controls with asbestos exposure (n = 26) Patients with asbestos-related diseases (n = 66)
Amati et al ²⁸	Epithelioid type (n = 11) Sarcomatoid type (n = 6) Other or not specified (n = 5)	Healthy controls without asbestos exposure (n = 54) Subjects with asbestos exposure (n = 94)
Shiomi et al ²⁹	Epithelioid type (n = 21) Sarcomatoid type (n = 9) Other or not specified (n = 9)	Patients with benign asbestos-related diseases and healthy controls with asbestos exposure (n = 201) Patients with lung cancer (n = 45) Others (n = 8)
Iwahori et al ³⁰	Epithelioid type (n = 13)	Healthy controls without asbestos exposure (n = 38)

	Sarcomatoid type (n = 3) Other or not specified (n = 11)	Healthy controls with asbestos exposure (n = 9) Patients with lung cancer (n = 47) Patients with other cancers (n = 35)
van den Heuvel ³¹	Epithelioid type (n = 43) Sarcomatoid type (n = 10) Other or not specified (n = 20)	Healthy controls (n = 50) Patients with lung cancer (n = 106)
Creaney et al ³²	Epithelioid type (n = 57) Sarcomatoid type (n = 9)	Healthy controls without asbestos exposure (n = 10) Healthy controls with asbestos exposure (n = 10) Patients with benign asbestos-related diseases (n = 21) Patients with lung cancer (n = 10)
Schneider et al ³³	Epithelioid type (n = 81) Sarcomatoid type (n = 14) Other or not specified (n = 34)	Patients with lung cancer (n = 139) Patients with benign asbestos-related diseases (n = 75)
Davies et al ³⁴	Epithelioid type (n = 11) Sarcomatoid type (n = 5) Other or not specified (n = 8)	Patients with nonmesothelioma malignancy (n = 67) Patients with benign pleural effusion (n = 75)
Rodriguez Portal et al ³⁵	Not specified (n = 36)	Healthy controls (n = 48) Patients with asbestos exposure and no pleural disease (n = 177)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		Patients with benign asbestos-related diseases (n = 101)
Fujimoto et al ³⁶	Epithelioid type (n = 15) Sarcomatoid type (n = 4) Other or not specified (n = 4)	Patients with lung cancer (n = 38) Patients with benign asbestos pleurisy (n = 26) Patients with tuberculosis pleurisy (n = 5) Patients with no pleural diseases (n = 4)
Hollevoet et al ³⁶	Epithelioid type (n = 73) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Healthy controls (n = 101) Healthy controls with asbestos exposure (n = 89) Patients with benign asbestos-related diseases (n = 123) Patients with benign respiratory diseases (n = 46) Patients with lung cancer (n = 63)
Creaney et al ³⁸	Epithelioid type (n = 59) Other or not specified (n = 7)	Patients with benign asbestos-related diseases (n = 47) Patients with benign respiratory diseases (n = 42)
Cristaudo et al ³⁹	Epithelioid type (n = 31)	Healthy controls (n = 93) Patients with benign respiratory diseases (n = 111)
Dipalma et al ⁴⁰	Epithelioid type (n = 29) Sarcomatoid type (n = 4) Other or not specified (n = 3)	Healthy controls without asbestos exposure (n = 109) Healthy controls with asbestos exposure (n = 26) Patients with benign asbestos-related diseases (n = 48) Patients with benign respiratory diseases (n = 110)

		Patients with lung cancer (n = 25)
Yamada et al ⁴¹	Epithelioid type (n = 37) Sarcomatoid type (n = 5) Other or not specified (n = 3)	Patients with non-malignant pleural effusions (n = 24) Patients with lung cancer (n = 29)
Ashour et al ⁴²	Not specified (n = 38)	Healthy controls with asbestos exposure (n = 32) Patients with benign pleural diseases (n = 29) Patients with pleural carcinomas (n = 24)
Blanquart et al ⁴³	Epithelioid type (n = 49) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Patients with adenocarcinoma effusions (n = 25) Patients with benign pleural effusions (n = 15)
Amany et al ⁴⁴	Epithelioid type (n = 14) Sarcomatoid type (n = 4) Other or not specified (n = 2)	Patients with benign asbestos pleural effusions (n = 10) Patients with tuberculosis pleural effusions (n = 10)
Canessa et al ⁴⁵	Epithelioid type (n = 35) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignant effusions (n = 94) Patients with benign pleural effusions (n = 129)
Creaney et al ⁴⁶	Epithelioid type (n = 32) Sarcomatoid type (n = 9)	Patients with non-MPM malignant effusions (n = 39) Patients with benign disease (n = 37)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	Other or not specified (n = 25)	Patients with chronic kidney disease (n = 53) Healthy controls without asbestos exposure (n = 18)
Ferro et al ⁴⁷	Epithelioid type (n = 26) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignancy (n = 23) Patients with benign diseases (n = 36)
Filiberti et al ⁴⁸	Epithelioid type (n = 43) Sarcomatoid type (n = 3) Other or not specified (n = 2)	Patients with malignant effusions (n = 64) Patients with benign effusions (n = 56)
Hooper et al ⁴⁹	Epithelioid type (n = 23) Sarcomatoid type (n = 3) Other or not specified (n = 2)	Patients with non-MPM malignant effusions (n = 74) Patients with benign asbestos-related effusions (n = 13) Patients with benign pleural diseases (n = 100)
Bayram et al ⁵⁰	Not specified (n = 24)	Patients with pleural plaques (n = 279) Healthy controls with asbestos exposure (n = 123) Healthy controls without asbestos exposure (n = 120)

MPM = malignant pleural mesothelioma.

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	0-2
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	7,8
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	11
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	12
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	12
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	12
<i>Test methods</i>	7	The reference standard and its rationale.	12
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	12
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	11,12
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	12
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	N/A
	13	Methods for calculating test reproducibility, if done.	N/A
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	N/A
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	11
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	12
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	12-15
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	14,15
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	14,15
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	18,19



Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analyses

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2013-004145.R3
Article Type:	Research
Date Submitted by the Author:	16-Jan-2014
Complete List of Authors:	Cui, Ai; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Jin, Xiao-Guang; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Zhai, Kan; Beijing Institute of Respiratory Diseases, Center of Medical Research Tong, Zhao-Hui; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine Shi, Huan-Zhong; Beijing Chaoyang Hospital, Capital Medical University, Department of Respiratory and Critical Care Medicine
Primary Subject Heading:	Diagnostics
Secondary Subject Heading:	Diagnostics, Respiratory medicine
Keywords:	Adult thoracic medicine < THORACIC MEDICINE, Immunology < THORACIC MEDICINE, RESPIRATORY MEDICINE (see Thoracic Medicine)

SCHOLARONE™
Manuscripts

only

1
2
3
4 Diagnostic values of soluble mesothelin-related peptides for malignant pleural
5
6 mesothelioma: updated meta-analyses
7
8
9

10
11 Short running head: SMRPs in mesothelioma
12
13

14
15
16 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
17
18
19

20
21 * These authors contributed equally to the present work
22
23
24
25

26
27 ¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
28
29 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
30
31 Respiratory Diseases, Beijing, China.
32
33
34
35

36
37 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
38
39 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
40
41 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
42
43 85231412; E-mail: shihuanzhong@sina.com
44
45
46
47
48

49 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin family proteins
50
51
52
53

54 **Word counts:** 2,767
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
ABSTRACT

Objective Although the values of soluble mesothelin-related peptides (SMRPs), including mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact diagnostic accuracy of these SMRPs remains controversial. The purpose of the present meta-analyses was to update the overall diagnostic accuracy of SMRPs in serum, and further to establish that of SMRPs in pleural fluid for MPM.

Design Systematic review and meta-analysis.

Methods In total, 30 articles of diagnostic studies were included in the current meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMRPs in serum and pleural fluid for the diagnosis of MPM were pooled using random effects models. Summary receiver operating characteristic curves were used to summarize overall test performance.

Results The summary estimates of sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.61, 0.87, 5.71, 0.43, and 14.43, respectively; pleural fluid: 0.79, 0.85, 4.78, 0.30, and 19.50, respectively. It was also found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy compared to mesothelin for MPM.

Conclusions SMRPs in both serum and pleural fluid were helpful markers for diagnosing MPM with similar diagnostic accuracy. The negative results of SMRP determinations were not sufficiently to exclude non-MPM, and the positive test results indicated that further invasive diagnostic steps might be necessary for the diagnosis of MPM.

ARTICLE SUMMARY

Article focus

- The diagnosis of malignant pleural mesothelioma is always a challenging endeavor.
- To date, no single marker or panel of soluble biomarkers is available for a clear diagnosis of malignant pleural mesothelioma.
- The concentrations of soluble mesothelin family proteins, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Key messages

- Soluble mesothelin family proteins in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- Determination of soluble mesothelin family proteins might be helpful in confirming pleural mesothelioma if the results were higher than the cut-off values, while the negative results were not sufficiently to exclude non-mesothelioma.

Strengths and limitations of this study

- The studies included this meta-analyses were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural mesothelioma and the other diseases.

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers, such as mesothelin family proteins, in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in MPM, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble 31-kD N-terminal fraction, megakaryocyte potentiating factor (MPF), also denominated “N-ERC/mesothelin”.⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin-related peptides (SMRPs), including both soluble mesothelin and MPF, have been found in human serum and pleural

1
2
3 fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMRP detections for MPM has been
4
5 extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we
6
7 performed and published first meta-analysis reporting the overall diagnostic accuracy of
8
9 serum SMRPs for diagnosing MPM, and our results showed that serum SMRP determinations
10
11 could play a role in the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an
12
13 individual patient data meta-analysis to evaluate serum SMRP for diagnosing MPM, and
14
15 found that a positive test result at a high-specificity threshold is a strong incentive to urge
16
17 further diagnostic steps; however, the poor sensitivity of SMRPs limits its added value to
18
19 early diagnosis of MPM.¹² Since that time, many additional clinical studies determining the
20
21 concentrations of SMRPs in serum and PF have been reported. We thus performed the present
22
23 meta-analyses to update the overall diagnostic accuracy of serum SMRPs, and further to
24
25 establish that of PF SMRPs for diagnosing MPM.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until November 28, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin-related peptides/SMRP”, “mesothelin”, “megakaryocyte potentiating factor/MPF”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were further searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMRP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected to be included in the meta-analyses, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ). Data retrieved from the reports included author, publication year, study characteristics,

1
2
3
4 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
5
6 and methodological quality. All eligible studies were assessed for methodologic quality using
7
8 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
9
10 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
11
12 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
13
14 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
15
16 consensus to assess the quality of primary studies of diagnostic accuracy).
17
18
19

20 21 22 23 24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38
39

40
41 The analyses were based on a summary receiver operating characteristic (SROC)
42
43 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
44
45 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
46
47 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
48
49 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
50
51 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
52
53 potential presence of this bias using funnel plots and the Egger test.²⁰
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, sixty-two publications determining concentrations of human SMRPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, thirty-two were excluded (Online supplementary appendix 1). Subsequently, thirty publications²¹⁻⁵⁰ were available for analysis of diagnostic accuracy of SMRPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 19 publications from 28 studies³²⁻⁵⁰ were added in the current meta-analyses.

Multiple ELISA kits were available for determining SMRP concentrations. Mesomark, which has been approved by the US Food and Drug Administration, was used to determine mesothelin in most studies, and the other mesothelin ELISA kits were used in the other 4 studies.^{21,30,31,34} Serum mesothelin concentrations were determined in 23 studies (22 articles),^{21,23-31,33,35,37-40,42,44,46,47,49,50} and serum MPF concentrations were determined in 5 studies^{22,30,32,37,46} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMRP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. SMRP concentrations in PF were determined in 11 articles from 12 studies (mesothelin in 11 and MPF in 1) (Table 2).^{23,34,36,41-47,49}

The clinical characteristics of the studies, along with STARD and QUADAS scores, are

1
2
3 outlined in Table 1 and Table 2.
4
5
6
7

8 **Study characteristics**

9
10 On review, the studies showed large differences in number of participants, clinical
11 characteristics (especially histologic subtypes of MPM, and type of control groups), and
12 reported diagnostic cut-off values of SMRPs (Online supplementary appendix 2). For serum
13 SMRP studies, the average samples size was 265 (range from 40 – 1,086), the subjects
14 included 1,562 patients with MPM and 5,988 non-MPM. For PF SMRP studies, the average
15 samples size was 126 (range from 40 – 275), the subjects included 460 patients with MPM
16 and 1,046 non-MPM.
17
18
19
20
21
22
23
24
25
26
27

28 In 21 publications, MPM diagnosis was completely based on pathological findings in
29 pleural biopsies, with or without positive cytological results; while in the remaining 9
30 publications, some MPM patients were diagnosed just based on the cytological findings.
31 Totally, the quality of study design and reporting diagnostic accuracy of most studies were
32 good, since 26 of 30 publications had higher STARD scores (≥ 13) and 21 studies had higher
33 QUADAS scores (≥ 10).
34
35
36
37
38
39
40
41
42
43
44
45

46 **Publication bias**

47
48 The funnel plots for publication bias showed asymmetry for serum SMRP studies (Figure 1A),
49 evaluation of publication bias showed that Egger tests were significant for serum SMRPs ($p =$
50 0.038). Similarly, the funnel plots for publication bias also showed asymmetry for PF SMRP
51 studies (Figure 1B), Egger tests showed that this was significant for PF SMRPs ($p = 0.035$).
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

These results indicated a potential for publication bias for both serum and PF SMRP studies.

Diagnostic accuracy

Figure 2A shows forest plot of sensitivity and specificity for 28 serum SMRP studies in the diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.61, 95% CI 0.58 – 0.63), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was also noted that PLR was 5.71 (95% CI 4.28 – 7.62), NLR was 0.43 (95% CI 0.38 – 0.50), and DOR was 14.43 (95% CI 9.98 – 20.87). X^2 values of sensitivity, specificity, PLR, NLR, and DOR were 153.68, 460.32, 272.50, 143.64, and 142.07, respectively, with all $p < 0.001$, indicating a significant heterogeneity between studies.

Figure 2B shows forest plot of sensitivity and specificity for 12 PF SMRP studies in the diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.79, 95% CI 0.75 – 0.83), while specificity ranged from 0.65 – 0.95 (pooled 0.85, 95% CI 0.83 – 0.87). We also noted that PLR was 4.78 (95% CI 3.52 – 6.50), NLR was 0.30 (95% CI 0.24 – 0.36), and DOR was 19.50 (95% CI 12.14 – 31.33). X^2 values of sensitivity, specificity, PLR, NLR, and DOR were 41.33 ($p < 0.001$), 46.78 ($p < 0.001$), 38.64 ($p < 0.001$), 14.53 ($p = 0.205$), and 23.49 ($p = 0.015$), respectively, indicating some a heterogeneity between studies.

The graphs of SROC curves for SMRP determinations showing sensitivity versus 1 – specificity from individual studies are shown in Figure 3. SROC curve of serum SMRPs was not positioned near the desirable upper left corner of SROC curve, and the maximum joint sensitivity and specificity was 0.741 (SEM, 0.029) (Figure 3A); while area under curve (AUC) was 0.806 (SEM, 0.032). The maximum joint sensitivity and specificity of PF SMRP was

0.820 (SEM, 0.022); while AUC was 0.890 (SEM, 0.021) (Figure 3B).

Totally, the diagnostic performance of SMRPs in serum and PF was similar.

Subgroup analysis

We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR, NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of serum mesothelin.

Data from 6 studies^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of serum SMRPs differentiating MPM from healthy control subjects, 9 studies^{21,23,24,26,30,31,33,45,47} were available for comparing that of differentiating MPM from other malignancies, 8 studies^{21,23,24,25,28,30,33,40} were available for comparing that of differentiating MPM from asbestos-exposed subjects. As shown in Table 4, the values of sensitivity, specificity, PLR, NLR, DOR, and AUC of SMRPs for discriminating MPM from healthy control subjects were quite acceptable, which were better than those for discriminating MPM from patients with the other cancers or from asbestos-exposed people. By using serum SMRPs, it was the most difficult to identify MPM from other cancers, compared with healthy controls or asbestos-exposed people.

Five studies^{23,35,41,42,48} provided required data for comparing diagnostic accuracy of PF mesothelin differentiating MPM from the other cancers, and 4 studies^{36,41,42,48} for differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was very similar to that of

1
2
3
4 differentiating MPM from benign pleural effusions.
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{51,52}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMRPs was 0.61 and 0.79, respectively; and their specificity was 0.87 and 0.85 respectively. These data indicated that sensitivity and specificity of SMRPs in serum and PF were not as high as expected. SMRPs might be helpful in confirming (ruling in) MPM if the results were higher than the cut-off values. Thus, positive SMRP test results suggested that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. On the other hand, the low sensitivity will not allow exclusion of non-MM patients even if patients have mesothelin concentrations lower than the cutoff value. Therefore, the associated poor sensitivity of SMRPs clearly limits their added value to diagnosis of MPM.

As previously described,¹¹ SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity, while DOR is a single indicator of test accuracy that combines the data from sensitivity and specificity into a single number. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMRPs were 0.741 and 0.820, respectively; while their AUCs were 0.806 and 0.890, respectively, indicating level of overall accuracy were also not as high

1
2
3
4 as expected. We also found that the pooled DORs of serum and PF SMRPs were 14.43, and
5
6 19.50, respectively, indicating that SMRPs seemed to be helpful in the diagnosis of MPM,
7
8 although they were not perfect.
9

10
11 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
12
13 PLR and NLR are considered more clinically meaningful,^{53,54} we further presented both PLR
14
15 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
16
17 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
18
19 (indicating high accuracy).⁵⁵ A PLR value of 5.71 with serum SMRPs suggests that patients
20
21 with MPM have a near 6-fold higher chance of being SMRP-positive compared with patients
22
23 without MPM, and this was not high enough for the clinical purpose. On the other hand, NLR
24
25 of serum SMRPs was found to be 0.43. If serum SMRP results were negative, the probability
26
27 that this patient has MPM is 43%, which is not low enough to rule out MPM. The very similar
28
29 results were found with PF SMRPs.
30
31
32
33
34
35

36
37 Although both mesothelin and MPF belong to mesothelin family proteins, we noted in
38
39 the current meta-analyses that the overall diagnostic measures, including sensitivity,
40
41 specificity, PLR, NLR, DOR, and AUC, of serum MPF, were better than those of serum
42
43 mesothelin. Therefore, MPF had a superior diagnostic accuracy compared to mesothelin for
44
45 MPM. We also noted that diagnostic performance of serum SMRP for discriminating MPM
46
47 from healthy control subjects was the best (although not as good as expected), followed by
48
49 that for discriminating MPM from patients with other cancers or from asbestos-exposed
50
51 people. In addition, the overall diagnostic accuracy of PF SMRP differentiating MPM from
52
53 the other cancers was similar to that of differentiating MPM from benign pleural effusions.
54
55
56
57
58
59
60

1
2
3
4 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
5
6 letters to the editors, and non-English language studies may have led to publication bias.
7
8 Indeed, we observed a publication bias for both serum and PF SMRP studies. Publication bias
9
10 may also be introduced by inflation of diagnostic accuracy estimates since studies that report
11
12 positive results are more likely to be accepted for publication. Second, pathological types of
13
14 MPM were not specified in 5 studies,^{35,42,50} epithelioid subtype of MPM was the most
15
16 common pathological type in all studies, excluding the one reported by Creaney et al.²⁵
17
18 Totally, 69.9% (982/1404) MPM were epithelioid subtype (ranged from 29.9% to 100%).
19
20 Analysis in terms of histologic type has shown that SMRP levels were significantly elevated
21
22 in epithelioid subtype MPM than other types.^{21,23,29} This could explain partly the quite low
23
24 sensitivity of SMRPs in MPM diagnosis. Third, control populations were very heterogeneous
25
26 from one study to another; and various cutoff points were used for distinguishing between
27
28 MPM and controls, other cancers or benign respiratory diseases, according to the best
29
30 combination of sensitivity and specificity. These issues regarding accuracy of diagnosis could
31
32 also lead to biased results.
33
34
35
36
37
38
39
40

41 It should be mentioned that since our previous meta-analysis¹¹ had been published, the
42
43 field concerning the use of SMRPs in clinical practice moved forward significantly.¹⁰ It has
44
45 been recognized that SMRPs are not only diagnostic markers, but also serve as markers of
46
47 disease course and response to treatment.^{56,57} Therefore, the application of SMRPs in the near
48
49 future clinical practice may probably be in monitoring response to therapy, rather than in
50
51 guiding diagnostic decisions and risk assessment of asbestos-exposed populations.
52
53
54
55

56 In conclusion, current evidence supported that SMRPs in both serum and PF were
57
58
59
60

1
2
3
4 helpful markers for the diagnosis of MPM. The overall diagnostic performance of SMRPs in
5
6 serum and PF was similar, and serum MPF had superior diagnostic accuracy compared to
7
8 serum mesothelin. The negative results of SMRP determinations were not sufficiently to
9
10 exclude non-MPM, whereas the positive test results might be helpful in confirming MPM.
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Funding: This work was supported in part by a grant from National Natural Science Foundation of China (No. 81270149), and in part by a grant from the 12th Five-Year National Science and Technology Program of Social Development, Ministry of Science and Technology, China (No. 2012BAI05B02).

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Competing interests: The authors have declared that no conflict of interest exists.

Data sharing statement: No additional data available.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin family proteins for malignant pleural mesothelioma: updated meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ Group products and to exploit all subsidiary rights, as set out in our license set out at:

http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.p

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.
- 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.

- 1
2
3
4 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum
5
6 diagnostic markers. *Pathol Int* 2006; 56:649-54.
7
8
9 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins
11
12 and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
13
14 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides
15
16 for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
17
18
19 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant
20
21 pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012;
22
23 30:1541-9.
24
25
26 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of
27
28 studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
29
30
31 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the
32
33 quality assessment of studies of diagnostic accuracy included in systematic reviews.
34
35 *BMC Med Res Methodol* 2003; 3:25.
36
37
38 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic
39
40 studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
41
42
43 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test
44
45 into a summary ROC curve: data-analytic approaches and some additional
46
47 considerations. *Stat Med* 1993; 12:1293-316.
48
49
50 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant
51
52 pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.
53
54
55 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
56
57
58
59
60

- 1
2
3
4 J Clin Epidemiol 1995; 48:119-30.
- 5
6 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
7
8 review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-86.
- 9
10
11 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
12
13 graphical test. BMJ 1997; 315:629-34.
- 14
15
16 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
17
18 mesothelioma. Lancet 2003; 362:1612-6.
- 19
20
21 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
22
23 mesothelin precursor is a useful tumor marker in the serum of patients with
24
25 mesothelioma. Clin Cancer Res 2006; 12:4225-31.
- 26
27
28 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
29
30 diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;
31
32 173:1155-60.
- 33
34
35 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
36
37 pleural mesothelioma. Clin Chem 2007; 53:666-72.
- 38
39
40 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
41
42 diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
- 43
44
45 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
46
47 patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
- 48
49
50 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
51
52 mesothelioma: analytical evaluation of an automated immunoassay and preliminary
53
54 clinical results. Clin Chem Lab Med 2007; 45:634-8.
- 55
56
57
58
59
60

- 1
2
3
4 28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early
5
6 detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol*
7
8 *Biomarkers Prev* 2008; 17:163-70.
9
- 10
11 29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked
12
13 immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum
14
15 tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.
16
17
- 18
19 30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker
20
21 of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung*
22
23 *Cancer* 2008; 62:45-54.
24
25
- 26
27 31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural
28
29 malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.
30
- 31
32 32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte
33
34 potentiating factor, and mesothelin proteins as markers in the serum of patients with
35
36 malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.
37
38
- 39
40 33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble
41
42 mesothelin-related proteins in patients with malignant pleural mesothelioma in
43
44 comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.
45
- 46
47 34 Davies HE, Sadler RS, Bielsa S, et al. Clinical impact and reliability of pleural fluid
48
49 mesothelin in undiagnosed pleural effusions. *Am J Respir Crit Care Med* 2009; 180:
50
51 437-44.
52
53
- 54
55 35 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of
56
57 soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related
58
59
60

- 1
2
3
4 pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers*
5
6 *Prev* 2009; 18:646-50.
7
8
9 36 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
10
11 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
12
13 1:313-7.
14
15
16 37 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
17
18 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
19
20 *Care Med* 2010; 181:620-5.
21
22
23
24 38 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
25
26 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
27
28 2011; 74:55-60.
29
30
31 39 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
32
33 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
34
35 6:1587-93.
36
37
38
39 40 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
40
41 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
42
43 26:160-5.
44
45
46 41 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
47
48 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.
49
50
51 42 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin
52
53 and osteopontin for the diagnosis of malignant pleural mesothelioma. *Egyptian*
54
55 *Journal of Chest Diseases and Tuberculosis* 2012; 61:121-8.
56
57
58
59
60

- 1
2
3
4 43 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination
5
6 improves the diagnosis of mesothelioma in pleural effusions. *J Thorac Oncol* 2012;
7
8 7:883-9.
9
- 10
11 44 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic
12
13 and prognostic markers of malignant pleural mesothelioma in Egyptian patients
14
15 undergoing pleurodesis. *Egyptian Journal of Chest Diseases and Tuberculosis* 2013;
16
17 62:115-20.
18
19
- 20
21 45 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related
22
23 peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its
24
25 contribution to cytology. *Cancer Invest* 2013; 31:43-50.
26
27
- 28
29 46 Creaney J, Sneddon S, Dick IM, et al. Comparison of the diagnostic accuracy of the
30
31 MSLN gene products, mesothelin and megakaryocyte potentiating factor, as
32
33 biomarkers for mesothelioma in pleural effusions and serum. *Dis Markers* 2013; 35:
34
35 119-27.
36
37
- 38
39 47 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in
40
41 serum in the diagnosis of pleural mesothelioma. *Anticancer Res* 2013; 33:2707-13.
42
- 43
44 48 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids:
45
46 comparison with CYFRA 21-1 and CEA. *Med Oncol* 2013; 30:543.
47
48
- 49
50 49 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin
51
52 in undiagnosed pleural effusions. *Eur Respir J* 2013; 41:18-24.
53
- 54
55 50 Bayram M, Dongel I, Akbaş A, et al. Serum biomarkers in patients with mesothelioma and
56
57 pleural plaques and healthy subjects exposed to naturally occurring asbestos. *Lung*.
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
- DOI 10.1007/s00408-013-9526-9.
- 51 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of
malignant mesothelioma: a consensus statement from the International Mesothelioma
Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.
- 52 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant
pleural mesothelioma. *Biomark Med* 2011; 5:261-73.
- 53 Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M,
Smith GD, Altman DG, eds. *Systematic reviews in health care. Meta-analysis in
context*. London: BMJ Publishing Group 2001:248-82.
- 54 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. *Users' guides to
the medical literature. A manual for evidence-based clinical practice*. Chicago: AMA
Press, 2002; 121-40.
- 55 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in
mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85:265-72.
- 56 Grigoriu BD, Chahine B, Vachani A, et al. Kinetics of soluble mesothelin in patients with
malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009;
179: 950-4.
- 57 Wheatley-Price P, Yang B, Patsios D, et al. Soluble mesothelin-related Peptide and
osteopontin as markers of response to treatment in malignant mesothelioma. *J Clin
Oncol* 2010; 28: 3316-22.

Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of soluble mesothelin-related peptides in sera

Study	Subjects, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	MPF	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

1										
2										
3										
4										
5	Portal et al ³⁵	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
6										
7	Hollevoet et al ³⁷	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
8										
9	Hollevoet et al ³⁷	507	MPF	13.46 ng/ml	58	13	27	409	20	11
10										
11	Creaney et al ³⁸	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
12										
13	Cristaudo et al ³⁹	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
14										
15	Dipalma et al ⁴⁰	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
16										
17	Ashour et al ⁴²	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
18										
19	Amany et al ⁴⁴	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
20										
21	Creaney et al ⁴⁶	121	Mesothelin	2.4 nmol/L	40	3	26	52	13	11
22										
23	Creaney et al ⁴⁶	121	MPF	33.2 ng/mL	34	3	32	52	13	11
24										
25	Ferro et al ⁴⁷	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
26										
27	Hooper et al ⁴⁹	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12
28										
29	Bayram et al ⁵⁰	546	Mesothelin	1.63 nmol/L	14	89	10	433	13	10

SMRP = soluble mesothelin-related peptide; MPF = megakaryocyte potentiating factor, OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 2. Study summary of soluble mesothelin-related peptides in pleural fluids *

Study	Patients, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Davies et al ³⁴	166	Mesothelin	20.0 nmol/L	17	14	7	128	14	11
Fujimoto et al ³⁶	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴¹	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴²	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴³	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴⁴	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁵	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Creaney et al ⁴⁶	98	Mesothelin	20.0 nmol/L	30	3	13	52	13	11
Creaney et al ⁴⁶	98	MPF	600.0 ng/mL	35	3	6	52	13	11
Filiberti et al ⁴⁸	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁹	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMRP = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23-28, 30, 31, 33, 35, 37-40, 42, 44, 46, 47, 49, 50	22, 29, 30, 32, 37, 46
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.62 (0.56 – 0.67)
Heterogeneity* (p)	70.20 (< 0.001)	53.08 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.96 (0.94 – 0.97)
Heterogeneity (p)	352.24 (< 0.001)	17.60 (0.001)
PLR (95% CI)	4.78 (3.59 – 6.36)	12.39 (5.53 – 27.74)
Heterogeneity (p)	185.80 (< 0.001)	14.42 (0.006)
NLR (95% CI)	0.45 (0.40 – 0.51)	0.34 (0.19 – 0.63)
Heterogeneity (p)	50.65 (< 0.001)	67.07 (< 0.001)
DOR (95% CI)	11.84 (8.12 – 17.27)	36.08 (12.91 – 100.85)
Heterogeneity (p)	95.80 (< 0.001)	13.40 (0.009)
AUC (SEM)	0.785 (0.033)	0.941 (0.094)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 45, 47	21, 23, 24, 25, 28, 30, 33, 40
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM vs other cancers	MPM vs benign diseases
Study, Ref. No.	23, 34, 36, 41, 42, 48	36, 41, 42, 48
Sensitivity (95% CI)	0.75 (0.69 – 0.80)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.36 (0.929)	1.08 (0.783)
Specificity (95% CI)	0.76 (0.71 – 0.82)	0.87 (0.80 – 0.93)
Heterogeneity (p)	4.88 (0.430)	6.74 (0.081)
PLR (95% CI)	2.95 (2.32 – 3.75)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.83 (0.437)	7.01 (0.071)
NLR (95% CI)	0.34 (0.27 – 0.43)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.94 (0.857)	1.83 (0.608)
DOR (95% CI)	8.96 (5.78 – 13.89)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.34 (0.648)	5.26 (0.154)
AUC (SEM)	0.809 (0.025)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

1
2
3
4
5
6
7 Diagnostic values of soluble mesothelin-related peptides for malignant pleural
8 mesothelioma: updated meta-analyses
9
10

11
12
13
14 Short running head: SMRPs in mesothelioma
15

16
17
18 Ai Cui^{1*}, Xiao-Guang Jin^{1*}, Kan Zhai², Zhao-Hui Tong¹, Huan-Zhong Shi^{1,2}
19

20
21
22 * These authors contributed equally to the present work
23

24
25
26
27 ¹ Department of Respiratory and Critical Care Medicine, Beijing Chaoyang Hospital, Capital
28 Medical University, Beijing, China; ² Center of Medical Research, Beijing Institute of
29 Respiratory Diseases, Beijing, China.
30
31
32

33
34
35 Correspondence to Huan-Zhong Shi, MD, PhD, Department of Respiratory and Critical Care
36 Medicine, Beijing Chaoyang Hospital, Capital Medical University, 8 Gongren Tiyuchang
37 Nanlu, Chaoyang District, Beijing 100020, China; Telephone: (86) 10 85231412; Fax: (86) 10
38 85231412; E-mail: shihuanzhong@sina.com
39
40
41
42
43
44

45
46 **Keywords:** Diagnosis; malignant pleural mesothelioma; soluble mesothelin family proteins
47
48

49
50 **Word counts:** 2,767
51
52
53
54
55
56
57
58
59
60

Contributors

HZS was responsible for the study conception and protocol design, and wrote the first draft of the paper. AC and XGJ were responsible for the overall study co-ordination under the supervision of HZS with contributions from KZ and ZHT. All literature searching, abstract screening, study selection and data extraction was undertaken independently by AC and XGJ with referral to KZ as a third reviewer as necessary. Assessment of methodological quality was also undertaken by ZHT and HZS. All authors have read and approved the final version of the manuscript.

Funding: This work was supported in part by a grant from National Natural Science Foundation of China (No. 81270149), and in part by a grant from the 12th Five-Year National Science and Technology Program of Social Development, Ministry of Science and Technology, China (No. 2012BAI05B02).

Competing interests: The authors have declared that no conflict of interest exists.

License for publication: I [Huan-Zhong Shi] The Corresponding Author of this article contained within the original manuscript which includes any diagrams & photographs and any related or stand alone film submitted (Diagnostic values of soluble mesothelin family proteins for malignant pleural mesothelioma: updated meta-analyses) has the right to grant on behalf of all authors and does grant on behalf of all authors, a license to the BMJ Publishing Group Ltd and its licensees, to permit this Contribution (if accepted) to be published in any BMJ

1
2
3
4
5
6
7 Group products and to exploit all subsidiary rights, as set out in our license set out at:
8

9 http://group.bmj.com/products/journals/instructions-for-authors/co_owned_licence.pdf
10
11

12
13
14 **Data sharing statement:** There is no additional data available.
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 ABSTRACT
8
9

10
11 **Objective** Although the values of soluble mesothelin-related peptides (SMRPs), including
12 mesothelin and megakaryocyte potentiating factor, in serum or/and pleural fluid for
13 diagnosing malignant pleural mesothelioma (MPM) have been extensively studied, the exact
14 diagnostic accuracy of these SMRPs remains controversial. The purpose of the present
15 meta-analyses was to update the overall diagnostic accuracy of SMRPs in serum, and further
16 to establish that of SMRPs in pleural fluid for MPM.
17
18
19

20
21 **Design** Systematic review and meta-analysis.
22
23

24
25 **Methods** In total, 30 articles of diagnostic studies were included in the current
26 meta-analyses. Sensitivity, specificity, and other measures of accuracy of SMRPs in serum
27 and pleural fluid for the diagnosis of MPM were pooled using random effects models.
28
29 Summary receiver operating characteristic curves were used to summarize overall test
30 performance.
31
32

33
34 **Results** The summary estimates of sensitivity, specificity, positive likelihood ratio, negative
35 likelihood ratio, and diagnostic odds ratio were as follows: serum: 0.61, 0.87, 5.71, 0.43, and
36 14.43, respectively; pleural fluid: 0.79, 0.85, 4.78, 0.30, and 19.50, respectively. It was also
37 found that megakaryocyte potentiating factor in serum had a superior diagnostic accuracy
38 compared to mesothelin for MPM.
39
40
41
42
43
44
45
46
47

48
49 **Conclusions** SMRPs in both serum and pleural fluid were helpful markers for diagnosing
50 MPM with similar diagnostic accuracy. The negative results of SMRP determinations were
51 not sufficiently to exclude non-MPM, and the positive test results indicated that further
52
53
54

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

invasive diagnostic steps might be necessary for the diagnosis of MPM.

For peer review only

ARTICLE SUMMARY

Article focus

- The diagnosis of malignant pleural mesothelioma is always a challenging endeavor.
- To date, no single marker or panel of soluble biomarkers is available for a clear diagnosis of malignant pleural mesothelioma.
- The concentrations of soluble mesothelin-related peptides, including mesothelin and megakaryocyte potentiating factor, have been found to be increased in serum and pleural fluid of patients with malignant pleural mesothelioma.

Comment [U1]: mesothelin family proteins

Key messages

- Soluble mesothelin-related peptides in both serum and pleural fluid are helpful markers for the diagnosis of malignant pleural mesothelioma.
- Determination of soluble mesothelin-related peptides might be helpful in confirming pleural mesothelioma if the results were higher than the cut-off values, while the negative results were not sufficiently to exclude non-mesothelioma.

Comment [U2]: mesothelin family proteins

Comment [U3]: mesothelin family proteins

Strengths and limitations of this study

- The studies included this meta-analyses were methodologically satisfactory and their results were consistent and close.
- The subjects in control groups were very heterogeneous from one study to another; and various cutoff points were used for distinguishing between malignant pleural

mesothelioma and the other diseases.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Malignant pleural mesothelioma (MPM) is a highly aggressive, almost uniformly fatal tumor, primarily caused by exposure to asbestos.¹ Current therapeutic options for MPM are limited, and the prognosis is poor.² When the patients are treated with standard of care chemotherapy, cisplatin and an antifolate, median survival is approximately one year.^{3,4} Early diagnosis offers the best hope for a favorable prognosis, however, the early and reliable diagnosis of MPM is extremely difficult, only 5% of patients with MPM present with stage IA disease.^{5,6} Therefore, there is a critical need for reliable and noninvasive tools that shorten this diagnostic delay.

Many soluble markers, such as mesothelin family proteins, in serum or pleural fluid have been evaluated to facilitate the non-invasive diagnostic work-up for MPM.⁶ Mesothelin is a 40-kDa cell surface glycoprotein that is highly expressed in MPM, pancreatic cancers, ovarian cancers, and some other cancers. Mesothelin is synthesized as a precursor 69-kDa protein and forms two proteins, the membrane-bound mesothelin and a soluble 31-kD N-terminal fraction, megakaryocyte potentiating factor (MPF), also denominated “N-ERC/mesothelin”.⁷ Although mesothelin is bound to cell membrane, a circulating form termed soluble mesothelin has been reported to be related to abnormal splicing events leading to synthesis of a secreted protein and to an enzymatic cleavage from membrane-bound mesothelin.⁸

It has been well documented that soluble mesothelin-related peptides (SMRPs), including both soluble mesothelin and MPF, have been found in human serum and pleural fluid (PF).^{9,10} Actually, the diagnostic accuracy of SMRP detections for MPM has been

Comment [U4]: added

1
2
3
4
5
6
7 extensively studied, but the exact role of these detections needs to be elucidated. In 2010, we
8 performed and published first meta-analysis reporting the overall diagnostic accuracy of
9 serum SMRPs for diagnosing MPM, and our results showed that serum SMRP determinations
10 played a role in the diagnosis of MPM.¹¹ More recently, Hollevoet et al performed an
11 individual patient data meta-analysis to evaluate serum SMRP for diagnosing MPM, and
12 found that a positive test result at a high-specificity threshold is a strong incentive to urge
13 further diagnostic steps; however, the poor sensitivity of SMRPs limits its added value to
14 early diagnosis of MPM.¹² Since that time, many additional clinical studies determining the
15 concentrations of SMRPs in serum and PF have been reported. We thus performed the present
16 meta-analyses to update the overall diagnostic accuracy of serum SMRPs, and further to
17 establish that of PF SMRPs for diagnosing MPM.
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Comment [U5]: could play

METHODS

Search strategy and study selection

MEDLINE (PubMed database) and EMBASE were searched for suitable studies until November 28, 2013; no lower date limit was applied. Search keywords included: “soluble mesothelin-related peptides/SMRP”, “mesothelin”, “megakaryocyte potentiating factor/MPF”, “mesothelioma”. Articles were also identified by use of the related-articles function in PubMed. References of articles identified were further searched manually. Although no language restrictions were imposed initially, for the full-text review and final analysis our resources only permitted review of English articles. Conference abstracts and letters to the journal editors were excluded because of the limited data presented in them.

A study was included in the meta-analyses when it provided SMRP values in serum or/and PF for both sensitivity and specificity of the diagnosis of MPM. The studies including at least 10 specimens were selected to be included in the meta-analyses, since very small studies may be vulnerable to selection bias. Publications with evidence of possible overlap of patients with other studies were discussed by AC, XGJ, and KZ and only the best-quality study was used. Two reviewers (ZHT and HZS) independently judged study eligibility while screening the citations. Disagreements were resolved by consensus.

Data extraction and quality assessment

The final set of English articles was assessed independently by two reviewers (AC and XGJ). Data retrieved from the reports included author, publication year, study characteristics,

1
2
3
4
5
6
7 participant characteristics, diagnostic methods, sensitivity and specificity data, cut-off value
8
9 and methodological quality. All eligible studies were assessed for methodologic quality using
10
11 guidelines published by the STARD (standards for reporting diagnostic accuracy, maximum
12
13 score 25) initiative¹³ (ie, guidelines that aim to improve the quality of reporting in diagnostic
14
15 studies) and the QUADAS (quality assessment for studies of diagnostic accuracy, maximum
16
17 score 14) tool¹⁴ (ie, appraisal by use of empirical evidence, expert opinion, and formal
18
19 consensus to assess the quality of primary studies of diagnostic accuracy).
20
21
22
23

24 **Statistical analyses**

25
26 Standard methods recommended for meta-analyses of diagnostic test evaluations¹⁵ were used.
27
28 Analyses were performed using two statistical software programs (Stata, version 9; Stata
29
30 Corporation; College Station, TX; and Meta-DiSc for Windows; XI Cochrane Colloquium;
31
32 Barcelona, Spain). We computed the following measures of test accuracy for each study:
33
34 sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and
35
36 diagnostic odds ratio (DOR).
37
38

39
40 The analyses were based on a summary receiver operating characteristic (SROC)
41
42 curves.^{15,16} The sensitivity and specificity for the single test threshold identified for each study
43
44 were used to plot an SROC curve.^{16,17} A random-effects model was used to calculate the
45
46 average sensitivity, specificity and the other measures across studies.^{18,19} The Chi-square and
47
48 Fisher's exact tests were used to detect statistically significant heterogeneity across studies.
49
50 Since publication bias is of concern for meta-analyses of diagnostic studies, we tested for the
51
52 potential presence of this bias using funnel plots and the Egger test.²⁰
53
54
55
56
57
58
59
60

RESULTS

Studies included

After independent review, sixty-two publications determining concentrations of human SMRPs in serum or/and PF were considered to be eligible for inclusion in the meta-analyses. Of these publications, thirty-two were excluded (Online supplementary appendix 1). Subsequently, thirty publications²¹⁻⁵⁰ were available for analysis of diagnostic accuracy of SMRPs. Eleven publications from 12 studies²¹⁻³¹ were included in our previous meta-analysis.¹¹ After that, additional 19 publications from 28 studies³²⁻⁵⁰ were added in the current meta-analyses.

Multiple ELISA kits were available for determining SMRP concentrations. Mesomark, which has been approved by the US Food and Drug Administration, was used to determine mesothelin in most studies, and the other mesothelin ELISA kits were used in the other 4 studies.^{21,30,31,34} Serum mesothelin concentrations were determined in 23 studies (22 articles),^{21,23-31,33,35,37-40,42,44,46,47,49,50} and serum MPF concentrations were determined in 5 studies^{22,30,32,37,46} (Table 1). In the study by Scherpereel et al,²³ the authors compared serum SMRP concentrations in MPM patients with those in asbestos exposed-patients with benign pleural lesions and with patients with pleural metastasis of carcinomas separately, using two different cut-off values, we thus treated these research data as two independent studies. SMRP concentrations in PF were determined in 11 articles from 12 studies (mesothelin in 11 and MPF in 1) (Table 2).^{23,34,36,41-47,49}

The clinical characteristics of the studies, along with STARD and QUADAS scores, are

1
2
3
4
5
6
7 outlined in Table 1 and Table 2.
8
9

10 11 **Study characteristics**

12
13 On review, the studies showed large differences in number of participants, clinical
14 characteristics (especially histologic subtypes of MPM, and type of control groups), and
15 reported diagnostic cut-off values of SMRPs (Online supplementary appendix 2). For serum
16 SMRP studies, the average samples size was 265 (range from 40 – 1,086), the subjects
17 included 1,562 patients with MPM and 5,988 non-MPM. For PF SMRP studies, the average
18 samples size was 126 (range from 40 – 275), the subjects included 460 patients with MPM
19 and 1,046 non-MPM.
20
21

22 In 21 publications, MPM diagnosis was completely based on pathological findings in
23 pleural biopsies, with or without positive cytological results; while in the remaining 9
24 publications, some MPM patients were diagnosed just based on the cytological findings.
25 Totally, the quality of study design and reporting diagnostic accuracy of most studies were
26 good, since 26 of 30 publications had higher STARD scores (≥ 13) and 21 studies had higher
27 QUADAS scores (≥ 10).
28

29 30 **Publication bias**

31 The funnel plots for publication bias showed asymmetry for serum SMRP studies (Figure 1A),
32 evaluation of publication bias showed that Egger tests were significant for serum SMRPs ($p =$
33 0.038). Similarly, the funnel plots for publication bias also showed asymmetry for PF SMRP
34 studies (Figure 1B), Egger tests showed that this was significant for PF SMRPs ($p = 0.035$).
35
36
37
38
39
40
41
42
43
44
45

1
2
3
4
5
6
7 These results indicated a potential for publication bias for both serum and PF SMRP studies.
8
9

10 11 **Diagnostic accuracy**

12
13
14 Figure 2A shows forest plot of sensitivity and specificity for 28 serum SMRP studies in the
15 diagnosis of MPM. The sensitivity ranged from 0.33 to 0.95 (pooled 0.61, 95% CI 0.58 –
16 0.63), while specificity ranged from 0.60 – 1.00 (pooled 0.87, 95% CI 0.86 – 0.88). It was
17 also noted that PLR was 5.71 (95% CI 4.28 – 7.62), NLR was 0.43 (95% CI 0.38 – 0.50), and
18 DOR was 14.43 (95% CI 9.98 – 20.87). X^2 values of sensitivity, specificity, PLR, NLR, and
19 DOR were 153.68, 460.32, 272.50, 143.64, and 142.07, respectively, with all $p < 0.001$,
20 indicating a significant heterogeneity between studies.
21
22
23
24
25
26
27

28
29 Figure 2B shows forest plot of sensitivity and specificity for 12 PF SMRP studies in the
30 diagnosis of MPM. The sensitivity ranged from 0.70 to 1.00 (pooled 0.79, 95% CI 0.75 –
31 0.83), while specificity ranged from 0.65 – 0.95 (pooled 0.85, 95% CI 0.83 – 0.87). We also
32 noted that PLR was 4.78 (95% CI 3.52 – 6.50), NLR was 0.30 (95% CI 0.24 – 0.36), and
33 DOR was 19.50 (95% CI 12.14 – 31.33). X^2 values of sensitivity, specificity, PLR, NLR, and
34 DOR were 41.33 ($p < 0.001$), 46.78 ($p < 0.001$), 38.64 ($p < 0.001$), 14.53 ($p = 0.205$), and
35 23.49 ($p = 0.015$), respectively, indicating some a heterogeneity between studies.
36
37
38
39
40
41
42
43

44 The graphs of SROC curves for SMRP determinations showing sensitivity versus 1 –
45 specificity from individual studies are shown in Figure 3. SROC curve of serum SMRPs was
46 not positioned near the desirable upper left corner of SROC curve, and the maximum joint
47 sensitivity and specificity was 0.741 (SEM, 0.029) (Figure 3A); while area under curve (AUC)
48 was 0.806 (SEM, 0.032). The maximum joint sensitivity and specificity of PF SMRP was
49
50
51
52
53
54

0.820 (SEM, 0.022); while AUC was 0.890 (SEM, 0.021) (Figure 3B).

Totally, the diagnostic performance of SMRPs in serum and PF was similar.

Subgroup analysis

We first analyzed the diagnostic values of serum mesothelin and MPF separately, and the results are presented in Table 3. Based on the comparisons of sensitivity, specificity, PLR, NLR, DOR, and AUC, the diagnostic performance of serum MPF was superior to that of serum mesothelin.


Data from 6 studies^{21,22,24,28,30,31} were available for comparing diagnostic accuracy of serum SMRPs differentiating MPM from healthy control subjects, 9 studies^{21,23,24,26,30,31,33,45,47} were available for comparing that of differentiating MPM from other malignancies, 8 studies^{21,23,24,25,28,30,33,40} were available for comparing that of differentiating MPM from asbestos-exposed subjects. As shown in Table 4, the values of sensitivity, specificity, PLR, NLR, DOR, and AUC of SMRPs for discriminating MPM from healthy control subjects were quite acceptable, which were better than those for discriminating MPM from patients with the other cancers or from asbestos-exposed people. By using serum SMRPs, it was the most difficult to identify MPM from other cancers, compared with healthy controls or asbestos-exposed people.

Five studies^{23,35,41,42,48} provided required data for comparing diagnostic accuracy of PF mesothelin differentiating MPM from the other cancers, and 4 studies^{36,41,42,48} for differentiating MPM from benign pleural effusions (Table 5). Totally, diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was very similar to that of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

differentiating MPM from benign pleural effusions.

For peer review only



DISCUSSION

The diagnosis of MPM is always a challenging endeavor because (1) MPM may appear in patients up to 30 – 40 years after exposure to asbestos, (2) the clinical and imaging signs of MPM are unspecific, and (3) a definitive diagnosis, which relies on histology, can sometimes be very difficult to achieve, even with the use of immunohistochemistry.⁵ To date, no single marker or panel of soluble biomarkers are available for a clear diagnosis of MPM.^{51,52}

In the present meta-analyses, our results indicated that the pooled sensitivity of serum and PF SMRPs was 0.61 and 0.79, respectively; and their specificity was 0.87 and 0.85 respectively. These data indicated that sensitivity and specificity of SMRPs in serum and PF were not as high as expected. SMRPs might be helpful in confirming (ruling in) MPM if the results were higher than the cut-off values. Thus, positive SMRP test results suggested that invasive diagnostic steps, such as medical thoracoscopy, might be necessary. However, the relative low sensitivity, especially serum SMRPs, that was not sufficiently low to exclude non-MPM when a patient's SMRP results were lower than the cut-off values. Therefore, the associated poor sensitivity of SMRPs clearly limits their added value to diagnosis of MPM.

As previously described,¹¹ SROC curve presents a global summary of test performance, and shows the trade off between sensitivity and specificity, while DOR is a single indicator of test accuracy that combines the data from sensitivity and specificity into a single number. The results of our analyses based SROC curves showed the maximum joint sensitivity and specificity of serum and PF SMRPs were 0.741 and 0.820, respectively; while their AUCs were 0.806 and 0.890, respectively, indicating level of overall accuracy were also not as high

Comment [U7]: revised

1
2
3
4
5
6
7 as expected. We also found that the pooled DORs of serum and PF SMRPs were 14.43, and
8
9 19.50, respectively, indicating that SMRPs seemed to be helpful in the diagnosis of MPM,
10
11 although they were not perfect.

12
13 Since SROC curve and DOR are not easy to interpret and use in clinical practice, and since
14
15 PLR and NLR are considered more clinically meaningful,^{53,54} we further presented both PLR
16
17 and NLR as our measures of diagnostic accuracy. If a value is greater than 10 or less than 0.1,
18
19 PLR or NLR generates large and often conclusive shifts from pretest to post-test probability
20
21 (indicating high accuracy).⁵⁵ A PLR value of 5.71 with serum SMRPs suggests that patients
22
23 with MPM have a near 6-fold higher chance of being SMRP-positive compared with patients
24
25 without MPM, and this was not high enough for the clinical purpose. On the other hand, NLR
26
27 of serum SMRPs was found to be 0.43. If serum SMRP results were negative, the probability
28
29 that this patient has MPM is 43%, which is not low enough to rule out MPM. The very similar
30
31 results were found with PF SMRPs.
32
33
34

35 Although both mesothelin and MPF belong to SMRPs, we noted in the current
36
37 meta-analyses that the overall diagnostic measures, including sensitivity, specificity, PLR,
38
39 NLR, DOR, and AUC, of serum MPF, were better than those of serum mesothelin. Therefore,
40
41 MPF had a superior diagnostic accuracy compared to mesothelin for MPM. We also noted
42
43 that diagnostic performance of serum SMRP for discriminating MPM from healthy control
44
45 subjects was the best (although not as good as expected), followed by that for discriminating
46
47 MPM from patients with other cancers or from asbestos-exposed people. In addition, the
48
49 overall diagnostic accuracy of PF SMRP differentiating MPM from the other cancers was
50
51 similar to that of differentiating MPM from benign pleural effusions.
52
53
54

Comment [U8]: mesothelin family proteins

1
2
3
4
5
6
7 Our meta-analyses had several limitations. First, exclusion of conference abstracts,
8 letters to the editors, and non-English language studies may have led to publication bias.
9
10 Indeed, we observed a publication bias for both serum and PF SMRP studies. Publication bias
11 may also be introduced by inflation of diagnostic accuracy estimates since studies that report
12 positive results are more likely to be accepted for publication. Second, pathological types of
13 MPM were not specified in 5 studies,^{35,42,50} epithelioid subtype of MPM was the most
14 common pathological type in all studies, excluding the one reported by Creaney et al.²⁵
15
16 Totally, 69.9% (982/1404) MPM were epithelioid subtype (ranged from 29.9% to 100%).
17
18 Analysis in terms of histologic type has shown that SMRP levels were significantly elevated
19 in epithelioid subtype MPM than other types.^{21,23,29} This could explain partly the quite low
20 sensitivity of SMRPs in MPM diagnosis. Third, control populations were very heterogeneous
21 from one study to another; and various cutoff points were used for distinguishing between
22 MPM and controls, other cancers or benign respiratory diseases, according to the best
23 combination of sensitivity and specificity. These issues regarding accuracy of diagnosis could
24 also lead to biased results.
25
26
27
28
29
30
31
32
33
34
35
36
37
38

39 In conclusion, current evidence supported that SMRPs in both serum and PF were
40 helpful markers for the diagnosis of MPM. The overall diagnostic performance of SMRPs in
41 serum and PF was similar, and serum MPF had superior diagnostic accuracy compared to
42 serum mesothelin. The negative results of SMRP determinations were not sufficiently to
43 exclude non-MPM, whereas the positive test results might be helpful in confirming MPM.
44
45
46
47
48
49

50
51 Finally, it should be mentioned that since our previous meta-analysis¹¹ had been
52 published, the field concerning the use of SMRPs in clinical practice moved forward
53
54

Comment [U9]: deleted

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

significantly.¹⁰ It has been recognized that SMRPs are not only diagnostic markers, but also serve as markers of disease course and response to treatment.^{56,57} Therefore, the application of SMRPs in the near future clinical practice may probably be in monitoring response to therapy, rather than in guiding diagnostic decisions and risk assessment of asbestos-exposed populations.

Comment [U10]: moved forward.

For peer review only

References

- 1 Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. *Lancet* 2005; 366:397-408.
- 2 West SD, Lee YC. Management of malignant pleural mesothelioma. *Clin Chest Med* 2006; 27:335-54.
- 3 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. *J Clin Oncol* 2003; 21:2636-44.
- 4 van Meerbeeck JP, Gaafar R, Manegold C, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. *J Clin Oncol* 2005; 23:6881-9.
- 5 Scherpereel A, Astoul P, Baas P, et al. Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. *Eur Respir J* 2010; 35:479-95.
- 6 van der Bij S, Schaake E, Koffijberg H, et al. Markers for the non-invasive diagnosis of mesothelioma: a systematic review. *Br J Cancer* 2011; 104:1325-33.
- 7 Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. *Proc Natl Acad Sci U S A* 1996; 93:136-40.
- 8 Sapede C, Gauvrit A, Barbieux I, et al. Aberrant splicing and protease involvement in

- mesothelin release from epithelioid mesothelioma cells. *Cancer Sci* 2008; 99:590-4.
- 9 Maeda M, Hino O. Molecular tumor markers for asbestos-related mesothelioma: serum diagnostic markers. *Pathol Int* 2006; 56:649-54.
- 10 Pantazopoulos I, Boura P, Xanthos T, et al. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. *Eur Respir J* 2013; 41:706-15.
- 11 Luo L, Shi HZ, Liang QL, et al. Diagnostic value of soluble mesothelin-related peptides for malignant mesothelioma: a meta-analysis. *Respir Med* 2010; 104:149-56.
- 12 Hollevoet K, Reitsma JB, Creaney J, et al. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis. *J Clin Oncol* 2012; 30:1541-9.
- 13 Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. *BMJ* 2003; 326:41-4.
- 14 Whiting P, Rutjes AW, Reitsma JB, et al. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. *BMC Med Res Methodol* 2003; 3:25.
- 15 Deville WL, Buntinx F, Bouter LM, et al. Conducting systematic reviews of diagnostic studies: didactic guidelines. *BMC Med Res Methodol* 2002; 2:9.
- 16 Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. *Stat Med* 1993; 12:1293-316.
- 17 Liang QL, Shi HZ, Qin XJ, et al. Diagnostic accuracy of tumour markers for malignant pleural effusion: a meta-analysis. *Thorax* 2008; 63:35-41.

- 1
2
3
4
5
6
7 18 Irwig L, Macaskill P, Glasziou P, et al. Meta-analytic methods for diagnostic test accuracy.
8
9 J Clin Epidemiol 1995; 48:119-30.
10
11 19 Vamvakas EC. Meta-analyses of studies of the diagnostic accuracy of laboratory tests: a
12
13 review of the concepts and methods. Arch Pathol Lab Med 1998; 122:675-86.
14
15 20 Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple,
16
17 graphical test. BMJ 1997; 315:629-34.
18
19 21 Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of
20
21 mesothelioma. Lancet 2003; 362:1612-6.
22
23 22 Onda M, Nagata S, Ho M, et al. Megakaryocyte potentiation factor cleaved from
24
25 mesothelin precursor is a useful tumor marker in the serum of patients with
26
27 mesothelioma. Clin Cancer Res 2006; 12:4225-31.
28
29 23 Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the
30
31 diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 2006;
32
33 173:1155-60.
34
35 24 Beyer HL, Geschwindt RD, Glover CL, et al. MESOMARK: a potential test for malignant
36
37 pleural mesothelioma. Clin Chem 2007; 53:666-72.
38
39 25 Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the
40
41 diagnosis of malignant mesothelioma. Chest 2007; 132:1239-46.
42
43 26 Cristaudo A, Foddìs R, Vivaldi A, et al. Clinical significance of serum mesothelin in
44
45 patients with mesothelioma and lung cancer. Clin Cancer Res 2007; 13:5076-81.
46
47 27 Di Serio F, Fontana A, Loizzi M, et al. Mesothelin family proteins and diagnosis of
48
49 mesothelioma: analytical evaluation of an automated immunoassay and preliminary
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7 clinical results. *Clin Chem Lab Med* 2007; 45:634-8.

8
9
10 28 Amati M, Tomasetti M, Scartozzi M, et al. Profiling tumor-associated markers for early
11 detection of malignant mesothelioma: an epidemiologic study. *Cancer Epidemiol*
12 *Biomarkers Prev* 2008; 17:163-70.

13
14
15
16 29 Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked
17 immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum
18 tumor marker for mesothelioma. *Clin Cancer Res* 2008; 14:1431-7.

19
20
21
22 30 Iwahori K, Osaki T, Serada S, et al. Megakaryocyte potentiating factor as a tumor marker
23 of malignant pleural mesothelioma: evaluation in comparison with mesothelin. *Lung*
24 *Cancer* 2008; 62:45-54.

25
26
27
28 31 van den Heuvel MM, Korse CM, Bonfrer JM, et al. Non-invasive diagnosis of pleural
29 malignancies: the role of tumour markers. *Lung Cancer* 2008; 59:350-4.

30
31
32
33 32 Creaney J, Yeoman D, Demelker Y, et al. Comparison of osteopontin, megakaryocyte
34 potentiating factor, and mesothelin proteins as markers in the serum of patients with
35 malignant mesothelioma. *J Thorac Oncol* 2008; 3:851-7.

36
37
38
39 33 Schneider J, Hoffmann H, Dienemann H, et al. Diagnostic and prognostic value of soluble
40 mesothelin-related proteins in patients with malignant pleural mesothelioma in
41 comparison with benign asbestosis and lung cancer. *J Thorac Oncol* 2008; 3:1317-24.

42
43
44
45 34 Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, Davies RJ, Ferry BL, Lee YC.
46 Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural
47 effusions. *Am J Respir Crit Care Med* 2009; 180: 437-44.

48
49
50
51 35 Rodriguez Portal JA, Rodriguez Becerra E, Rodriguez Rodriguez D, et al. Serum levels of
52

1
2
3
4
5
6
7 soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related
8
9 pleural disease: relation with past asbestos exposure. *Cancer Epidemiol Biomarkers*
10
11 *Prev* 2009; 18:646-50.

12
13 36 Fujimoto N, Gemba K, Asano M, et al. Soluble mesothelin-related protein in pleural
14
15 effusion from patients with malignant pleural mesothelioma. *Exp Ther Med* 2010;
16
17 1:313-7.

18
19 37 Hollevoet K, Nackaerts K, Thimpont J, et al. Diagnostic performance of soluble
20
21 mesothelin and megakaryocyte potentiating factor in mesothelioma. *Am J Respir Crit*
22
23 *Care Med* 2010; 181:620-5.

24
25 38 Creaney J, Yeoman D, Musk AW, et al. Plasma versus serum levels of osteopontin and
26
27 mesothelin in patients with malignant mesothelioma--which is best? *Lung Cancer*
28
29 2011; 74:55-60.

30
31 39 Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma
32
33 osteopontin measurements in malignant pleural mesothelioma. *J Thorac Oncol* 2011;
34
35 6:1587-93.

36
37 40 Dipalma N, Luisi V, Di Serio F, et al. Biomarkers in malignant mesothelioma: diagnostic
38
39 and prognostic role of soluble mesothelin-related peptide. *Int J Biol Markers* 2011;
40
41 26:160-5.

42
43 41 Yamada S, Tabata C, Tabata R, et al. Clinical significance of pleural effusion mesothelin
44
45 in malignant pleural mesothelioma. *Clin Chem Lab Med* 2011; 49:1721-6.

46
47 42 Ashour WM, Amin H, Sabri IM, et al. Combined blood and pleural levels of mesothelin
48
49 and osteopontin for the diagnosis of malignant pleural mesothelioma. *Egyptian*
50
51

Journal of Chest Diseases and Tuberculosis 2012; 61:121-8.

43 Blanquart C, Gueugnon F, Nguyen JM, et al. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions. *J Thorac Oncol* 2012; 7:883-9.

44 Amany FM, Mohamed NA, El-Ghamry R, et al. Mesothelin and osteopontin as diagnostic and prognostic markers of malignant pleural mesothelioma in Egyptian patients undergoing pleurodesis. *Egyptian Journal of Chest Diseases and Tuberculosis* 2013; 62:115-20.

45 Canessa PA, Franceschini MC, Ferro P, et al. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology. *Cancer Invest* 2013; 31:43-50.

46 Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum. *Dis Markers* 2013; 35: 119-27.

47 Ferro P, Canessa PA, Battolla E, et al. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma. *Anticancer Res* 2013; 33:2707-13.

48 Filiberti R, Parodi S, Libener R, et al. Diagnostic value of mesothelin in pleural fluids: comparison with CYFRA 21-1 and CEA. *Med Oncol* 2013; 30:543.

49 Hooper CE, Morley AJ, Virgo P, et al. A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. *Eur Respir J* 2013; 41:18-24.

50 Bayram M, Dongel I, Akbaş A, Benli I, Akkoyunlu ME, Bakan ND. Serum biomarkers in

1
2
3
4
5
6
7 patients with mesothelioma and pleural plaques and healthy subjects exposed to
8 naturally occurring asbestos. *Lung*. DOI 10.1007/s00408-013-9526-9.

9
10
11 51 Husain AN, Colby TV, Ordonez NG, et al. Guidelines for pathologic diagnosis of
12 malignant mesothelioma: a consensus statement from the International Mesothelioma
13 Interest Group. *Arch Pathol Lab Med* 2009; 133:1317-31.

14
15
16 52 Cristaudo A, Bonotti A, Simonini S, et al. Soluble markers for diagnosis of malignant
17 pleural mesothelioma. *Biomark Med* 2011; 5:261-73.

18
19
20 53 Deeks J. Systematic reviews of evaluations of diagnostic and screening tests. In: Egger M,
21 Smith GD, Altman DG, eds. *Systematic reviews in health care. Meta-analysis in*
22 *context*. London: BMJ Publishing Group 2001:248-82.

23
24
25 54 Jaeschke R GG, Lijmer J. Diagnostic tests. In: Guyatt G, Rennie D, eds. *Users' guides to*
26 *the medical literature. A manual for evidence-based clinical practice*. Chicago: AMA
27 Press, 2002; 121-40.

28
29
30 55 Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in
31 mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85:265-72.

32
33
34 56 Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte
35 H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with
36 malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009;
37 179: 950-4.

38
39
40 57 Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leighl N, Feld R, Cho BC,
41 O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M,
42 Liu G. Soluble mesothelin-related Peptide and osteopontin as markers of response to
43
44
45
46
47

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

treatment in malignant mesothelioma. J Clin Oncol 2010; 28: 3316-22.

For peer review only




Figure legends

Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.

Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.

Table 1. Study summary of soluble mesothelin-related peptides in sera

Study	Subjects, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Robinson et al ²¹	272	Mesothelin	0.218 OD	37	10	7	218	16	11
Onda et al ²²	126	MPF	0.034 OD	51	0	5	70	11	9
Scherpereel et al ²³	83	Mesothelin	0.93 nmol/L	48	4	12	19	14	10
Scherpereel et al ²³	90	Mesothelin	1.85 nmol/L	35	8	25	22	14	10
Beyer et al ²⁴	1,086	Mesothelin	1.5 nmol/L	46	66	42	932	16	12
Creaney et al ²⁵	233	Mesothelin	2.5 nmol/L	56	2	61	114	13	11
Cristaudo et al ²⁶	714	Mesothelin	1.0 nmol/L	73	149	34	458	14	9
Di Serio et al ²⁷	116	Mesothelin	1.5 nmol/L	16	7	8	85	14	12
Amati et al ²⁸	170	Mesothelin	1.9 nmol/L	16	15	6	133	12	9
Shiomi et al ²⁹	293	MPF	5.6 ng/ml	28	17	11	237	20	13
Iwahori et al ³⁰	156	MPF	19.1 ng/ml	20	14	7	115	14	11
Iwahori et al ³⁰	156	Mesothelin	123.7 ng/ml	11	8	16	121	14	11
van den Heuvel et al ³¹	229	Mesothelin	1.3 nmol/L	44	22	29	134	17	12
Creaney et al ³²	107	MPF	1.0 ng/ml	22	2	44	39	13	11
Schneider et al ³³	343	Mesothelin	1.35 nmol/L	68	37	61	177	15	10

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

Portal et al ³⁵	362	Mesothelin	0.55 nmol/L	26	91	10	235	15	11
Hollevoet et al ³⁷	507	Mesothelin	1.89 nmol/L	56	25	29	397	20	11
Hollevoet et al ³⁷	507	MPF	13.46 ng/ml	58	13	27	409	20	11
Creaney et al ³⁸	155	Mesothelin	1.6 nmol/L	44	4	22	85	13	11
Cristaudo et al ³⁹	235	Mesothelin	1.0 nmol/L	19	41	12	163	16	10
Dipalma et al ⁴⁰	354	Mesothelin	1.2 nmol/L	22	66	14	252	15	10
Ashour et al ⁴²	123	Mesothelin	0.55 nmol/L	30	34	8	51	13	9
Amany et al ⁴⁴	40	Mesothelin	3.3 nmol/L	19	1	1	19	12	9
Creaney et al ⁴⁶	121	Mesothelin	2.4 nmol/L	40	3	26	52	13	11
Creaney et al ⁴⁶	121	MPF	33.2 ng/mL	34	3	32	52	13	11
Ferro et al ⁴⁷	102	Mesothelin	1.08 nmol/L	20	9	23	50	14	9
Hooper et al ⁴⁹	203	Mesothelin	1.5 nmol/L	16	62	11	114	15	12
Bayram et al ⁵⁰	546	Mesothelin	1.63 nmol/L	14	89	10	433	13	10

SMRP = soluble mesothelin-related peptide; MPF = megakaryocyte potentiating factor, OD = optical density; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 2. Study summary of soluble mesothelin-related peptides in pleural fluids *

Study	Patients, n	SMRPs	Cut-off	Test Results				Quality Scores	
				TP	FP	FN	TN	STARD	QUADAS
Scherperel et al ²³	92	Mesothelin	10.4 nmol/L	33	15	10	34	14	10
Davies et al ³⁴	166	Mesothelin	20.0 nmol/L	17	14	7	128	14	11
Fujimoto et al ³⁶	96	Mesothelin	8.0 nmol/L	16	23	7	50	16	9
Yamada et al ⁴¹	98	Mesothelin	10.0 nmol/L	36	9	9	44	16	9
Ashour et al ⁴²	74	Mesothelin	3.0 nmol/L	19	9	7	39	13	9
Blanquart et al ⁴³	101	Mesothelin	24.05 nmol/L	61	14	0	26	12	9
Amany et al ⁴⁴	40	Mesothelin	3.5 nmol/L	19	2	1	18	12	9
Canessa et al ⁴⁵	275	Mesothelin	9.3 nmol/L	38	27	14	196	16	10
Creaney et al ⁴⁶	98	Mesothelin	20.0 nmol/L	30	3	13	52	13	11
Creaney et al ⁴⁶	98	MPF	600.0 ng/mL	35	3	6	52	13	11
Filiberti et al ⁴⁸	177	Mesothelin	12.0 nmol/L	42	17	15	103	14	12
Hooper et al ⁴⁹	193	Mesothelin	20.0 nmol/L	18	21	7	147	15	12

SMRP = soluble mesothelin-related peptide; TP = true positive; FP = false positive; FN= false negative; TN = true negative; STARD = standards for reporting diagnostic accuracy; QUADAS = quality assessment for studies of diagnostic accuracy.

Table 3. Comparison of diagnostic accuracy of mesothelin and megakaryocyte potentiating factor in sera

	Mesothelin	Megakaryocyte potentiating factor
Study, Ref. No.	21, 23-28, 30, 31, 33, 35, 37-40, 42, 44, 46, 47, 49, 50	22, 29, 30, 32, 37, 46
Sensitivity (95% CI)	0.62 (0.59 – 0.65)	0.62 (0.56 – 0.67)
Heterogeneity* (p)	70.20 (< 0.001)	53.08 (< 0.001)
Specificity (95% CI)	0.85 (0.84 – 0.86)	0.96 (0.94 – 0.97)
Heterogeneity (p)	352.24 (< 0.001)	17.60 (0.001)
PLR (95% CI)	4.78 (3.59 – 6.36)	12.39 (5.53 – 27.74)
Heterogeneity (p)	185.80 (< 0.001)	14.42 (0.006)
NLR (95% CI)	0.45 (0.40 – 0.51)	0.34 (0.19 – 0.63)
Heterogeneity (p)	50.65 (< 0.001)	67.07 (< 0.001)
DOR (95% CI)	11.84 (8.12 – 17.27)	36.08 (12.91 – 100.85)
Heterogeneity (p)	95.80 (< 0.001)	13.40 (0.009)
AUC (SEM)	0.785 (0.033)	0.941 (0.094)

* Q value

CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio;

AUC = area under curve; SEM = standard error of mean.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 4. Comparisons of diagnostic accuracy of SMRPs in sera for differentiating MPM from different control subpopulations

	MPM vs healthy controls	MPM vs other cancers	MPM vs benign asbestos-related diseases
Study, Ref. No.	21, 22, 24, 28, 30, 31	21, 23, 24, 26, 30, 31, 33, 45, 47	21, 23, 24, 25, 28, 30, 33, 40
Sensitivity (95% CI)	0.66 (.61 – 0.71)	0.60 (0.56 – 0.64)	0.58 (0.54 – 0.62)
Heterogeneity* (p)	42.46 (< 0.001)	31.33 (< 0.001)	39.91 (< 0.001)
Specificity (95% CI)	0.97 (0.96 – 0.98)	0.81 (0.78 – 0.83)	0.89 (0.86 – 0.91)
Heterogeneity (p)	46.70 (< 0.001)	52.59 (< 0.001)	39.48 (< 0.001)
PLR (95% CI)	24.07 (4.03 – 143.68)	2.81 (2.11 – 3.73)	6.65 (3.69 – 12.00)
Heterogeneity (p)	48.35 (< 0.001)	26.73 (0.001)	25.91 (0.001)
NLR (95% CI)	0.33 (0.22 – 0.50)	0.52 (0.43 – 0.63)	0.44 (0.36 – 0.55)
Heterogeneity (p)	32.11 (< 0.001)	25.45 (0.001)	24.89 (0.001)
DOR (95% CI)	69.27 (15.67 – 306.21)	5.62 (3.67 – 8.59)	18.03 (8.90 – 36.52)
Heterogeneity (p)	20.80 (0.001)	22.70 (0.004)	19.16 (0.008)
AUC (SEM)	0.870 (0.120)	0.734 (0.055)	0.845 (0.057)

* Q value

SMRP = soluble mesothelin-related peptide; MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio; NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.

Table 5. Comparisons of diagnostic accuracy of mesothelin in pleural fluid for differentiation of MPM from different control subpopulations

	MPM vs other cancers	MPM vs benign diseases
Study, Ref. No.	23, 34, 36, 41, 42, 48	36, 41, 42, 48
Sensitivity (95% CI)	0.75 (0.69 – 0.80)	0.75 (0.67 – 0.82)
Heterogeneity* (p)	1.36 (0.929)	1.08 (0.783)
Specificity (95% CI)	0.76 (0.71 – 0.82)	0.87 (0.80 – 0.93)
Heterogeneity (p)	4.88 (0.430)	6.74 (0.081)
PLR (95% CI)	2.95 (2.32 – 3.75)	4.74 (2.30 – 9.76)
Heterogeneity (p)	4.83 (0.437)	7.01 (0.071)
NLR (95% CI)	0.34 (0.27 – 0.43)	0.30 (0.22 – 0.40)
Heterogeneity (p)	1.94 (0.857)	1.83 (0.608)
DOR (95% CI)	8.96 (5.78 – 13.89)	16.87 (6.79 – 41.92)
Heterogeneity (p)	3.34 (0.648)	5.26 (0.154)
AUC (SEM)	0.809 (0.025)	0.818 (0.050)

* Q value

MPM = malignant pleural mesothelioma; CI = confidence interval; PLR = positive likelihood ratio;

NLR = negative likelihood ratio; DOR = diagnostic odds ratio; AUC = area under curve; SEM = standard error of mean.




Figure 1. Funnel graphs for the assessment of potential publication bias in soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The funnel graph plots the log of the diagnostic odds ratio (DOR) against the standard error of the log of the DOR (an indicator of sample size). Each solid circle represents each study in the meta-analysis. The line in the center indicates the summary DOR.

160x66mm (300 x 300 DPI)

Peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 2. Forest plots of estimates of sensitivity and specificity for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. The point estimates of sensitivity and specificity from each study are shown as solid circles. Error bars are 95% confidence intervals. Numbers indicate the reference numbers of studies cited in the reference list.
94x134mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 3. Summary receiver operating characteristic curves with 95% confidence intervals for soluble mesothelin family proteins in serum (A) and pleural fluid (B) for diagnosing malignant pleural mesothelioma. Each solid circle represents each study in the meta-analyses. The size of each study is indicated by the size of the solid circle. The regression summary receiver operating characteristic curves summarize the overall diagnostic accuracy.
160x78mm (300 x 300 DPI)

Review only

Online supplementary appendix 1

Excluded References

One were excluded because it recruited less than 10 patients in one of study groups [1], nine were excluded because the same authors published several reports on the same patients, and only the best-quality study was considered [2-10], twenty-two were excluded because they did not allow the calculation of sensitivity or specificity [11-32].

1. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, Maeda M, Takahashi K, Masuda K, Sakao Y, Hino O. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. *Cancer Sci* 2006; 97(9): 928-932.
2. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, de Klerk N, Winzell P, Hellstrom KE, Hellstrom I. Soluble mesothelin-related protein--a blood test for mesothelioma. *Lung Cancer* 2005; 49 Suppl 1: S109-111.
3. Creaney J, Christansen H, Lake R, Musk AB, de Klerk N, Robinson BW. Soluble mesothelin related protein in mesothelioma. *J Thorac Oncol* 2006; 1(2): 172-174.
4. Hassan R, Remaley AT, Sampson ML, Zhang J, Cox DD, Pingpank J, Alexander R, Willingham M, Pastan I, Onda M. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. *Clin Cancer Res* 2006; 12(2): 447-453.
5. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, Lebailly P, Gregoire M, Porte H, Copin MC, Lassalle P. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. *Clin Cancer Res* 2007; 13(10): 2928-2935.
6. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, Harbut M, Carbone M, Allard J. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. *Ann Thorac Surg* 2008; 85(1): 265-272; discussion 272.

7. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, Copin MC, Devos P, Lassalle P, Scherpereel A. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. *Clin Biochem* 2009; 42(10-11): 1046-1050.
8. Hollevoet K, Nackaerts K, Thas O, Thimpont J, Germonpre P, De Vuyst P, Bosquee L, Legrand C, Kellen E, Kishi Y, Delanghe JR, van Meerbeeck JP. The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor. *Chest* 2012; 141(2): 477-484.
9. Canessa PA, Ferro P, Manta C, Sivori M, Franceschini MC, Fedeli F, Roncella S. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report. *Med Oncol* 2013; 30(3): 649.
10. Creaney J, Dick IM, Segal A, Musk AW, Robinson BW. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma. *Lung Cancer*, 2013;82: 491-498.
11. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, Musk AW, De Klerk N, Horick N, Skates SJ, Robinson BW. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. *Thorax* 2007; 62(7): 569-576.
12. Weber DG, Taeger D, Pesch B, Kraus T, Bruning T, Johnen G. Soluble mesothelin-related peptides (SMRP) - high stability of a potential tumor marker for mesothelioma. *Cancer Biomark* 2007; 3(6): 287-292.
13. Roe OD, Creaney J, Lundgren S, Larsson E, Sandeck H, Boffetta P, Nilsen TI, Robinson B, Kjaerheim K. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study. *Lung Cancer* 2008; 61(2): 235-243.
14. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. *Am J Respir Crit Care Med* 2009; 179(10): 950-954.
15. Aleman C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, Ruiz E, Bielsa S, de Sevilla TF. Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. *Med Clin (Barc)* 2009; 133(12): 449-453.
16. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, Ladanyi M, Rusch V, Fleisher M. Soluble mesothelin related peptides (SMRP) and osteopontin as protein

1
2
3 biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and
4 characterization at mRNA and protein levels. *Clin Chem Lab Med* 2010; 48(2): 271-278.

5
6
7 17. Creaney J, Olsen NJ, Brims F, Dick IM, Musk AW, de Klerk NH, Skates SJ, Robinson
8 BW. Serum mesothelin for early detection of asbestos-induced cancer malignant
9 mesothelioma. *Cancer Epidemiol Biomarkers Prev* 2010; 19(9): 2238-2246.

10
11
12 18. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, Xu W, Leigh N, Feld R, Cho BC,
13 O'Sullivan B, Roberts H, Tsao MS, Tammemagi M, Anraku M, Chen Z, de Perrot M, Liu G.
14 Soluble mesothelin-related Peptide and osteopontin as markers of response in malignant
15 mesothelioma. *J Clin Oncol* 2010; 28(20): 3316-3322.

16
17
18 19. Gube M, Taeger D, Weber DG, Pesch B, Brand P, Johnen G, Muller-Lux A, Gross IM,
19 Wiethage T, Weber A, Raithel HJ, Kraus T, Bruning T. Performance of biomarkers SMRP,
20 CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung
21 cancer in a cohort of workers formerly exposed to asbestos. *Arch Toxicol* 2011; 85(3):
22 185-192.

23
24
25 20. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK. Serum
26 soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor
27 volume, clinical stage and changes in tumor burden. *Clin Cancer Res* 2011; 17(5): 1181-1189.

28
29
30 21. Nelson HH, Almquist LM, LaRocca JL, Plaza SL, Lambert-Messerlian GM, Sugarbaker
31 DJ, Bueno R, Godleski JJ, Marsit CJ, Christensen BC, Kelsey KT. The relationship between
32 tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma. *Epigenetics* 2011;
33 6(8): 1029-1034.

34
35
36 22. Imashimizu K, Shiomi K, Maeda M, Aoki N, Igarashi K, Suzuki F, Koizumi M, Suzuki K,
37 Hino O. Feasibility of large-scale screening using N-ERC/mesothelin levels in the blood for
38 the early diagnosis of malignant mesothelioma. *Exp Ther Med* 2011; 2(3): 409-411.

39
40
41 23. Hollevoet K, Van Cleemput J, Thimpont J, De Vuyst P, Bosquee L, Nackaerts K,
42 Germonpre P, Vansteelandt S, Kishi Y, Delanghe JR, van Meerbeeck JP. Serial measurements
43 of mesothelioma serum biomarkers in asbestos-exposed individuals: a prospective
44 longitudinal cohort study. *J Thorac Oncol* 2011; 6(5): 889-895.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
24. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, De Vuyst P, Germonpre P, Kellen E, Legrand C, Kishi Y, Delanghe JR, van Meerbeeck JP. Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. *J Thorac Oncol* 2011; 6(11): 1930-1937.
25. Boudville N, Paul R, Robinson BW, Creaney J. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening. *Lung Cancer* 2011; 73(3): 320-324.
26. Santarelli L, Strafella E, Staffolani S, Amati M, Emanuelli M, Sartini D, Pozzi V, Carbonari D, Bracci M, Pignotti E, Mazzanti P, Sabbatini A, Ranaldi R, Gasparini S, Neuzil J, Tomasetti M. Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma. *PLoS One* 2011; 6(4): e18232.
27. Park EK, Wilson D, Yates DH. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels. *Clin Chem Lab Med* 2012; 50(12): 2199-2204.
28. Franko A, Dolzan V, Kovac V, Arneric N, Dodic-Fikfak M. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma. *Dis Markers* 2012; 32(2): 123-131.
29. Mori T, Tajima K, Hiramama M, Sato T, Kido K, Iwakami S, Sasaki S, Iwase A, Shiomi K, Maeda M, Hino O, Takahashi K. The N-ERC index is a novel monitoring and prognostic marker for advanced malignant pleural mesothelioma. *J Thorac Dis* 2013; 5(2): 145-148.
30. Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J. Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer. *J Thorac Oncol* 2013; 8(7): 947-951.
31. Creaney J, Dick IM, Dare H, Demelker Y, Nowak AK, Musk AW, Robinson BW. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma? *Lung Cancer* 2013; 80(1): 39-44.
32. Mundt F, Nilsson G, Arslan S, Csürös K, Hillerdal G, Yildirim H, Metintas M, Dobra K, Hjerpe A. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma. *PLoS One* 2013; 8(8): e72030.

1
2
3
4
5
6 **Online supplementary appendix 2**
7
8
9

10
11 **The characteristics of subjects studied**
12

Study	MPM Patients	Non-MPM Subjects
Robinson et al ²¹	Epithelioid type (n = 25) Sarcomatoid type (n = 4) Other or not specified (n = 15)	Healthy controls without asbestos exposure (n = 28) Healthy controls with asbestos exposure (n = 40) Patients with inflammatory non-pleural lung disease (n = 92) Patients with non-MPM pleural diseases (n = 38) Patients with non-pleural malignant lung disease (n = 30)
Onda et al ²²	Epithelioid type (n = 56)	Healthy controls (n = 70)
Scherpereel et al ²³	Epithelioid type (n = 55) Sarcomatoid type (n = 6) Other or not specified (n = 13)	Patients with benign asbestos-related pleural diseases (n = 28) Patients with pleural metastasis of carcinomas (n = 35)
Beyer et al ²⁴	Epithelioid type (n = 59) Sarcomatoid type (n = 8) Other or not specified (n = 21)	Healthy controls (n = 409) Patients with non-MPM malignancy (n = 412) Patients with nonmalignant conditions (n = 116)

1

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

		Subjects with asbestos exposure (n = 61)
Creaney et al ²⁵	Epithelioid type (n = 35) Sarcomatoid type (n = 15) Other or not specified (n = 67)	Healthy controls with asbestos exposure (n = 33) Patients with benign asbestos-related diseases (n = 53) Patients with benign pleural effusions (n = 30)
Cristaudo et al ²⁶	Epithelioid type (n = 72) Sarcomatoid type (n = 10) Other or not specified (n = 25)	Healthy controls (n = 262) Patients with benign respiratory diseases (n = 130) Patients with lung cancer (n = 215)
Di Serio et al ²⁷	Epithelioid type (n = 20) Sarcomatoid type (n = 2) Other or not specified (n = 2)	Healthy controls with asbestos exposure (n = 26) Patients with asbestos-related diseases (n = 66)
Amati et al ²⁸	Epithelioid type (n = 11) Sarcomatoid type (n = 6) Other or not specified (n = 5)	Healthy controls without asbestos exposure (n = 54) Subjects with asbestos exposure (n = 94)
Shiomi et al ²⁹	Epithelioid type (n = 21) Sarcomatoid type (n = 9) Other or not specified (n = 9)	Patients with benign asbestos-related diseases and healthy controls with asbestos exposure (n = 201) Patients with lung cancer (n = 45) Others (n = 8)
Iwahori et al ³⁰	Epithelioid type (n = 13)	Healthy controls without asbestos exposure (n = 38)

	Sarcomatoid type (n = 3) Other or not specified (n = 11)	Healthy controls with asbestos exposure (n = 9) Patients with lung cancer (n = 47) Patients with other cancers (n = 35)
van den Heuvel ³¹	Epithelioid type (n = 43) Sarcomatoid type (n = 10) Other or not specified (n = 20)	Healthy controls (n = 50) Patients with lung cancer (n = 106)
Creaney et al ³²	Epithelioid type (n = 57) Sarcomatoid type (n = 9)	Healthy controls without asbestos exposure (n = 10) Healthy controls with asbestos exposure (n = 10) Patients with benign asbestos-related diseases (n = 21) Patients with lung cancer (n = 10)
Schneider et al ³³	Epithelioid type (n = 81) Sarcomatoid type (n = 14) Other or not specified (n = 34)	Patients with lung cancer (n = 139) Patients with benign asbestos-related diseases (n = 75)
Davies et al ³⁴	Epithelioid type (n = 11) Sarcomatoid type (n = 5) Other or not specified (n = 8)	Patients with nonmesothelioma malignancy (n = 67) Patients with benign pleural effusion (n = 75)
Rodriguez Portal et al ³⁵	Not specified (n = 36)	Healthy controls (n = 48) Patients with asbestos exposure and no pleural disease (n = 177)

		Patients with benign asbestos-related diseases (n = 101)
Fujimoto et al ³⁶	Epithelioid type (n = 15) Sarcomatoid type (n = 4) Other or not specified (n = 4)	Patients with lung cancer (n = 38) Patients with benign asbestos pleurisy (n = 26) Patients with tuberculosis pleurisy (n = 5) Patients with no pleural diseases (n = 4)
Hollevoet et al ³⁶	Epithelioid type (n = 73) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Healthy controls (n = 101) Healthy controls with asbestos exposure (n = 89) Patients with benign asbestos-related diseases (n = 123) Patients with benign respiratory diseases (n = 46) Patients with lung cancer (n = 63)
Creaney et al ³⁸	Epithelioid type (n = 59) Other or not specified (n = 7)	Patients with benign asbestos-related diseases (n = 47) Patients with benign respiratory diseases (n = 42)
Cristaudo et al ³⁹	Epithelioid type (n = 31)	Healthy controls (n = 93) Patients with benign respiratory diseases (n = 111)
Dipalma et al ⁴⁰	Epithelioid type (n = 29) Sarcomatoid type (n = 4) Other or not specified (n = 3)	Healthy controls without asbestos exposure (n = 109) Healthy controls with asbestos exposure (n = 26) Patients with benign asbestos-related diseases (n = 48) Patients with benign respiratory diseases (n = 110)

		Patients with lung cancer (n = 25)
Yamada et al ⁴¹	Epithelioid type (n = 37) Sarcomatoid type (n = 5) Other or not specified (n = 3)	Patients with non-malignant pleural effusions (n = 24) Patients with lung cancer (n = 29)
Ashour et al ⁴²	Not specified (n = 38)	Healthy controls with asbestos exposure (n = 32) Patients with benign pleural diseases (n = 29) Patients with pleural carcinomas (n = 24)
Blanquart et al ⁴³	Epithelioid type (n = 49) Sarcomatoid type (n = 4) Other or not specified (n = 8)	Patients with adenocarcinoma effusions (n = 25) Patients with benign pleural effusions (n = 15)
Amany et al ⁴⁴	Epithelioid type (n = 14) Sarcomatoid type (n = 4) Other or not specified (n = 2)	Patients with benign asbestos pleural effusions (n = 10) Patients with tuberculosis pleural effusions (n = 10)
Canessa et al ⁴⁵	Epithelioid type (n = 35) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignant effusions (n = 94) Patients with benign pleural effusions (n = 129)
Creaney et al ⁴⁶	Epithelioid type (n = 32) Sarcomatoid type (n = 9)	Patients with non-MPM malignant effusions (n = 39) Patients with benign disease (n = 37)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

	Other or not specified (n = 25)	Patients with chronic kidney disease (n = 53) Healthy controls without asbestos exposure (n = 18)
Ferro et al ⁴⁷	Epithelioid type (n = 26) Sarcomatoid type (n = 9) Other or not specified (n = 8)	Patients with non-MPM malignancy (n = 23) Patients with benign diseases (n = 36)
Filiberti et al ⁴⁸	Epithelioid type (n = 43) Sarcomatoid type (n = 3) Other or not specified (n = 2)	Patients with malignant effusions (n = 64) Patients with benign effusions (n = 56)
Hooper et al ⁴⁹	Epithelioid type (n = 23) Sarcomatoid type (n = 3) Other or not specified (n = 2)	Patients with non-MPM malignant effusions (n = 74) Patients with benign asbestos-related effusions (n = 13) Patients with benign pleural diseases (n = 100)
Bayram et al ⁵⁰	Not specified (n = 24)	Patients with pleural plaques (n = 279) Healthy controls with asbestos exposure (n = 123) Healthy controls without asbestos exposure (n = 120)

MPM = malignant pleural mesothelioma.

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	0-2
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	7,8
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	11
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	12
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	12
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	12
<i>Test methods</i>	7	The reference standard and its rationale.	12
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	12
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	11,12
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	N/A
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	12
<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	N/A
	13	Methods for calculating test reproducibility, if done.	N/A
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	N/A
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	11
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	N/A
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	N/A
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	12
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	12-15
	20	Any adverse events from performing the index tests or the reference standard.	N/A
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	14,15
	22	How indeterminate results, missing data and outliers of the index tests were handled.	N/A
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	14,15
	24	Estimates of test reproducibility, if done.	N/A
DISCUSSION	25	Discuss the clinical applicability of the study findings.	18,19